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Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors increase survival and 
improve quality of life for patients with non-small cell lung cancer (NSCLC). Because oral 
EGFR inhibitors are a new therapy, the implications for medication-taking are unknown. We 
used grounded theory to explore the process of medication-taking for patients with NSCLC who 
were receiving therapy with oral EGFR inhibitors. We sought to describe the medication-taking 
process and identify factors influencing medication-taking. We enrolled men and women from a 
National Cancer Institute-designated cancer center aged 18 years or older with NSCLC receiving 
oral EGFR inhibitors who were able to speak, read, and understand English. Exclusion criteria 
included central nervous system metastases and evidence of cognitive impairment as assessed by 
the Mini-Mental Status Exam. Thirteen participants were purposively selected for variation in 
gender (5 men/8 women), race/ethnicity (2 non-whites), age (52-83 years), time in therapy (one 
week to six or more years), dose reductions (n = 5), and therapy discontinuation (n = 2). 
Theoretical sampling focused on age and health insurance carrier. Data were collected through 
32 semiformal and brief interviews concerning one’s medication-taking behaviors related to 
therapy with oral EGFR inhibitors. We employed constant comparative and dimensional 
analyses. The basic psychosocial process, Surviving Lung Cancer, which participants framed 
within the recognition of NSCLC as a life-limiting illness without cure, included a dynamic 
process of (a) Deciding to take targeted therapy with erlotinib, (b) Preparing for erlotinib, and 
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 v 
(c) Treating lung cancer as a chronic condition. Participants described thresholds that may result 
in stopping erlotinib, including side effects and cost. Men described taking erlotinib therapy in 
partnership with their spouse; most women managed erlotinib alone. These findings may provide 
the theoretical basis for developing patient-centered interventions to address medication-taking. 
 vi 
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1.0  INTRODUCTION 
Traditionally, patients with non-small cell lung cancer (NSCLC) have been treated with surgery, 
radiation therapy, and/or intravenous (IV) chemotherapy. However, in recent years a paradigm 
shift has occurred in the approach to NSCLC treatment to the use of oral targeted therapies, such 
as tyrosine kinase inhibitors (Aisner, 2007). For patients with NSCLC clinical development of 
novel, oral targeted therapies has focused on the epidermal growth factor receptor (EGFR) with 
some agents already approved for clinical use. One such agent, erlotinib (Tarceva®, OSI 
Pharmaceuticals, Farmingdale, NY), an EGFR tyrosine kinase inhibitor, has been shown to 
increase survival, decrease tumor-related symptoms, and improve physical functioning and 
overall quality of life (QoL) in patients with NSCLC (Bezjak et al., 2006). 
Adherence is only one aspect of medication-taking, a multifaceted process requiring one 
to perform complex activities such as identifying and counting pills, timing pill taking, and 
refilling medication prescriptions (Russell, Kilburn, Conn, & Ashbaugh, 2003). While 
assessment of adherence describes how closely an individual follows a prescribed regimen, 
assessment of medication-taking behavior illustrates how individuals take their medicines. 
Unfortunately, the process of medication-taking in patients with NSCLC taking oral targeted 
therapy has not been studied. Therefore, the purpose of this qualitative, grounded theory study 
was to explore the process of medication-taking for adult patients with NSCLC receiving oral 
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EGFR inhibitor therapies. Specifically, we aimed to (a) describe the process of medication-
taking, and (b) identify factors influencing medication-taking regarding their prescribed regimen. 
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2.0  BACKGROUND 
Understanding the process of medication-taking in relation to EGFR tyrosine kinase inhibitor 
therapy requires addressing the treatment of NSCLC and the challenges patients and health care 
providers face with regard to medication-taking. The following four sections provide (a) an 
overview of NSCLC, past and current treatments, and the benefits and challenges of oral targeted 
therapy; (b) a brief summary of the general state of the science concerning medication-taking and 
adherence for patients with chronic disorders; (c) a summary of what is known regarding 
medication-taking and adherence for patients with cancer who are taking oral cancer therapies; 
and (d) a summary of what is known regarding adherence and genetics for patients with cancer. 
2.1 NON-SMALL CELL LUNG CANCER AND ORAL TARGETED THERAPY 
Cancer is the second most common cause of death in the US exceeded only by heart disease 
(American Cancer Society [ACS], 2011). Lung cancer is the leading cause of cancer deaths in 
the US for both men and women with approximately 160,340 (87,750 men, 72,590 women) 
deaths estimated for 2012 (Siegel, Naishadham, & Jemal, 2012). In fact, lung cancer accounts for 
approximately 28% of all cancer deaths; more individuals die from lung cancer than from colon 
cancer, breast cancer, and prostate cancer combined (ACS, 2011). About 80% of new lung 
cancer cases are former or never smokers (The Centers for Disease Control and Prevention, 
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2007). The 5-year relative survival rate for persons of all stages is 16% (Siegel et al., 2012). 
Black males have higher lung cancer incidence and mortality rates than all other male racial 
groups as well as a lower 5-year relative survival rate (12%) (ACS, 2011). From 2004-2008, the 
average incidence of lung cancer among black men was higher than that of white men, but lower 
for black women than for white women (Siegel et al., 2012). 
NSCLC adenocarcinoma is largely a disease of older adults (Edwards et al., 2002; 
Edwards et al., 2005; Horn, Visbal, & Leighl, 2007; Molina, Yang, Cassivi, Schild, & Adjei, 
2008). The mean age at diagnosis is 71 years of age. Approximately two out of three individuals 
are older than 65 years of age at diagnosis and only 3% are younger than 45 years of age at 
diagnosis (ACS, 2011); therefore, lung cancer represents a major disease burden in older adults 
(Ganti, deShazo, Weir, & Hurria, 2012). Overall, approximately 70% of patients with NSCLC 
are diagnosed at an advanced stage (stage III/IV), are over 65 years of age at the time of 
diagnosis, and have a 16% five-year relative survival rate (Horn et al., 2007; Molina et al., 2008).  
Lung cancer is typically diagnosed as one of two types: (a) small cell, constituting 
approximately 15-20% of lung cancer cases, is generally associated with smoking, and usually 
occurs in the bronchus or bronchi; and (b) NSCLC, comprising approximately 80-85% of lung 
cancer cases, occurs in both smokers and nonsmokers, is usually found in the periphery of the 
lungs (National Comprehensive Cancer Network [NCCN], 2011). NSCLC can be further 
classified into two main types:  (a) nonsquamous which includes adenocarcinoma, large-cell, and 
other cell types; and (b) squamous including epidermoid. Bronchoalveolar carcinoma (BAC) is a 
less invasive type of NSCLC and is characterized by slow-growing well-differentiated cells 
(Neal, 2010). Adenocarcinoma can be further classified into three subtypes:  bronchoid, 
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squamoid, and magnoid (Finkelstein, Ettinger, & Ruckdesschel, 1986). Approximately 55-65% 
of all lung cancers are NSCLC adenocarcinoma (Genentech, 2008).  
Treatment of lung cancer is based on tumor histology and staging according to the TNM 
(primary tumor [T], evidence of regional nodes [N], and metastases [M]) guide (Lababede, 
Meziane, & Rice, 2011). Clinical effectiveness of NSCLC treatment is generally measured 
through effects on patient survival, QoL, and adverse effect profile (Horn et al., 2007). For 
earlier disease stages (Stages I and II) surgery provides the best chance for a cure (Bonomi, 
2003; NCCN, 2011). For individuals with advanced disease stages (Stages IIIB/IV) surgical 
resection is not considered to be a viable option; rather, individuals may benefit from systemic 
treatment that prolongs survival and alleviates symptoms (Bonomi, 2003) such as IV 
chemotherapeutic regimens. 
Chemotherapy with platinum-based agents is considered to be the standard of care as first 
line treatment in persons with good performance status (PS) (Eastern Cooperative Oncology 
Group [ECOG] PS 0, 1, or 2) (Horn et al., 2007; Maione et al., 2010). Paclitaxel, docetaxel, 
vinorelbine, gemcitabine, and irinotecan are IV chemotherapeutic agents that have been shown to 
have significant single-agent activity against NSCLC (Genentech, 2008). Common side effects 
of IV platinum-based or taxane chemotherapy include nausea, vomiting, diarrhea, fatigue, and 
peripheral neuropathy (Taxol® Package Insert, 2008). In addition, radiation therapy has been 
used since the 1950s as local therapy for NSCLC and is commonly used to treat painful bone 
metastases, although innovative techniques have been developed to improve clinical outcomes 
and decrease side effects (Davies, Houlihan, & Joyce, 2004).  
Advances in treatment for NSCLC have included bevacizumab (Avastin®) (Genentech, 
Inc.; San Francisco, CA), a monoclonal antibody that inhibits the vascular endothelial growth 
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factor receptor. When added to platinum-based chemotherapy, bevacizumab has improved 
clinical outcomes. In a clinical trial of 878 patients with recurrent or advanced NSCLC (Stage 
IIIB/IV), patients treated with bevacizumab (every three weeks until disease progression) and 
chemotherapy (every three weeks for six cycles) had a median survival of 12.3 months, versus 
10.3 months for those treated with chemotherapy alone (Maione et al., 2010; Sandler et al., 
2006). Bevacizumab is now approved for first-line therapy for treatment with paclitaxel and 
carboplatin for patients with nonsquamous NSCLC. Most recently, a chemotherapeutic agent, 
pemetrexed (Alimta®) (Eli Lilly, Indianapolis, IN) has been approved as first-line therapy in 
combination with cisplatin and alone as maintenance therapy for patients with advanced 
nonsquamous NSCLC (Maione et al., 2010). 
Positive prognostic indicators of NSCLC include early stage of disease at diagnosis, good 
PS (ECOG PS 0, 1, or 2), no significant weight loss (5%), and female gender (Hayes et al., 
2006). Biological prognostic factors, such as mutation of the tumor supressor gene p53 or 
inactivation of the Kirsten-Rou sarcoma (K-ras) virus gene may be predictive of poor prognosis 
(Horio et al., 1993; Massarelli et al., 2007; Slebos et al., 1990). Even in cases with positive 
prognostic indicators, late diagnosis represents a primary barrier to improving NSCLC outcomes. 
Chemotherapy and radiation therapy have modest response rates with respect to QoL and 
overall survival; however, the efficacies of traditional treatments have plateaued (Bunn & 
Thatcher, 2008) and most patients succumb to the disease within two years (Gridelli et al., 2007). 
Chemotherapy and radiation therapy are complicated and expensive, are nonselective in that they 
affect dividing cells in the body, and have significant adverse effect profiles that may undermine 
overall treatment goals by exchanging disease symptoms for treatment related adverse effects 
(Gridelli et al., 2007). Additionally, NSCLC treatment is costly; annual direct medical care costs 
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of lung cancer in the US were estimated to be approximately US $10.3 billion in 2006 (National 
Cancer Institute [NCI], 2011) (current estimates not available), which represents approximately 
one-tenth of direct medical care expenditures for cancer treatment (Horn et al., 2007). Costs may 
be significantly higher for patients who receive than for those who do not receive chemotherapy. 
Therefore, researchers and clinicians have identified a significant need for more novel treatment 
approaches selectively pinpointing specific receptors in cancer cells (Bunn & Thatcher, 2008). 
2.1.1 Oral targeted therapy 
Targeted therapies act on, or “target”, specific sites on or in cancer cells in order to stop or slow 
tumor growth (NCI, 2008). The first targeted therapies were IV monoclonal antibodies, with the 
first of these approved in 1997 for the treatment of non-Hodgkin’s lymphoma. Oral, small 
molecule, targeted therapies comprise about 5% of currently available anticancer therapies; 
however, they represent 25% of all cancer therapies in development (Bedell, 2003). Most 
recently, targeted therapies under development and approved for use for patients with NSCLC 
include oral EGFR inhibitors and therapies targeting the rearrangement of echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) (Table 1). 
Table 1: Tyrosine kinase inhibitors approved for patients with cancer 
Generic name Trade Name Year 
Approved 
Manufacturer Target Gene or 
Receptor 
Disease Process 
Dasatinib Sprycell® 2006 Bristol-Myers 
Squibb 
BCR-ABL Philadelphia 
chromosome-
positive (Ph+) 
chronic myeloid 
leukemia (CML)  
Imatinib Gleevec® 2001 Novartis BCR-ABL Ph+ CML 
Gastrointestinal 
stromal tumors 
(GIST) 
      
Nilotinib Tasigna® 2007 Novartis BCR-ABL Ph+ CML 
Gefinitib Iressa® 2003 AstraZeneca EGFR Non-small cell 
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lung cancer 
(NSCLC) 
Erlotinib Tarceva® 2004 OSI 
Pharmaceuticals 
EGFR NSCLC 
Pancreatic cancer 
Crizotinib Xalkori® 2011 Pfizer EML4-ALK NSCLC 
Lapatinib Tykerb® 2007 GlaxoSmithKline EGFR, 
HER2/neu 
Breast cancer 
Sunitinib Sutent® 2006 Pfizer PDGFR, VEGF, 
KIT, RET, 
CSF-1R, flt3 
GIST 
Renal cell 
carcinoma (RCC) 
Sorafenib Nexavar® 2006 Bayer VEGF, PDGF, 
C-Raf, B-Raf, 
MAP Kinase,  
c-kit 
RCC 
Hepatocellular 
carcinoma 
Pazopanib Votrient™ 2009 GlaxoSmithKline VEGF, c-kit, 
PDGFR 
RCC 
Soft tissue 
sarcoma 
Note.  BCR-ABL = fusion of Abelson (Abl) tyrosine kinase gene at chromosome 9 and break point cluster (Bcr) 
gene at chromosome 22; EGFR = epidermal growth factor receptor; EML4-ALK = rearrangement of echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma kinase; HER2/neu = one of four membrane proteins in 
EGFR family; PDGFR = platelet-derived growth factor receptor; VEGF = vascular endothelial growth factor; RET 
= proto-oncogene, encodes receptor tyrosine kinase for the neurotrophic factor family; CSF-1R = colony stimulating 
factor 1; flt3 = encodes receptor tyrosine kinase that regulates hematopoiesis; MAP Kinase = family of 
serine/threonine proteins responsible for regulating cellular activities, such as apoptosis; c-kit = tyrosine kinase stem 
cell factor receptor. 
Source:  National Cancer Institute (www.cancer.gov). 
2.1.2 Epidermal growth factor receptor (EGFR) 
EGFR is a family of four membrane proteins that are structurally similar to tyrosine kinase 
proteins: ErbB1 (EGFR; Human Epidermal Growth Factor Receptor Type 1 [HER1]), ErbB2 
(HER2/neu), ErbB3 (HER3), and ErbB4 (HER4) (Jones, 2003). Activation of EGFR results in 
tumor growth stimulation and progression (Molina et al., 2008). EGFR is over-expressed in most 
squamous subtypes and in 80-85% of non-small cell lung cancers (Harari, 2004; NCCN, 2011; 
Press & Lenz, 2007). Thus, these new oral agents such as erlotinib (Tarceva®, OSI 
Pharmaceuticals, Farmingdale, NY) and gefitinib (Iressa®, AstraZeneca, Wilmington, DE) were 
developed to inhibit EGFR over-expression. Gefitinib was approved for use in 2003 for salvage 
treatment of advanced NSCLC; however, it was withdrawn from the market in June 2005 due to 
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the incidence of interstitial lung disease (Gridelli et al., 2007). The FDA has restricted its use to 
individuals in a clinical trial or those benefiting from treatment (Harari, 2004). 
Erlotinib blocks the activity of HER1/EGFR, and was approved for use in 2004 for 2nd 
and 3rd line treatment of advanced NSCLC. In a randomized clinical trial, erlotinib was the first 
oral EGFR inhibitor to show an increase in median overall survival (6.7 months compared to 4.7 
months for placebo, p = 0.001) and progression free survival (2.23 months versus 1.84 months 
for placebo, p = 0.001) (Tarceva® Package Insert, 2010). In April 2010, erlotinib was approved 
for maintenance therapy for patients with advanced stage NSCLC who had stable disease (cancer 
had not grown or spread) after initial treatment (4 cycles) of chemotherapy. In addition, research 
has shown that approximately 10% of patients with NSCLC have EGFR mutations (Fukuoka et 
al., 2003; Kris et al., 2003), specifically deletions of exon 19 (45%) and exon 21 (40%), and 
respond well to EGFR inhibitor therapy (Miller et al., 2008; Sequist et al. 2008). As such, the 
NCCN (2011) recommends treatment with erlotinib as first-line therapy for those patients with 
NSCLC with EGFR mutation. Generally, patients remain on therapy with erlotinib until evidence 
of disease progression or they experience unacceptable toxicity (Tarceva® Package Insert, 2010). 
2.1.3 The advantages and disadvantages of oral targeted therapy 
Cutting edge agents, such as oral EGFR inhibitors, are clearly beneficial; however, they present 
new challenges when prescribed for individuals with NSCLC. First, since persons with advanced 
cancer are living longer, they may be taking anticancer or other supportive therapies on a 
continual basis for up to 20 years (Szetela & Gibson, 2007). Therefore, the expense of long-term 
oral targeted therapy may result in a substantial burden to persons with NSCLC and their 
families. For example, it is estimated that a 30-day supply of 150 mg erlotinib tablets may cost 
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US $2,330 (Securities Exchanges Commission, 2008). Furthermore, Medicare reimbursement is 
problematic; oral cancer agents are covered under Medicare parts B and D, but require selection 
of a prescription medication plan and monthly premiums (Bartel, 2007; Winkeljohn, 2007). 
Medicare Part B covers 80% of the costs of IV chemotherapy or their oral equivalent (Conwell et 
al., 2011). Medicare Part D covers the cost of most oral targeted therapies; however, patients 
with high medication costs (such as NSCLC) have difficulty with the “doughnut hole”, where 
patients are responsible for all costs in the spending thresholds between $2,510-$5,726 (Bach, 
2009; Conwell et al., 2011). 
Further complicating oral targeted therapy use is the timing of dosing regimens and 
unique side effect profiles. Patients undergoing therapy with erlotinib are instructed to take their 
dose either one hour before or two hours after a meal since food considerably changes its 
bioavailability and may increase the risk of adverse events (Tarceva® Package Insert, 2010). 
Generally, oral targeted therapies are considered to be less toxic than IV chemotherapy but have 
distinctive side effect profiles due to pathway-specific mechanisms of action. By far, the most 
common side effect of erlotinib is a generally mild to moderate, dose-dependent papulopustular 
rash (PPR) that affects the face, neck, and upper trunk (Perez-Soler et al., 2005; Viele, 2007). 
PPR occurs in 45% to 100% of patients (Perez-Soler & Saltz, 2005; Perez-Soler et al., 2005; 
Segaert & Van Cutsem, 2005). The exact role of HER1/EGFR in skin is not well understood, 
though the sebaceous glands are usually not affected (Perez-Soler & Saltz, 2005). Testing with 
immunohistochemistry and in situ hybridization has shown upregulation of the negative 
epidermal-growth regulator p27Kip1 (Busam et al., 2011). In fact, p27Kip1 increased 3 to 4 times by 
the eighth day of treatment with cetuximab, an intravenous EGFR inhibitor (Busam et al., 2011). 
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 Skin toxicity has been suggested as a proxy marker for clinical effectiveness of oral 
EGFR inhibitors (Eames et al., 2010); however, an explanation for the relationship between the 
rash and response to EGFR inhibitor therapy is elusive (Amador et al., 2004). One reason could 
be the potential for genetic differences among individuals. Amador and colleagues (2004) found 
a correlation between CA-single sequence repeats (CA-SSRs) in patients with head and neck 
squamous carcinoma and increased response to oral EGFR inhibitor therapy. Specifically, 
individuals with shorter CA dinucleotide repeats had higher incidence of rash when treated with 
oral EGFR inhibitors. 
Other dermatological toxicities such as trichomegaly, conjunctivitis and dry eye, hair 
changes, fatigue, and interstitial lung disease have been reported with erlotinib use (Lynch et al., 
2004). In addition, EGFR-inhibition associated diarrhea is experienced by approximately 75% of 
patients taking erlotinib (Sipples, 2006).  
No randomized clinical trials of agents for treating EGFR inhibitor-associated rash have 
been conducted and no established guidelines exist (Perez-Soler et al., 2005), although 
algorithms have been developed at the institution level. Rash related to EGFR inhibitor therapy 
is commonly treated with thick, emollient moisturizers, topical corticosteroids, topical 
antibiotics, and/or dose reductions (NCI, 2008). Erlotinib-related diarrhea is generally treated 
with loperamide or diphenoxylate and atropine. Depending on the grade and severity of side 
effects, targeted therapy doses may be reduced or delayed (Bartel, 2007); for example, if 
untreated, dermatological toxicities can result in reduction in EGFR dose for 72% of episodes or 
discontinuation in 30% of episodes (Boone et al., 2005). Dermatological toxicities of oral EGFR 
inhibitors can affect patients’ health-related quality of life (Joshi et al., 2010), but the 
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implications of dose reductions and dose delays on disease progression and overall survival are 
not yet known. 
Despite these challenges, oral targeted therapy clearly has its advantages over traditional 
cancer therapies. The most advantageous aspects of oral targeted therapy are the flexibility and 
independence these therapies offer (Jones, 2003). Oral targeted therapies provide more 
prolonged drug exposure and may reduce the use of health care resources (Aisner, 2007); for 
example, office visits may be reduced, and therefore patients may spend less in terms of required 
office visit co-pays (Bartel, 2007). Additionally, EGFR inhibitors, whether administered alone or 
in combination with chemotherapy, may lead to improved clinical outcomes (Abou-Jawade, 
Choueiri, Alemany, & Mekhail, 2003), such as improved survival and reduced symptoms. Future 
directions for clinical research include combining targeted therapy with IV chemotherapy or 
other targeted therapies, such as bevacizumab; development of new targeted therapies, such as 
crizotinib (Xalkori®, Pfizer, New York, NY) which targets EML4-ALK; and, examining the 
effects of targeted therapy in patients with previously treated brain metastases (Sandler, 2008).  
However, these increasingly complex regimens may further compound the side effects of oral 
targeted therapy. Oral targeted therapies may be examined alone or with another therapy in a 
clinical trial, which may potentially decrease costs for a patient; however, not all oral targeted 
therapies are provided free of cost in clinical trials. Additionally, costs of the agents and lack of 
Medicare reimbursement may result in an increased financial burden for patients and their 
families. Finally, treatment costs may increase as survival rates rise and therapies are taken for 
longer periods of time. 
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2.1.4 Summary 
Oral EGFR inhibitors provide patients with an efficacious, less invasive, and more convenient 
treatment for NSCLC, potentially resulting in an increase in QoL as compared to IV 
chemotherapy and a sense of control over treatment (Bartel, 2007), but the costs, unique side 
effect profiles, and changing dose regimens bring increased challenges for health care 
professionals in monitoring and assessing medication-taking behavior. Although some 
information is available regarding the association between IV chemotherapy adherence and 
disease-free survival, there is no evidence specifically related to oral EGFR inhibitors adherence 
and overall patient survival. Moreover, prior research demonstrates that patients have difficulty 
adhering to daily administration of oral targeted therapies, highlighting the imperative of 
monitoring patient adherence (Jones, 2003). Because there is little evidence of research 
evaluating medication-taking or adherence in patients with NSCLC receiving oral EGFR 
inhibitors therapy, a qualitative study exploring the process of medication-taking of oral targeted 
therapy in patients with NSCLC was a critical first step in a program of research to improve 
clinical outcomes for these patients. 
2.2 MEDICATION-TAKING AND ADHERENCE FOR PATIENTS WITH CHRONIC 
DISORDERS EXCLUDING CANCER 
The terms “adherence” and “medication-taking” are often used interchangeably in the literature, 
but there is a distinction between the two concepts. Medication-taking is a process that requires 
one to perform activities including identifying pills, counting pills, timing pill taking, and 
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refilling medication prescriptions (Russell et al., 2003). Medication-taking represents the work of 
adherence (McCoy, 2009), the “extent to which patients follow the instructions they are given for 
prescribed treatment” (Haynes, Ackloo, Sahota, McDonald, & Yao, 2008, p. 2). Estimates are 
that 50% of patients with chronic disorders are nonadherent to their prescribed drug regimens 
(Dunbar-Jacob et al., 2000). The costs to the US health care system of nonadherence in patients 
with chronic diseases are estimated to be US $300 billion a year (DiMatteo, 2004). Furthermore, 
nonadherence to prescription medication has been linked to increased emergency room visits, 
increased psychiatric admissions, increased nursing home admissions, and poor health status 
(Piette, Heisler, & Wagner, 2004). 
2.2.1 Medication-taking 
Assessment of medication-taking behavior illustrates how individuals actually take their 
medicines. Qualitative inquiry has provided essential and unique information concerning the 
medication-taking experiences for patients with chronic disorders excluding cancer, which is 
summarized in Table 2. 
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Table 2: Qualitative studies of medication-taking in patients with chronic conditions excluding 
cancer 
Authors Sample 
size (N) 
Method Chronic 
condition 
Sampling 
method 
Analytic 
approach 
Results 
       
Bacjar, 2006 10 Grounded 
theory 
General chronic 
condition 
Maximum 
variation; 
theoretical 
Constant 
comparative 
analysis 
Model of 
medication-
taking practice:  
making sense of 
medication-
taking, 
medication-
taking acts, 
medication-
taking self-
assessment. 
       
Chambers et 
al., 2011 
(adherence) 
26 Qualitative 
descriptive 
comparison of 
high- and low-
adherers 
Stroke Purposive Thematic 
analysis 
Major themes:  
importance of 
stability of a 
medication 
routine and 
beliefs about 
medication. 
       
Chen et al., 
2007 
19 Grounded 
theory 
Cardiovascular 
disease 
Purposive; 
theoretical 
Constant 
comparative 
analysis 
Behavioral 
model for 
elderly patients 
with chronic 
diseases 
comprised of 
four themes: 
perceived 
effectiveness, 
perceived 
partnership, 
perceived 
reality, and 
interpersonal 
influences.  
       
Clatworthy 
et al., 2007 
(adherence) 
16 Qualitative 
description 
Bipolar disorder Convenience Coding 
structured 
around Self-
Regulation 
Model and 
Necessity-
Concerns 
Framework 
Concepts 
concerning 
intentional and 
unintentional 
adherence. 
Dowell & 
Hudson, 
1997 
50 Grounded 
theory 
General 
practice 
Convenience Iterative Eight decision-
making themes 
with 39 sub-
categories. 
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Gray, 2006 
(adherence) 
11 Grounded 
theory approach 
HIV/AIDS Purposive; Analytic 
coding 
Five themes:  
choosing life, 
riding it out, 
figuring it out, 
sticking to it, 
realizing the 
benefits. 
Erlen & 
Mellors, 
1999 
(adherence) 
6 Qualitative 
description 
HIV/AIDS Purposive Thematic 
analysis 
Four major 
themes:  
decision-
making 
regarding 
initiating 
treatment, 
difficulties, 
problem 
solving, and 
quality of life. 
Hon, 2012 
(adherence) 
12 Grounded 
theory approach 
Adults 
receiving 
antipsychotic 
medication 
(bipolar, 
schizophrenia, 
schizo-affective 
disorder) 
Purposive 
until 
theoretical 
saturation 
Constant 
comparative 
analysis 
Quality of life, 
health status, 
and 
discernment 
that were inter-
related with a 
cyclical 
outcome.  Core 
category was 
quality of life. 
       
Johnson et 
al., 1999 
21  Qualitative 
description 
Older adults (< 
65 years) with 
hypertension 
Convenience Constant 
comparative 
content 
analysis using 
the ethnograph 
program for 
data 
management 
Four major 
domains: 
purposeful 
adherence, 
patterned 
adherence, 
purposeful 
nonadherence, 
and 
unintentional 
nonadherence. 
       
       
Lehane et 
al., 2008 
10 Qualitative 
description 
Coronary artery 
disease 
Convenience Content 
analysis 
Three themes:  
keeping track, 
reasoning about 
medications, 
social/ 
professional 
influences. 
       
Lewis et al., 
2006 
(adherence) 
13 Qualitative 
description 
HIV/AIDS Purposive 
(100% 
adherent to 
therapy) 
Content 
analysis 
Core category:  
successful 
medication 
management.   
 
Three sub-
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categories:  
regimen, self, 
and 
environment. 
       
McCoy, 
2009 
(adherence) 
79 Sub-study of 
larger study, 
institutional 
ethnographic 
approach 
HIV/AIDS Purposive Institutional 
ethnographic 
approach 
Realizing the 
medication day: 
scheduling, 
realizing dose 
time, keeping 
track, and 
managing the 
problem of will. 
       
Orr et al., 
2007 
(adherence) 
26 Phenomenology Adult renal 
transplant 
Purposive Thematic 
analysis 
(Krueger, 
1998); 
constant 
comparison 
(Strauss 
&Corbin, 
1990). 
Themes:  fear 
of transplant 
failure, loyalty 
to the renal 
team and 
donors, health 
beliefs, 
forgetting and 
side effects. 
       
Proulx et al., 
2007 (non-
compliance) 
27 Qualitative 
description 
High blood 
pressure 
Purposive Content 
analysis 
Broad 
categories: 
stress and living 
conditions in 
the occasional 
skipping or 
deferral of 
medication-
taking; 
doubt as the 
motivating 
factor for 
transitory, 
irregular 
medication use; 
subjective risk 
as the 
motivating 
factor for 
persistent 
irregular use. 
Reid et al., 
2006 
17 Qualitative 
description 
Congestive 
heart failure 
Purposive Constant 
comparative 
Knowledge of 
their condition, 
complexity of 
medication 
taken, 
strategies, low 
concordance, 
teaching and 
learning. 
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Remien et 
al., 2003 
(adherence) 
110 Qualitative 
description 
HIV/AIDS Convenience Grounded 
theory 
principles 
Prevalent 
themes:  
ambivalence 
towards HIV 
medication, 
intentional 
nonadherence 
related to side 
effects. 
Rifkin et al., 
2010 
(adherence) 
20 Qualitative 
description 
Chronic kidney 
disease 
Convenience 
(<55 years of 
age) 
Qualitative 
data analysis 
(not specified) 
Four themes:  
concerns about 
polypharmacy, 
medication 
prioritization, 
experiences 
with side 
effects, and 
barriers to 
discussions of 
adherence with 
physicians. 
Ruppar & 
Russell, 
2009 
(adherence) 
19 Qualitative 
description 
Kidney 
transplant 
recipients 
Convenience Constant 
comparative 
analysis 
Four themes:  
reminder 
methods, 
obtaining 
medications, 
maintaining 
routines, and 
problem-
solving 
strategies. 
Russell et 
al., 2003 
16 Qualitative 
description 
Adult renal 
transplant 
Purposive Manifest 
content 
analysis, 
guided by 
Theory of 
Planned 
Behavior. 
Comparisons 
between those 
> and <50 
years of age.   
Four categories:  
behavioral, 
normative, 
control, and 
problem-
solving. 
Note.  HIV/AIDS = human immunodeficiency virus/acquired immune deficiency syndrome. Studies that examined 
the work of adherence but used the term “adherence” or “non-compliance” to represent medication-taking are 
denoted with (adherence) or (non-compliance). 
2.2.2 Adherence 
For individuals with chronic disorders, more research has focused on adherence, the outcome of 
medication-taking. Factors associated with adherence have been studied in numerous patient 
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samples undergoing therapies with varying regimen complexity (Osterberg & Blaschke, 2005; 
World Health Organization [WHO], 2003). These factors include the patient-provider 
relationship, patient beliefs, complexity of dosing regimen, side effects, and other cognitive 
factors such as forgetting (WHO, 2003). For example, Choo and colleagues (1999) reported that 
baseline items regarding forgetting to take medication were significantly predictive of adherence 
to antihypertensive medication and also correlated with concurrent pharmacy refilling records. 
Similar findings have been uncovered in other populations, including patients prescribed 
complex treatment regimens, for example, patients with renal transplantation (Butler et al., 2004) 
and women with HIV taking protease inhibitors (Erlen, Sereika, Cook, & Hunt, 2002). 
Accurate measurement of adherence is a challenge in adherence research. First, there is 
no agreement on what defines adequate adherence (Osterberg & Blaschke, 2005). The most 
widely accepted rate for patients with chronic conditions is 80%; higher rates of 95% have been 
proposed for persons with serious conditions, such as HIV infection (Osterberg & Blaschke, 
2005), as higher rates of adherence are needed for optimal viral suppression (Rosenblum, Deeks, 
van der Laan, & Bangsberg, 2009). For studies of medication adherence for patients with cancer 
taking oral cancer therapies, the accepted rate for patients with chronic illnesses (80%) is most 
often implemented. Second, there are varying measurement methods of adherence. Electronic 
monitoring has been considered the “gold” standard (DeGeest et al., 2006; Evangelista et al., 
2003) since it can detect lower levels of adherence. Direct methods of adherence assessment, 
such as continuous dose observation and evaluation of pharmacologic blood levels, provide 
accurate data but are inconvenient, invasive, costly, and difficult to implement in everyday 
practice (Macintosh, Pond, Pond, Leung, & Siu, 2007; Osterberg & Blaschke, 2005). Indirect 
methods, such as pill counts and patient self-report, are inexpensive and convenient for clinical 
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practice (Rolley et al., 2008); however, these methods tend to overestimate adherence due to 
challenges with patient recall or social desirability (Osterberg & Blaschke, 2005), and pill counts 
verify that one took the right number of pills, but not whether they were taken on schedule 
(Macintosh et al., 2007).  
2.2.3 Summary 
Prior medication-taking and adherence research examining patients with chronic illnesses, such 
as hypertension, renal transplantation, and HIV/AIDS, has demonstrated that there are many 
factors associated with medication-taking and adherence, as well as measurement challenges of 
adherence. Knowledge gained from research in these patient samples can inform medication-
taking research in patients with cancer; however, oral EGFR inhibitors therapy presents specific 
challenges concerning dosing, cost, and management of side effects. The unique factors that 
influence the process of medication-taking for patients with NSCLC taking these therapies 
remain unknown. Therefore, a qualitative study exploring the process of medication-taking in 
patients with NSCLC receiving oral targeted therapy was an appropriate, critical first step. 
2.3 MEDICATION-TAKING AND ADHERENCE FOR PATIENTS WITH CANCER 
2.3.1 Medication-Taking 
Little research has focused on the medication-taking experiences for patients with cancer. 
Kingsnorth and Wilkinson (1996) examined nonadherence to palliative care medications for 
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patients with cancer; intentional nonadherence due to lack of understanding about the medication 
and challenges such as forgetting, difficulty taking, or lack of access to the medication comprised 
the major themes. Ersek, Kraybill, and Du Pen (1999) explored the reasons patients with cancer 
have trouble taking their pain medication; however, the purposes of analgesia and palliative care 
medications are different from that of medications for active treatment of NSCLC.  
One published report of a qualitative descriptive study that assessed adherence to 
capecitabine (oral chemotherapy) for patients with breast cancer and colon cancer was found 
(Denois et al., 2011). Forty-two patients and 10 oncologists from two clinics in France 
participated in either individual or group interviews to discuss their experiences with 
capecitabine. Use of oral chemotherapy was noted to be a major change for oncologists, who had 
varying attitudes toward prescribing capecitabine. Most of the oncologists did not specifically 
ask their patients about adherence to capecitabine. The major themes expressed by the patients 
concerned their adherence with dose and schedule, information, communication, and evaluation 
of side effects. While the results of this study provided information about patients’ observance of 
dosing schedule and inability to identify and report toxicities, it should be noted that capecitabine 
is an oral chemotherapeutic agent that is generally prescribed alone or in combination with 
another therapy for a finite period of time. EGFR tyrosine kinase inhibitor therapy for treatment 
of NSCLC has a different mechanism of action, different side effect profiles, and is generally 
taken until disease progression (weeks to years). 
2.3.2  Adherence 
Adherence to oral cancer therapy has been identified as a significant problem by clinicians and 
has been evaluated in patients with lymphoma, acute lymphocytic leukemia (ALL), breast 
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cancer, gastrointestinal stromal tumors (GIST), ovarian cancer, and non-Hodgkin’s lymphoma 
(Mazzeo et al., 2011; Waterhouse, Caizone, Mele, & Brenner, 1993) with adherence rates 
ranging from less than 20% to 100% (Partridge, Wang, Winer, & Avorn, 2003). No published 
studies were identified addressing medication-taking or adherence for patients with NSCLC. 
Most data regarding adherence to oral cancer therapy, including medication-taking beliefs and 
factors associated with adherence, are based on studies of women with breast cancer taking oral 
hormonal therapy with either tamoxifen (Viele, 2007) or anastrozole (Partridge et al., 2008) or 
patients with leukemia taking oral targeted therapy with imatinib (Gleevec®, Novartis 
Pharmaceuticals Corporation, East Hanover, NJ) (Ganesan, et al., 2011; Ibrahim et al., 2011; 
Noens et al., 2009). 
2.3.2.1 Oral hormonal therapy for breast cancer  
Generally, studies of tamoxifen report adherence rates to be 80% or less, but these rates are 
influenced by differences in measurement methods (Fink, Gurwitz, Rakowski, Guadagnoli, & 
Silliman, 2004; Lash, Fox, Westrup, Fink, & Silliman, 2006; Partridge et al., 2003; Waterhouse 
et al., 1993). Adherence to tamoxifen has been shown to relate to patients’ awareness of risks 
associated with breast cancer, beliefs regarding the benefits of therapy, and the character and 
severity of side effects (Barron et al., 2007; Fink et al., 2004; Grunfeld, Hunter, Sikka, & Mittal, 
2005; Lash et al., 2006; Love, Cameron, Connell, & Leventhal, 1991). For example, 
sociodemographic factors related to adherence to therapy with tamoxifen have been examined in 
a number of studies, but with mixed results. Kahn and colleagues (2007) evaluated patient-
centered measures related to ongoing use of tamoxifen. Younger age (< 65) (p = .04) was 
associated with ongoing tamoxifen use four years after diagnosis; however, no other 
demographic, clinical, cancer- or treatment-related factors were associated with ongoing 
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tamoxifen use. Partridge and colleagues (2003) found that both younger (< 45 years) and older 
women (> 65 to 85 years) were more likely to discontinue tamoxifen therapy than women ages 
45 to 65. Fink and colleagues (2004) found that age was not associated with discontinuation of 
tamoxifen. Most recently, Sedjo and Devine (2011) reported that 23% of women were 
nonadherent at one year to their aromatase inhibitor therapy. The researchers reported that risk 
factors for nonadherence included younger age. 
Fewer studies have found a relationship between race or ethnicity and adherence for 
women taking tamoxifen therapy. Partridge and colleagues (2003) found that non-white women 
were more likely to discontinue tamoxifen therapy than white women. Lebovits and colleagues 
(1990) found that women who discontinued oral chemotherapy had a significantly lower socio-
economic status (p < .02) than women who continued their therapy; however, oral 
chemotherapeutic agents typically have a different side effect profile than that of oral hormonal 
therapies due to different mechanisms of action.   
Women with higher breast cancer stage (Stage II) (Lebovits et al., 1990) and who had 
received chemotherapy before beginning tamoxifen (Fink et al., 2004) have been reported to be 
less likely to discontinue tamoxifen therapy. Kahn and colleagues (2007) reported that positive 
hormone receptor status was associated with ongoing tamoxifen use at four years; however, Fink 
and colleagues (2004) found that positive estrogen receptor status and positive nodes were 
associated with stopping therapy with tamoxifen by the second year. Partridge and colleagues 
(2003) found that women who had a mastectomy versus breast conserving surgery were more 
likely to be nonadherent to tamoxifen therapy.   
The relationship between side effect severity and discontinuation of tamoxifen is unclear. 
Fink and colleagues (2004) reported that side effects were not associated with discontinuation of 
  
 24 
tamoxifen, but other researchers have reported that women with side effects were more likely to 
stop taking tamoxifen (Demissie et al., 2001; Kahn et al., 2007). Grunfeld and colleagues (2005) 
reported that of the women who discontinued tamoxifen, 46% discontinued due to side effects.  
Adherence rates to another hormonal agent for breast cancer, anastrozole, are similar to 
those reported for tamoxifen therapy. In a recent study defining adherence as a medication 
possession ratio (the number of days one had anastrozole or another oral endocrine therapy 
available) of 80% or greater, 72% to 81% of eligible women in three large datasets were 
considered to be adherent during their first year of anastrozole therapy (Partridge et al., 2008). 
Adherence declined to 62% to 79% at year three. Furthermore, a comparison of adherence to 
hormonal therapy for postmenopausal women with breast cancer demonstrated 80% adherence 
for women taking tamoxifen and 69% for women taking anastrozole (Ziller et al., 2009). 
Nonadherence or nonpersistence to aromatase inhibitors related to side effects has been 
evaluated mostly in the context of clinical trials. In the Arimidex, Tamoxifen, Alone or in 
Combination (ATAC) trial (2002), there were fewer women who withdrew from therapy with 
anastrozole compared to tamoxifen; however, higher nonpersistence rates with aromatase 
inhibitors were noted in similar trials comparing exemestane and letrozole with tamoxifen 
(Coombes, Hall, & Gibson, 2004; Goss, Ingle, & Martino, 2003).  In a qualitative analysis of the 
medication-taking experiences for women taking oral anastrozole therapy (Wickersham, Happ, 
& Bender, under review; Wickersham, Happ, & Bender, 2011; Wickersham, Happ, & Bender, 
2010), despite side effect severity, most women (11/12) (91.7%) continued to take anastrozole 
due to a strong belief in its importance.  
Few studies have compared rates of or factors affecting adherence to therapy with 
tamoxifen and anastrozole. Ziller and colleagues (2009) measured adherence in 100 
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postmenopausal women (n = 50 tamoxifen, n = 50 anastrozole) and found no correlation of 
adherence to any baseline characteristics or side effects. Atkins and Fallowfield (2006) found 
that younger women were more likely to non-adhere to oral treatment for breast cancer (p = 
.015); disliking aspects of treatment was predictive of nonadherence. It should be noted that the 
sample of women included those taking oral chemotherapy, as well as women taking oral 
hormonal therapy. Side effects and reasons for discontinuation were not reported. 
2.3.2.2 Oral targeted therapy for chronic myeloid leukemia (CML)  
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor that blocks the adenosine triphosphaste 
(ATP)-binding site of the BCR-ABL tyrosine kinase and has been shown to be effective in 
treating the chronic and accelerated phases of CML as well as blast crisis. Imatinib is generally 
prescribed at a starting dose of 400 mg/day. Individuals taking imatinib have received 
therapeutic benefit from 18 months to 7 years (Druker et al., 2001; Hehlman et al., 2005; 
Kantarjian et al., 2002; Schindler et al., 2000; Talpaz et al., 2009).   
In the last five years, several published reports of research examining adherence to 
imatinib have become available. Darkow and colleagues (2007) found that the mean adherence 
rate in 267 persons with CML was 77% (measured by MPR); 30.7% failed to refill their imatinib 
prescription within 30 days. Adherence was lower in female patients, those with more 
concomitant medications, higher cancer complexity, and those taking higher doses of imatinib 
(600 mg/day or higher). Similar results were reported by Halpern, Barghout, Mody-Patel, & 
Williams (2008). Both Darkow and colleagues (2007) and Halpern and colleagues (2008) found 
that lower imatinib adherence was associated with higher medical expenditures. 
The ADAGIO Study (Adherence Assessment with Glivec:  Indicators and Outcomes) (N 
= 169) examined the prevalence of nonadherence for patients with CML, the association of 
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determinants of adherence with measures of nonadherence, and whether treatment response is 
associated with adherence beliefs (Noens et al., 2009). Adherence was measured using the Basel 
Assessment of Adherence Scale (BAAS) with Immunosuppressive Medication, adapted for 
imatinib, and pill counts.  The BAAS is a four-question interview guide; a positive answer to any 
of the four questions equals nonadherence. Only 14.2% of the participants had perfect 100% 
adherence. There were no significant associations between adherence behavior and length of 
illness or duration of treatment at baseline or follow-up. They found a weak correlation between 
the bothersomeness of symptoms and adherence per the BAAS (rbs = -240, p = .007), but no 
other statistically significant correlations between BAAS and other variables. A multivariate 
analysis demonstrated that the patient-related variables associated with nonadherence were 
higher age, longer time since CML diagnosis, living along, male sex, longer time on imatinib 
therapy, higher doses of imatinib (600 mg or greater), higher degrees of chronic care, higher self-
reported functional status, and quality of life. Participants with suboptimal response to imatinib 
had higher mean percentages of nonadherence (23.2%) than those with optimal responses 
(7.3%).  Conversely, in a retrospective analysis of 430 persons with CML under the age of 65, 
key factors that were associated with nonadherence were lower age, shorter exposure to imatinib, 
lower starting dose (< 400 mg), longer lag time between CML diagnosis and filling of imatinib 
prescription, increased number of concomitant medications, and increased copayment (St. 
Charles et al., 2009). 
Ganesan and colleagues (2011) retrospectively examined nonadherence in persons with 
chronic phase (CP) CML (N = 516) in India. All participants received imatinib through the 
Glivec International Patient Assistance Program (GIPAP), because patients could not afford the 
drug as the marketed price. Five-year event free survival (EFS) and nonadherence rates were 
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estimated from the GIPAP database. Approximately one-third (29.6%) of the participants were 
nonadherent (interruption in therapy of more than 1 week). Univariate analysis demonstrated that 
prolonged symptom duration before diagnosis, treatment with hydroxyurea for more than one 
month prior to imatinib therapy, and nonadherence were associated with EFS. Only 
nonadherence was significant in the multivariate analysis (HR 1.6; p = 0.048). This study is 
significantly limited by the method of adherence measurement. Because one had to return to the 
clinic to obtain his/her bottle of imatinib, adherence was measured by identifying those who did 
not return to the clinic and subsequently had an interruption in more than one week in therapy. 
This method is convenient and takes advantage of existing adherence data, but it does not 
distinguish between those who attended clinic visits from those who were fully adherent. 
Several studies have examined adherence to imatinib and response to treatment. Marin 
and colleagues (2010) found a strong correlation between adherence measured by a medication 
event monitoring system (MEMS) (≤ 90% or > 90%) and the 6-year probability of a major 
molecular response (MMR) (p = .001) and a complete molecular response (CMP) (p = .002). 
Multivariate analyses showed that adherence and presence of molecular human organic cation 
transporter-1 (RR, 1.79, p = .038) were the only independent predictors of MMR. Adherence was 
the only independent predictor of CMR. Ibrahim and colleagues (2011) examined the association 
between MEMS adherence and the loss of a complete cytogenetic response (CCyR) and imatinib 
failure for patients with CML receiving imatinib (N = 87). The median adherence was 97.6%; 
26.4% had adherence lass than or equal to 90%. Multivariate analyses showed that adherence 
rate and failure to achieve a molecular response were the only predictors for loss of CCyR and 
discontinuation of imatinib therapy. 
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2.3.2.3 Oral chemotherapy for small cell lung cancer 
One study of medication adherence in patients with small cell lung cancer was found. Lee and 
colleagues (1993) examined medication adherence in a sample of 12 patients receiving palliative 
treatment with low dose etoposide for relapsed small cell lung cancer by using an “intelligent 
tablet bottle” with reported 93% adherence. Medication-taking behavior and factors affecting 
adherence were not assessed. 
2.3.3 Barriers to and interventions for adherence for patients with cancer 
Potential barriers to medication-taking and suggestions for managing patient adherence have 
been identified for oral chemotherapeutic agents, such as capecitabine (Macintosh et al., 2007).  
Barriers include a patient’s ability to identify his or her own medications, the ability to specify 
the correct dose and time of administration with respect to meals and other over the counter 
medications and cost (Aisner, 2007; Viele, 2007). In addition, individuals aged 70 years and 
older face unique challenges that may influence medication-taking behaviors related to oral 
targeted therapy, such as negotiating the effects of multiple co-morbidities (Jorgensen, 
Johansson, Kennerfalk, Wallander, & Svardsudd, 2001; Linjakumpa et al., 2002; Veehof et al., 
2000), managing complicated medication regimens (Elliott, 2006) suffering from functional and 
cognitive declines and experiencing depressive symptomatology (Gray, Mahoney, & Bough, 
2001; Spiers & Kutzik, 1995; Vik et al., 2006). The impact of these challenges on medication-
taking for older adults with NSCLC remains unexplored. 
Suggestions for adherence management for patients with cancer have included the use of 
blister packs and pill organizers, patient diaries, counseling regarding the unique adverse effects 
of specific oral agents, random pill counts, and follow up at clinic visits or by telephone using 
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questions specific to the promotion of patient monitoring and adherence (Macintosh et al., 2007; 
Szetela & Gibson, 2007; Viele, 2007; Winkeljohn, 2007). Little research has focused on the 
testing of these interventions in patients with cancer. Decker and colleagues (2009) developed a 
nursing intervention to monitor adherence using a Symptom Management Toolkit®, based on a 
modified health belief model approach, and an automated voice response (AVR) reminder 
system (once weekly for 10 weeks). Adherence was measured using a combination of medical 
record audit, patient report (name of oral agent, number of pills to be taken and when, number of 
days or weeks on/off per month or cycle), and pharmacy report. The intervention was tested in 
patients with breast, colon, and lung cancers receiving non-hormonal agents for treatment of 
their cancer. Adherence was defined as 100% (i.e., anything less was considered to be 
nonadherent). Findings showed a nonadherence rate of 23.3% due to symptoms and forgetting to 
take medication. An association between symptom management and adherence was reported; 
symptom severity and beliefs about medications were not significantly different between 
adherent and nonadherent patients.    
Despite the limitations in this study, the researchers offered some clinically important 
implications concerning the management of patient symptoms and adherence to medication for 
patients with cancer. The sample consisted predominately of patients with breast cancer (n = 17 
of 23; n = 3 with lung cancer) taking capecitabine, cyclophosphamide, and lapatinib. The 
researchers did not provide a rationale for the use of 100% as a determinant of good adherence in 
this pilot study.  
Oakley, Johnson, and Ream (2010) conducted an ethnographic study and a feasibility 
study to understand the experiences of patients with cancer receiving oral chemotherapy and the 
feasibility of a generic patient diary for sustaining adherence to therapy. Four patients with 
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lymphoma receiving oral chlorambucil and five patients receiving therapy with oral capecitabine 
participated in the study. Core themes included self-medication and symptom management and 
self-efficacy. Patients found the diary helpful and useful, but found it would be more helpful if 
the diary was supported by a model of care to augment education and reiterate information.  Both 
phases of the study were conducted at the same institution in the United Kingdom, and adherence 
to oral chemotherapy was not measured. It should be noted that capecitabine (Xeloda®, 
Genentech, San Francisco, CA) is an oral antimetabolite agent that is prescribed for patients with 
metastatic colon, breast, or renal cancer. When given as monotherapy, capecitabine is generally 
prescribed for 2 weeks, with one week off, for up to 6 months (8 cycles) of therapy, while oral 
EGFR inhibitors such as erlotinib may be given continuously for weeks to years (Xeloda® 
Package Insert). 
Two studies examining adherence for patients with NSCLC receiving erlotinib therapy 
were found. Gebbia and colleagues (2011) published an abstract of a study to evaluate the impact 
of a treatment-monitoring intervention on adherence for patients with advanced NSCLC who 
received erlotinib as second-line therapy. The study was conducted in two cohorts:  1) a 
retrospective non-interventional phase monitoring 50 participants without a treatment 
management strategy; and, 2) a prospective interventional phase following 150 participants who 
received a treatment-management program, which included identification of a caregiver, patient 
and caregiver education and training about treatment and side effects of therapy, a calendar for 
follow-up visits, and a dedicated fax phone line to receive instructions or use of a fast-track visit 
system. Adherence was measured with the BAAS self-report tool, a visual analogue scale (VAS), 
pill counts, and missed appointments. During the first two months, adherence measured by 
BAAS  > 95% was 72% for the first cohort, and 84% for the second cohort; by VAS, adherence 
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was 94% and 85% for the first and second cohorts, respectively. By pill count, adherence in the 
first two months was 78% and 87%, respectively. Mean adherence to study visits was 86% and 
96%, respectively. Correlations between adherence and clinical outcomes were evaluated; the 
disease control rate, defined as complete response plus partial response plus stable disease, was 
44% in the first cohort and 63% in the second cohort. A significant correlation was found 
between the number of adverse events and adherence (r = .176, p = .035).  The abstract is the 
first published report addressing medication adherence for patients with NSCLC receiving oral 
targeted therapy; however, the socio-demographic characteristics of the participants, the rationale 
for the use of 95% as a cut-off for adequate adherence, and the theoretical underpinnings of the 
intervention were not reported.  
Recently, a published report of an ongoing prospective observational cohort study 
(Timmers et al., 2011) was found. The study is examining 65 patients with NSCLC aged 18 
years or older who have been initiating erlotinib therapy.  Subjects are followed for up to 16 
weeks.  Adherence is measured at baseline and at 4, 8, 13, 16 weeks using MEMS and several 
questionnaires concerning adherence behavior (MARS), side effects (five point scale), dose 
adjustment, co-medication, quality of life (SF-12), and patient beliefs and attitudes toward 
medication and disease (the brief Illness Perception Questionnaire and the Beliefs About 
Medicines Questionnaire adjusted for erlotinib). Blood samples are drawn at 4, 8, and 16 weeks 
for plasma concentration of erlotinib. Taken together, the findings and limitations of these four 
studies imply that until medication-taking behavior is better understood, developing and testing 
theoretically-based interventions to enable patients with NSCLC need to proceed slowly. 
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2.3.4 Medication adherence and genetics for patients with cancer 
The shift to the use of oral targeted therapies for treatment of cancer has in part led to an 
emphasis on personalized medicine, or the matching of patient genotype with the appropriate 
treatment for cancer (Thompson et al., 2011). The relationship and/or the implications for 
personalized treatment for cancer and medication adherence have yet to be explored. Lash and 
colleagues (2011) examined the relationship of CYP2D6 inhibition (*4 allele) and recurrence of 
breast cancer in a large case control population study in Denmark. Women who were registered 
with Denmark’s Breast Cancer Cooperative Group and who were aged 35–69 years at the time of 
diagnosis of stage I–III breast cancer between 1985 and 2001 were examined for CYP2D6 
genotyping and recurrence of breast cancer. In this patient sample, there was little to no 
association of those with one functioning allele, or no functioning allele, with recurrence of 
breast cancer. Adherence to tamoxifen was not an aim of the study, and the potential impact of 
adherence on breast cancer recurrence was not discussed. 
Thompson and colleagues (2011) examined the association of CYP2D6 genotyping and 
recurrence of breast cancer in the context of adherence to tamoxifen in a large cohort of patients 
with breast cancer (n = 618).  Adequate adherence was defined as 80%, and was measured using 
a large prescription dataset. Adjusting for adherence to tamoxifen therapy increased the effect of 
CYP2D6 genotype on recurrence of breast cancer. The findings suggest that CYP2D6 genotype 
information may be helpful in determining who would most likely benefit from tamoxifen 
therapy. Similar studies examining patient genotype and adherence to oral targeted therapy were 
not found for patients with NSCLC taking an oral EGFR tyrosine kinase inhibitor. 
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2.3.5 Summary 
In summary, a comprehensive review of the literature has demonstrated that (a) NSCLC is a 
deadly and costly disease with complicated and expensive treatment regimens, (b) EGFR 
tyrosine kinase inhibitors have unique side effect profiles and potential barriers to medication-
taking including cost, (c) medication-taking behaviors for patients with chronic disorders 
receiving prescribed treatment regimens are well studied but difficult to apply to patients with 
NSCLC receiving EGFR tyrosine kinase inhibitors, and (d) medication-taking for patients with 
cancer has been studied primarily in women with breast cancer receiving hormonal therapy and 
individuals with leukemia taking imatinib. The knowledge learned is difficult to apply to 
individuals with NSCLC receiving EGFR tyrosine kinase inhibitor therapy due to the pathway-
specific nature of the medications, as well as the unique side effect profiles. Limitations to this 
research include samples of mostly women, younger age, and side effect profiles of hormonal 
targeted agents that are significantly different than those of oral EGFR inhibitors. Suggestions 
for adherence management have not been well studied in patients with cancer, and studies 
examining medication-taking behaviors in patients with NSCLC taking oral targeted therapy 
were not found. One report of a pilot study evaluating a theory-based adherence intervention in 
patients with cancer was identified, but generally, studies of medication adherence in patients 
with cancer have not been theory-driven. 
Therefore, examining the process of medication-taking in patients with NSCLC 
undergoing oral EGFR inhibitor therapy is timely, appropriate, and important. Exploratory 
research is needed to begin to develop the appropriate theoretical foundation to direct future 
investigations of adherence to cancer therapies, suggesting that qualitative, grounded theory 
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approach to examining the process of medication-taking of oral EGFR inhibitors (once chosen 
for treatment) is needed to address the identified gaps in the literature. 
2.4 SIGNIFICANCE AND INNOVATION 
Based on the review of the literature, this is the first study to describe the process of medication-
taking in patients with NSCLC who are prescribed oral targeted therapy. The examination of the 
process of medication-taking of oral EGFR inhibitor therapies for patients with NSCLC is 
significant and timely. Research has shown that novel therapies like oral EGFR inhibitor 
therapies can increase survival and improve QoL for patients with NSCLC; however, oral 
targeted therapies are a new technology with limited understanding of the implications for 
medication-taking. Cost, different side effect profiles, complicated regimens, and changing dose 
protocols may be important factors affecting medication-taking. Furthermore, patients with 
NSCLC have greater gender and ethnic diversity than published breast cancer studies of 
adherence and are older in age than published studies of individuals with CML taking imatinib 
therapy. This dissertation is timely as it has addressed the missions of the American Cancer 
Society and the National Institute for Nursing Research, specifically, the promotion and 
improvement of the health of individuals, families, communities, and populations, and is a 
research priority for the Oncology Nursing Society. 
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2.5 PRELIMINARY STUDIES 
Prior to the comprehensive exam and overview process, we conducted two pilot studies that were 
designed to answer research questions concerning medication-taking and adherence while 
developing the skills needed to perform qualitative and quantitative research.  The first is a 
qualitative study that examines medication-taking and women with early stage breast cancer who 
were taking oral hormonal therapy with anastrozole.  The second is a quantitative secondary 
analysis examining pre-treatment predictors of adherence to oral hormonal therapy for women 
with early stage breast cancer. The second manuscript is in draft form and will be finalized after 
the dissertation defense. 
2.5.1 Pilot Study #1—Keeping the boogie man away”:  Medication self-management 
among women receiving anastrozole therapy 
The impetus for this study stemmed from a discussion with the principal investigator of an 
ongoing study examining anastrozole therapy and cognitive function in women with early stage 
breast cancer. In that study, adherence is assessed continuously using the Medication Event 
Monitoring System (MEMS) (AARDEX, Ltd.), a bottle cap fitted with a microprocessor that 
records the date and time the cap is removed from a standard medication vial. It was noted that 
the MEMS cap records daily pill discharge, but the data do not provide information about how 
the women actually take their medication. Thus, the narrow concept of adherence for patients 
with cancer and the absence of research examining how women with breast cancer think about 
and take their medication left a gap in information necessary to develop and test interventions 
tailored to their needs. From 2009 to 2012, under the guidance of my mentors, we developed a 
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qualitative descriptive companion study to a larger cohort study (Cognitive Impairment Related 
to Anastrozole Use in Women; NCI 1 R01 CA 107408-01; Bender, PI; IRB0409010) to gain 
hands-on research skills through participation in their ongoing funded research. This manuscript 
was submitted to Nursing Practice and Research on June 11, 2012. 
2.5.1.1 Cover letter to Nursing Practice and Research 
June 11, 2012 
 
Annette DeVito Dabbs, PhD, RN, FAAN 
Professor 
University of Pittsburgh 
School of Nursing 
3500 Victoria Street 
Pittsburgh, PA 15231 
 
Dear Dr. DeVito Dabbs: 
 
We are submitting a manuscript for review and possible publication in Nursing Research and 
Practice. The paper discusses the methods and findings for a qualitative study examining the 
medication-taking experiences for post-menopausal women with early stage breast cancer 
receiving anastrozole therapy. This manuscript has been reviewed and approved by all authors.  
The paper has not been submitted to any other journal; this work has not been published 
elsewhere.    
 
Thank you for your consideration.  If you need further information, please contact me by mail, 
telephone or e-mail at:  
 
Karen Wickersham, PhD(c), RN 
University of Pittsburgh 
School of Nursing 
440 Victoria Building 
Pittsburgh, PA 15261 
Telephone: 412-721-5899 
E-mail: kew44@pitt.edu 
 
Sincerely, 
 
Karen E. Wickersham, PhD(c) 
Doctoral Candidate 
University of Pittsburgh 
School of Nursing  
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2.5.1.2 Abstract 
The hormonal agent anastrozole improves clinical outcomes for women with breast cancer, but 
women have difficulty taking it for the five-year course. The unique medication-taking 
experiences related to self-management of oral hormonal therapy for women with early-stage 
breast cancer are not known. Our purpose was to describe the medication-taking experiences for 
post-menopausal women with early stage breast cancer who were prescribed a course of 
anastrozole therapy. Twelve women aged 58 to 67 years, midway through therapy, participated 
in audio-recorded interviews. Women’s medication-taking experiences involved a belief in its 
importance and an imperative to take anastrozole. We found that women’s side effect 
experiences, particularly menopausal symptoms, were significant, but only one woman stopped 
anastrozole due to side effects. Medication-taking included routinization interconnected with 
remembering/forgetting and a storage strategy. Some women noted a mutual medication-taking 
experience with their spouse, but most felt taking anastrozole was something they had to do 
alone. Our results provide insight into the way women with early-stage breast cancer manage 
their hormonal therapy at approximately the midpoint of treatment. Next steps should include 
examinations of medication-taking in socioeconomically and ethnically diverse patient samples, 
potential differences between pre- and post-menopausal women, and the effects of medication-
taking on clinical outcomes. 
2.5.1.3 Introduction 
Treatment of cancer has shifted to greater use of oral cancer agents [1], transferring 
responsibility for medication management to the patient. For post-menopausal women with 
early-stage breast cancer, therapy with oral aromatase inhibitors (AIs) like anastrozole has been 
shown to improve clinical outcomes [2]; however, women have difficulty taking their medication 
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for the generally prescribed five-year course. Oral AI therapy is a “chronic” care cancer 
treatment prescribed to prevent recurrence, but most women receiving this treatment do not have 
active cancer.  
Self-management has been defined as one’s ability to manage symptoms, treatment, 
physical and psychosocial consequences and lifestyle changes fundamental to living with a 
chronic condition such as cancer [3]. For post-menopausal women with early stage breast cancer, 
self-management includes medication-taking with oral AI therapy, which requires women to 
perform complex activities, including identifying and counting pills, timing pill taking, obtaining 
and refilling prescriptions, generally for a period of five years [4]. Qualitative inquiry provides 
unique information concerning the medication-taking experiences for patients with chronic 
disorders [4-6], but little research has focused on the medication-taking experiences for patients 
with cancer. Ersek, Kraybill, and Du Pen [7] explored the reasons patients with cancer have 
trouble taking their pain medication; however, the purpose of analgesia is different from that of 
medication for prevention of recurrence of breast cancer. The two published studies examining 
medication-taking for patients with cancer have been conducted for children or adolescents with 
leukemia [8, 9], who have different issues related to medication-taking, including developmental 
concerns such as egocentrism, concrete thinking, and parental involvement [9]. Thus, our 
purpose was to describe the medication-taking experiences of post-menopausal women with 
early stage breast cancer who were receiving the oral hormonal agent, anastrozole. We sought to 
answer the question: “What are the experiences of women who take anastrozole therapy?” 
2.5.1.4 Methods 
We used qualitative description to generate a complete narrative of the medication-taking 
experiences of women with early stage breast cancer taking anastrozole therapy [10]. 
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Parent study We accessed an existing sample and data from an ongoing study, The 
Anastrozole Use in Menopausal Women (AIM) Study, which examines the effect of anastrozole 
on cognitive function in women with early stage breast cancer (“The AIM Study”). The study 
includes postmenopausal women less than 75 years old who speak and read English and have 
completed at least eight years of education. Women are excluded for self-reported hospitalization 
for psychiatric illness within the last two years, prior diagnosis of other cancers and neurologic 
illness (e.g., stroke, multiple sclerosis, dementia syndrome), and distant metastases. Women are 
followed for their 5-year course of hormonal therapy. Adherence to anastrozole is assessed 
continuously using the Medication Event Monitoring System (MEMS) (AARDEX, Ltd.), a bottle 
cap with a microprocessor that records the date and time it is removed from a standard 
medication bottle. While medication adherence measures the end-result of medication-taking, 
access to The AIM Study participants allowed us a unique opportunity to answer our research 
question about the full scope of medication-taking behaviors in this sample. 
Current study The "current study” reported here was a follow-up to The AIM Study. At 
the time we began our study (2009), most women in The AIM Study had completed at least six 
months of MEMS adherence monitoring. We conveniently sampled 12 post-menopausal women 
with early stage breast cancer from participants in The AIM Study. 
Procedure The University of Pittsburgh Institutional Review Board approved the current 
study. We contacted 47 women enrolled in The AIM Study for whom we had complete six-
month MEMS adherence data by mailings from The AIM Study PI to determine their interest in 
participating in the follow-up study. We interviewed all women who responded to the mailings. 
Interested women contacted the current study PI (KW), who then described the purpose of the 
interviews by telephone. The women provided written informed consent prior to the scheduled 
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interview, conducted at the participant’s home (n = 6) or at a convenient, private location (n = 6). 
Sixteen interviews for 12 women were audio-recorded with observational notes for recording of 
the participant’s non-verbal cues and eye contact [9]. Participants received $10 upon completion 
of the interview.   
Interviews The PI (KW) performed in-depth, semi-structured interviews, averaging 30 to 
40 minutes in length, using an interview guide of open-ended questions adapted from two 
previous qualitative studies of medication-taking [6, 11]. Questions included asking women 
about what it was like to take anastrozole, how and why they began taking it, how it made them 
feel, how it was different from their previous treatments, how they took it on a typical day and 
the strategies they used, what they found difficult about taking anastrozole, forgetting to take it, 
and who helped them. Interviews performed in a public place were shorter in duration, but not 
less informative, than those performed in the participant’s home. 
Sociodemographic and clinical data The following demographic and clinical data 
available from The AIM Study database were used to describe the sample. Sociodemographic 
information was collected using the University of Pittsburgh, School of Nursing, Center for 
Research in Chronic Disorders Sociodemographic Questionnaire. Women’s depressive 
symptoms were measured using the Beck Depression Inventory-II (BDI-II) [12]. Anxiety was 
assessed with the Profile of Mood States (POMS) Tension-Anxiety subscale [13]. Information 
concerning stage of breast cancer, tumor type, radiation therapy, and chemotherapy was 
abstracted from the patient medical record. Side effects of hormonal therapy were assessed with 
the Breast Cancer Prevention Trial (BCPT) Symptom Checklist [14, 15]. BDI-II, POMS, and 
BCPT data from The AIM Study 6-month and 18-month time points (closest to the interviews 
with the most complete data) were used for the analysis. 
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As another form of description of medication-taking of anastrozole, we categorized 
women according to their MEMS cap adherence rate: 100% adherers, good-adherers (90-99%), 
adequate-adherers (80-89%), and low-adherers (below 80%). These categories were established 
based on the literature focusing on various chronic disorders where 80% is generally good 
adherence and needed for disease maintenance [11, 16, 17]. We defined adherence as the percent 
of the prescribed doses taken. Women who discontinued or who were switched to another AI by 
their oncologist due to toxicities were included, as therapy discontinuation is an important 
variation (and consequence) of medication-taking. 
Data analyses The current study PI reviewed each transcript while listening to the 
audiotape with observational notes for accuracy and for an understanding of the participant’s 
focus. All interviews were transcribed and entered in a word document and in Atlas.ti (6.2.27) to 
manage and organize the data. Observational notes were summarized and included with each 
transcript. We developed a timeline for each woman outlining the timing of her breast cancer 
diagnosis, the start of anastrozole, and the side effects she experienced after beginning 
anastrozole to gain a sense of her overall experience with this treatment. As analysis progressed, 
interview language was refined for clarity. Probes were added concerning forgetting to take 
medication (e.g., “How did you realize you forgot?”), unexpected events that affected 
medication-taking (e.g., vacation/travel), and information received at therapy initiation (e.g., 
“What were you told about Arimidex®?”). 
Qualitative content analysis [18] was the primary method for data analysis. For each 
interview, the current study PI examined the data line by line to label (open code) text related to 
the woman’s medication-taking experiences, using the interview questions as a guide. Similar 
codes were grouped into categories, which were examined for central themes. Dimensional 
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analysis was applied to themes to detect variations, specificity, and range [19]. Matrices were 
constructed for comparison and pattern recognition of participant characteristics 
(sociodemographic, breast cancer type and treatment, adherence level), side effects, depressive 
symptoms, and anxiety merging qualitative data and quantitative measures (BCPT, BDI-II, 
POMS). Numerical counts were used to characterize the strength of the main themes and 
subthemes within each case [20]. In this report, we use “most” to describe occurrence of a theme 
in at least nine women. Turning points in the analysis included the realization that medication-
taking occurred despite side effect presence and severity and the pervasiveness of fear of breast 
cancer recurrence. Sampling, interviewing, and analysis continued until we reached 
informational redundancy, i.e., no new themes or patterns were recognized (n = 9); at that time, 
we enrolled three women for further sample diversity and to confirm existing findings. No new 
themes emerged and we achieved informational redundancy, but we cannot claim full saturation 
due to limited access to low-adherers and women who discontinued therapy. 
    We implemented the following steps to assure the trustworthiness of the data, analysis, 
and research process: a) A Co-Investigator (MBH) with expertise in qualitative methods and 
medication-taking research [6] audited the data to ensure the credibility of the analysis. b) 
Weekly group analysis meetings were conducted to discuss data exemplars, coding, and analytic 
decisions among all investigators. c) Four follow-up telephone interviews were performed to 
further clarify developing themes. For example, when several women mentioned that they had 
friends or relatives who were prescribed anastrozole and were no longer taking it, a follow-up 
question was added to further explore this experience and key informants were re-contacted to 
clarify this theme. d) All interview data, notes, and memos were documented using Atlas.ti 
(6.2.27) (ATLAS.ti Scientific Software Development GmbH, Berlin, Germany) software. 
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2.5.1.5 Results 
Participant characteristics Twelve women, aged 58 to 67 years, answered the mailings 
and were interviewed between June 2009 and April 2010. All women were white and well 
educated, and were similar to the women who participated in The AIM Study (Table 3). 
Table 3: Participant sociodemographic, breast cancer, and breast cancer treatment characteristics 
Characteristic Current study participants 
(n = 12) 
The AIM Study participants 
(N = 162) 
Age (in years) Mean 62.5 60.1 
Years of education Mean 14.8 15.1 
Marital status n (%) 
Married 
Divorced 
Never Married 
Widowed  
 
6 (50.0) 
2 (16.7) 
3 (25.0) 
1 (8.3) 
 
109 (67.3) 
20 (12.3) 
18 (11.1) 
13 (8.0) 
Ethnicity n (%) 
White 
 
12 (100.0) 
 
159(98.1) 
MEMS 6-month adherence  % 87.8 88.7 
Breast Cancer Treatment n (%) 
Radiation therapy 
Mammosite therapy 
Chemotherapy with     
anastrozole 
 
11 (91.7) 
1 (8.3) 
2 (16.7) 
 
32 (19.8) 
12 (7.4) 
25 (15.4) 
Note. MEMS = Medication Event Monitoring System (AARDEX, Ltd.) 
Eleven women had been taking anastrozole for two and one-half to three years at the time 
of the interview. One woman discontinued anastrozole after six months, and was then switched 
to another AI by her oncologist due to arthralgias. At the time of her interview, she had 
discontinued all AI therapy due to side effects. Women in the current study had 6-month 
adherence levels ranging from 38.4% to 100% (mean = 87.8%), which were similar to women 
participating in The AIM Study (mean = 88.1%). 
In their interviews, the women shared their perceptions about anastrozole (“what I 
think”), their experiences with side effects and side effect severity (“how it makes me feel”), and 
their day-to-day self-management of anastrozole (“what I do”). These three main topical 
categories describe their engagement in self-management of anastrozole and represent key 
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dimensions of self-management in this early phase of breast cancer survivorship. These 
categories involved an overarching belief in the importance of anastrozole, as well as an 
imperative to take it. We found that though the women’s side effect experiences were significant, 
only one woman stopped taking anastrozole due to side effects. The women’s day-to-day 
medication-taking experiences with anastrozole incorporated physical, temporal, and social 
aspects which women described as an individual responsibility or a social enterprise.  
“Keeping the boogie man away”:  Importance of taking oral hormonal therapy 
All women assigned a sense of the value, purpose, or importance to anastrozole that offset other 
challenges associated with managing anastrozole, including side effect severity. The importance 
of anastrozole was defined as a woman’s awareness or beliefs about therapy, the value, benefit, 
or relative worth of taking anastrozole, and her commitment or motivation to take anastrozole. 
Most women reported that side effects from anastrozole would not deter them from taking 
anastrozole therapy.  
I still take it. I still take it . . . if I thought that the medication was going to make 
me have early- onset dementia, I would think about it more, and I do know 
there’ve been some thoughts about that, but I still take it. I don’t want to, (lowers 
tone) get breast cancer again, so, I take it. 
 
 Most women used imagery rather than the term “cancer recurrence” when discussing 
their beliefs and motivation to take anastrozole: “I’m taking it to keep the boogie man away.” 
Another took it to keep “loose cells [from] traveling where they shouldn’t.” Another woman 
said, “That’s very important, that pill . . . I want to live . . . I want to stay healthy.” One 
participant with 100% adherence described a heightened consciousness about the role of 
anastrozole: 
I was conscious of saying, ‘Okay, do your job in there, Arimidex.’ . . . it was a 
funny thing. I didn’t experience that in the first year and maybe only because I 
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was experiencing those other things [side effects]. But, there was this short period 
of time where I’d take my water, drink it down and say, ‘Okay, do your thing, 
Arimidex, get in there, kill any cells that you see . . .’ 
 
 Conversely, two women implied nonchalance toward taking anastrozole and indicated 
that it was “no big deal” to take or to miss a dose of anastrozole. One woman stated, “Well, if I 
miss a day, it’s not a big deal.” The second woman described her views of missing a dose versus 
the medication’s importance, incorporating imagery:  
So I think if you’re taking Arimidex over years, they’re [adrenal glands] not going 
to all of a sudden, if you miss one, they’re not going to all of a sudden get back 
going again when they’ve been put to sleep as . . . for as long as they have been . . 
. I mean if you skipped a whole month . . . or even a whole week . . . that might be 
a different story . . .’ cause then they’d start getting their act back together. 
  
 Although all women recognized the value of taking anastrozole, some interviews 
suggested tension between the desire to prevent cancer recurrence and uncertainty about taking 
anastrozole. This woman’s comments further revealed ambiguity regarding the value of the 
medication in preventing cancer recurrence:  
To me, the benefit of not getting cancer, whether it’s breast or some other site, is 
certainly more advantageous than putting up with a little bit of wrinkles or some 
other problem . . . but on the other hand, you wonder. 
   
Women further indicated that there was a necessity or obligation to take anastrozole that 
went beyond their belief in its importance. This treatment imperative included her commitment 
to the program and “wanting to get to the finish line.” The imperative was self-motivated, “I 
would never dream of quitting” “I truthfully want to do the five years. I want to complete the 
program as is,” or externally motivated from a relative, a friend, or a health care provider, “My 
mom . . . would push me to take it and say ‘you need to continue on this.’” Several women 
mentioned the imperative to take anastrozole “on doctor’s orders.”  “He told me that I’d have to 
take it, and so I took it.” 
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Being thrown back into menopause: Side effects and side effect severity For all 
women, the opening question (“Tell me about your experience taking anastrozole”) led, without 
prompting, to a description of the side effects of anastrozole. All women immediately described 
their challenges with hot flashes and associated sleep disturbances, arthralgias, fatigue, “female 
things”, weight gain or loss, and their struggles with forgetfulness or memory loss, regardless of 
their MEMS cap adherence level. The women described the timing of when side effects occurred 
in relation to starting anastrozole (e.g., within a few months or right away), the time of day the 
side effects occurred, and the duration of the side effects (e.g., lasting a few minutes). They 
described how the side effects affected their daily life or altered their lifestyle, characterization 
(e.g., “like a torch”), frequency (e.g., occurring every few hours), and their attribution that the 
side effect was due to anastrozole, another therapy, or a process such as aging. One woman 
experiencing menopausal-like symptoms stated anastrozole “threw me back into menopause.” 
Another characterized her hot flashes: 
Overall it feels like a torch . . . the chest area and face and forehead; my 
forehead’s like soaking wet now . . . they come on real fast and last about a 
minute or two . . . during the night I might wake up it seems every two hours . . . 
like at midnight, two o’clock, four o’clock, six o’clock, and you know it wakes 
me up and sometimes I can’t go back to sleep so that is an additional problem. 
 
 One woman who took anastrozole in combination with chemotherapy described her 
experiences with memory problems: 
The only thing I do have a problem with, and I have noticed it, is my memory. 
Now I’m remembering a lot of things . . . today, talking to you, but if somebody 
said, ‘Well, I told you that yesterday,’ or ‘Don’t you remember I . . .’ ‘I can’t 
remember.’ I have to really think, and that scares me. I mean I had a bad memory 
before (laughs) . . . but it, it is worse. It is, it is worse. 
 
 The woman who discontinued AI therapy due to hip pain described her experiences and 
the related uncertainty of the underlying cause of her pain: 
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I think once you have cancer you start to think, ‘Is this mets to the bone, or is this 
mets somewhere else . . . or is it a side effect from the medication’…when I take 
medication, I try not to read the side effects unless I’m having problems and then 
I go to the side effects and say, ‘Ah, yeah, maybe this is it.’  But when I started . . 
. in my hips, and it was at night and I was having trouble sleeping, I just decided 
that . . . this [anastrozole] wasn’t for me. 
 
 To further explore the problem of the women’s side effects and side effect severity, we 
constructed profiles of side effects for each participant by combining those side effects reported 
in interviews with information from the BDI-II, POMS, and BCPT (Table 4).  
Table 4: The women’s self-reported side effects 
ID Hot 
flashes 
Arthralgias Sleep 
distur-
bance 
Fatigue Weight 
gain or 
loss 
Anxiety / 
Depressive 
symptoms 
“Female 
things” 
Cognitive 
problems 
1 B Both  I B BDI-II, P  B 
2  Both I  B BDI-II, P Both Both 
3*  Both   B BDI-II, P, I BCPT I 
4 Both  I  B BDI-II, P Both B 
5 B    Both BDI-II, P  B 
6 Both B I   BDI-II, P B B 
7 Both B   B BDI-II, P B B 
8 Both B I I Both BDI-II, P  Both 
9 Both B I I B BDI-II, P  B 
10 Both Both I   BDI-II, P B B 
11 B Both   B BDI-II, P B B 
12 Both Both I I  BDI-II, P  Both 
Note.  Arthralgias were defined as aches, pains, and joint pains.  “Female things” were defined as vaginal itching, 
vaginal bleeding, vaginal discharge, or pain with intercourse. 
B = Symptoms reported by the participant on the Breast Cancer Prevention Trial (BCPT) Symptom Checklist only 
I = Symptoms reported by the participant during the interview only. 
Both = Symptoms reported by the participant in both the interview and the BCPT. 
P = Anxiety reported by the participant in the Profile of Mood States (POMS) Tension-Anxiety Subscale 
BDI-II = Depressive symptoms reported by the participant in the Beck Depression Inventory-II Scale 
* = This participant was the only woman to specifically express depressive symptoms or anxiety in her interview. 
 
Participants reported three to six side effects; most women (n = 10) reported five or more 
side effects. The two women classified as “low-adherers” reported the same type and number of 
side effects as the two 100% adherers. The woman who discontinued AI therapy due to side 
effect severity was classified as a “good” adherer and reported the same five side effects as the 
other women. Women expressed varying levels of depressive symptoms and anxiety when 
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completing the BDI-II and POMS surveys, but only one expressed these symptoms during her 
interview, and her scores did not indicate depression or anxiety. This mixed data analysis 
revealed no patterns between symptom number, type, and severity and adherence category. 
 Women also described the strategies they used to treat their side effects (e.g., 
pharmaceuticals, physical therapy), as well as daily management or compensation strategies. For 
example, one woman avoided or limited her activities, while another wrote down tasks or names 
to remember them. The woman with “summertime blues” described how she compensated for 
her memory and word-finding problems: 
I’ve worked with lots of women, and we all say (laughter) estrogen, the 
menopausal breakdown.  But, I have days when I just . . . can’t remember things 
like names or specific words for thoughts . . . And I’m usually really good. I love 
words, and I’m usually pretty good with them. But, I just have days when I can’t, 
and I’m not as articulate . . . I just finished helping with the summer camp and we 
had about 18 college counselors . . . I remembered all their names, and once in a 
while I’d completely blank . . . but I had a notebook, I had my cheat sheet. 
Doing it yourself:  medication self-management 
Physical All women described in detail the actual hand-to-hand, tangible characteristics 
of taking anastrozole. Many women mentioned that the pill was tiny and easy to swallow. 
However, when anastrozole was packaged in blister packs for a short time (e.g., a few months), 
the women expressed extreme difficulty and irritation with opening the blister pack. One woman 
described receiving two three-month supplies of anastrozole packaged in blister packs: 
. . . My husband had to get them out . . . Arimidex people ought to know that that 
is not acceptable.  (Laughter)  Maybe they found that out . . . but I’ll tell you that 
was the only time that I considered stopping. Because I have arthritis in my hands 
. . . and they’re old hands. . . it was very, very difficult. I couldn’t put it through, 
you know, so I tried to use a penknife, I tried to flip up the little foil thing . . . and 
sometimes I’d try to slice off the bubbles like this.  (Gestures).  It’s just hard.  I 
couldn’t do it. 
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Temporal Central to self-management of anastrozole for all of the women was the 
routinization or integration of anastrozole into their everyday lives as anastrozole-taking became 
a consistent, accepted, or habitual medication self-management practice. They described timing 
anastrozole administration with meals or other medications, associating it with a visual cue (e.g., 
seeing the bottle on the window sill), a central location (e.g., kitchen), or a storage strategy (e.g., 
weekly pill minder). Women stated that participation in The AIM Study helped to routinize their 
medication-taking practice. Most (n = 11) were already taking other prescription medications, 
vitamins, or supplements and incorporated anastrozole within their established routine. 
Associated with routinization was remembering/forgetting to take anastrozole and their 
realization, reaction, and strategies for taking anastrozole after forgetting a dose: 
I was in that AIM Study and I had the little bottle, and I swear I took it every day, 
but there was a few times when she (study nurse) put it on the little machine to 
see that I had missed it a few times. Now last night I went to bed and I 
remembered about 1:00 [AM] and I came down the steps and took it. 
 
Frequently, remembering was linked to a certain time of day or a storage strategy, such as 
a weekly pill container. For example, one woman stated she did not forget to take her anastrozole 
“’Cause I take it with my morning vitamin, my calcium, and fish oil.”  Another woman 
described: 
When I started it, that’s when I put into my day [pill minder] . . . I’ve had no 
trouble remembering to take it, and that seems to be a good time [after supper] 
since its after my work day, except when I have a meeting, I don’t forget. 
 
Although women felt they remembered to take anastrozole, over half stated they 
occasionally missed a dose, only realizing it when noticing the pill was still in the container or 
her pocket, or when the MEMS cap was downloaded. Both low adhering women discussed the 
management of their missed doses in a similar manner.  
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Sometimes I might play the 12 hour shuffle if I know I didn’t take it the night 
before . . . maybe I’ll take it in the morning, and then at bedtime, so it’s probably 
putting two in one day, but trying to spread them apart, so it’s not quite the same.  
 
Social Some women described medication-taking as a social or a “mutual medication-
taking” experience, referring to taking anastrozole at the same time a spouse or other family 
member took their own medications. Several women mentioned they had friends or relatives who 
were prescribed anastrozole and were no longer taking it. They denied that this deterred them 
from taking their own anastrozole. Most women described a “solitary” experience in which no 
one can or needs to help with taking anastrozole. A woman who lived alone stated, “I just have 
to do it.” Another stated, “ . . . I don’t think he [husband] thinks about me taking my medication 
at all.”  
Women were told by their health care provider (HCP) to take anastrozole daily, but were 
given no other instructions. They expressed willingness to discuss their side effects with their 
oncologist or HCP; however, they were rarely asked about their experiences. In some cases, they 
received conflicting advice from HCPs. When discussing her foot pain, one woman indicated, 
“Foot doctor says no [unrelated to anastrozole]. Everyone else says ‘Ah, yeah.’”  
2.5.1.6 Discussion 
Our purpose was to describe the medication-taking experiences of post-menopausal women with 
early stage breast cancer who were receiving anastrozole therapy. The women’s engagement in 
the self-management of their anastrozole involved a predominant belief in the importance of 
anastrozole, as well as an imperative to take it. We found that though the women’s side effect 
experiences were significant, only one woman stopped taking anastrozole due to side effects. All 
medication-taking practices included routinization that was interconnected with 
remembering/forgetting to take anastrozole and a storage strategy (e.g., pill minder). Some 
  
 51 
women noted a mutual medication-taking experience with their spouse, but most felt that taking 
anastrozole was something they had to manage alone. 
Little research has addressed the beliefs about therapy for women with breast cancer 
receiving anastrozole therapy. For example, The ATAC Trialists’ Group [2] found that fewer 
women withdrew from therapy with anastrozole when compared to tamoxifen, but the reasons 
for discontinuation were not reported. In the current study, all women, particularly those 
classified as adequate- and low-adherers, mentioned in some way the importance of taking 
anastrozole, in some cases referring to it as “no big deal.” The use of personification in many of 
the women’s speech is further evidence of the value and power that the women assigned to 
anastrozole.  
In a qualitative comparison of 13 stroke patients who were classified as high- and low-
adherers, Chambers and colleagues [21] found that both groups reported intentional and non-
intentional adherence. Although some low-adherers in Chambers’ [21] study reported 
occasionally skipping a medication, stability of a medication routine and beliefs about 
medication were central themes describing medication self-management in our sample. Pound 
and colleagues [22] discussed in a metasynthesis of qualitative studies of lay medication-taking 
experiences that few studies focus on those who reject their medications or take their 
medications without questioning. Our results suggest that those who take anastrozole without 
question may do so because they believe in the medication’s value and importance. 
The side effects the women reported were consistent with reports of menopausal 
symptoms induced by breast cancer treatment [23, 24], as well as with previous qualitative 
research describing women’s experiences with hot flashes, the impact on daily life, and the 
higher priority that women placed on breast cancer treatment over menopausal symptoms [24-
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27]. Garreau and colleagues [28] found that women receiving AIs switched therapy more often 
(47.5%) than those taking tamoxifen (37%). Salgado and Zivian [29] found that 30% of women 
discontinued AI therapy; of those, 84% discontinued due to side effects. 
Given these findings, we would have expected women in the current study to describe 
switching or discontinuing AI therapy more often, but 11 of 12 women indicated that side effects 
did not deter them from taking anastrozole. The fact the women who were lower-adherers 
reported the same type and number of side effects as those who were 100% adherers is 
interesting and suggests that side effects related to AI therapy are significant to women midway 
through treatment. The impact of side effects on the medication-taking process with AI therapy 
for breast cancer prevention requires further examination. It is possible that completion of the 
BCPT, POMS, and BDI II surveys may have primed the women to describe the side effects that 
they felt were the most important, most persistent, and/or most present.  
  Self-management of anastrozole included physical, temporal, and social aspects of 
taking medication interwoven with remembering and forgetting. This is consistent with research 
examining medication-taking for patients with chronic conditions [4, 5, 30, 31]; however, in the 
current study, mutual-medication-taking went beyond social support, or reminding or assisting 
patients with their medications [4]. Rather, it included a partnership with a spouse in the physical 
taking of anastrozole that was part of her daily routine. Furthermore, self-management of 
medications often involves coordination between the patient and the health care team. In the 
current study, several women expressed taking anastrozole “on doctor’s orders,” but the women 
reported receiving little else in the way of instructions concerning medication use, side effects, 
and daily management of anastrozole. 
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The most significant limitation in the current study is the potential influence of 
participation in The AIM Study. The women who participated in the interviews were neither 
naïve to research nor to anastrozole adherence, which may have affected their responses. We 
interviewed all women who responded to the mailings, but most of them were already successful 
in self-management of anastrozole. Women may have had difficulty recalling their early 
experiences taking anastrozole, or they may have been primed to discuss side effects due to the 
recent completion of The AIM Study surveys. All women in the current study were white and 
well educated. Racial/ethnic disparities in treatment may affect self-management of medication 
and should be investigated. 
The women in the current study were all approximately midway through their five-year 
course of therapy; therefore, they may have been more established in their medication-taking 
routines and less likely to discontinue anastrozole therapy. Interviewing women at earlier points 
in their treatment may help elicit the full scope of how side effects of hormonal therapies affect 
medication-taking. While we reached information redundancy in our sample, we did not saturate 
with regard to those who were low-adherers or who had stopped AI therapy. We were able to 
interview one participant who had discontinued anastrozole; however, we may have missed 
women at the beginning of their treatment who discontinued or were switched to other AIs.  
Nonetheless, our results provide insight into the way women at approximately the midpoint of 
their hormonal therapy manage their medications, and thus may inform interventions that would 
aid them in completing the full five years of anastrozole therapy. 
2.5.1.7 Conclusion 
The women’s experiences suggest several implications for medication self-management. Given 
that women were offered minimal information about taking anastrozole therapy, provision of 
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information about anastrozole, its side effects, and how and when to take it may be beneficial, 
beginning with the first clinic visit with ongoing reassessment at subsequent clinic visits. 
Second, while most women indicated they experienced similar side effects, the trajectory of 
those side effects differed among the women. This suggests that ongoing side effect assessment 
is needed even after therapy is well established. Finally, questions focusing on the patient’s 
medication-taking experiences as a whole, rather than an overall verbal assessment of adherence, 
may prompt further discussion, including why they do or do not take their medication. 
Our study offers a unique perspective into the medication-taking experiences of 
postmenopausal women with early stage breast cancer who were midway through a course of 
anastrozole who were successful at self-management of anastrozole therapy. While reports 
examining the end result of self-management of medication have been published, reports of 
research explaining how women view their experiences taking oral hormonal therapy are 
lacking. Our results help explain why women, regardless of their measured adherence level, take 
anastrozole therapy without question and continue despite the side effects of anastrozole. Next 
steps should include examinations of medication-taking concerning: a) socioeconomically and 
ethnically diverse patient samples; b) potential differences between pre- and post-menopausal 
women, particularly side effect severity and medication-taking; c) effects of medication-taking 
on clinical outcomes; and, d) women with breast cancer taking oral targeted therapies.   
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2.5.2 Pilot Study #2—Patient-, illness-, or treatment-related baseline predictors of 
nonadherence to oral hormonal therapy 
This study provided training in quantitative methods and analysis and in-depth analysis of 
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oral hormonal therapy. The manuscript is in draft form and is formatted for Nursing Research.   
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2.5.2.3 Abstract 
Background: Adjuvant treatment with hormonal therapy improves clinical outcomes for breast 
cancer, but women have difficulty adhering to the five-year regimen. Objectives: To explore pre-
treatment predictors of short-term nonadherence to oral hormonal therapy for women with early 
stage breast cancer from the baseline assessment to six months post-treatment. Methods: A 
secondary analysis was performed using data collected from 198 women enrolled in one of two 
longitudinal cohort studies. Nonadherence was defined as the percentage of prescribed doses of 
hormonal therapy not taken during the first six months of therapy measured using an electronic 
medication event monitoring system. Information on predictor variables was measured at pre-
treatment using self-report and medical record review. Linear regression analysis was performed 
to examine relationships between predictor variables and six-month nonadherence in a univariate 
manner to first identify candidate predictors variables at p = .20 and then multivariately 
considering candidate predictors identified through stepwise and backward elimination 
regression methods. Results: Participants were white (98.3%), well educated (15.0 ± 2.9 years), 
and on average 59.1 ± 7.5 years of age. Mean nonadherence was 11.6%. Stepwise and backward 
elimination modeling algorithms identified the same set of predictors associated with six-month 
nonadherence and explained 11.0% of the variance (adjusted R2 = .10, s = 0.27). 
Clerical/administrative primary occupation (p = .015), ductal carcinoma in situ tumor type (p = 
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.006), and higher weight concern scores (p = .004) were jointly associated with nonadherence. 
Discussion: The findings suggest additional examinations of nonadherence concerning work and 
symptom burden and their relationship to nonadherence are indicated. 
2.5.2.4 Introduction 
For women with breast cancer, adjuvant treatment with oral hormonal agents has been shown to 
improve clinical outcomes. Five years of tamoxifen, a selective estrogen receptor modifier 
(SERM), is prescribed for pre- and peri-menopausal women with hormone receptor positive, 
early stage breast cancer (Jonat, Pritchard, Sainsbury, & Klijn, 2006). Aromatase inhibitors 
(AIs), such as anastrozole, are superior to tamoxifen in reducing the risk of disease recurrence 
and contralateral disease in postmenopausal women (Newman & Singletary, 2007). Despite the 
clear therapeutic benefits of oral hormonal therapy, adherence, the “extent to which patients 
follow the instructions they are given for prescribed treatment” (Haynes, Ackloo, Sahota, 
McDonald, & Yao, 2008, p. 2), remains challenging for women with breast cancer.    
A number of patient-, illness-, and treatment-related factors have been shown to affect 
nonadherence to both tamoxifen and AIs but with varied results. For example, researchers have 
examined patient-related factors such as age and socioeconomic status (SES) and their 
relationships to nonadherence to tamoxifen therapy; however, both younger (< 45 years)  (Kahn, 
Schneider, Malin, Adams, & Epstein, 2007; Partridge, Wang, Winer, & Avorn, 2003) and older 
women (> 65 to 85 years) (Barron, Connolly, Bennett, Feely, & Kennedy, 2007; Partridge et al., 
2003) have been shown to be more likely to discontinue tamoxifen therapy than women ages 45 
to 65. Partridge and colleagues (2003) found that “non-white” women were more likely to 
discontinue tamoxifen therapy than “white” women. Lebovits and colleagues (1990) found that 
women who discontinued oral chemotherapy had a significantly lower SES (p < .02) than 
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women who continued their therapy; however, oral chemotherapeutic agents typically have 
different side effect profiles from those of oral hormonal therapies due to different mechanisms 
of action that could differentially affect adherence.   
The relationships between other patient-related factors such as depression and anxiety 
and nonadherence to tamoxifen therapy are not well defined. Significantly higher tamoxifen 
nonpersistence (early discontinuation) rates have been shown for women who reported problems 
with mood (36%) versus women who reported no mood problems (12%) (Demissie, Silliman, & 
Lash, 2001). Use of antidepressant agents in the year before initiation of tamoxifen therapy has 
been associated with tamoxifen nonpersistence (Barron et al., 2007). Lebovits and colleagues 
(1990) found that women who discontinued self-administered chemotherapy had higher 
depressive symptom disturbances than women who did not discontinue therapy (p < .05). 
Nonetheless, depression and anxiety are related to nonadherence in individuals with chronic 
illness (Rubin, 2005) and in women at risk for breast cancer (Cohen, 2002).  
Treatment-related factors such as higher breast cancer stage (stage II) (Lebovits et al., 
1990) and prior chemotherapy (Fink, Gurwitz, Rakowski, Guadagnoli, & Silliman al., 2004) 
have been reported to be less associated with discontinuation of tamoxifen therapy. Positive 
hormone receptor status has ben associated with both ongoing tamoxifen use at four years (Kahn 
et al., 2007) and with stopping tamoxifen therapy by the second year (Fink et al., 2004). 
Partridge and colleagues (2003) found that women with mastectomy versus breast conserving 
surgery were more likely to be nonadherent to tamoxifen therapy. No published reports 
specifically examining women’s menopausal status as a potential predictor of adherence to either 
tamoxifen or AIs were found. 
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Side effect severity and discontinuation of tamoxifen has been examined with mixed 
results. Fink and colleagues (2004) reported that side effects were not associated with 
discontinuation of tamoxifen; however, other researchers have reported that women who 
experienced side effects were more likely to stop taking tamoxifen (Demissie et al., 2001; Kahn 
et al., 2007). Grunfeld, Hunter, Sikka, and Mittal (2005) have reported that of those who 
discontinued therapy with tamoxifen, 46% discontinued due to side effects. Generally, hot 
flushes and night sweats were the primary concern.  
Nonadherence or nonpersistence to AIs related to side effects has been evaluated mostly 
in the context of clinical trials. In the Arimidex, Tamoxifen, Alone or in Combination (ATAC) 
trial (2002), there were fewer women who withdrew from therapy with anastrozole compared to 
tamoxifen; however, higher nonpersistence rates with AIs were noted in similar trials comparing 
exemestane and letrozole with tamoxifen (Coombes, Hall, & Gibson, 2004; Goss, Ingle, & 
Martino, 2003). Younger age, out-of-pocket costs of greater than $30 US per AI prescription, no 
mastectomy, and higher co-morbid condition burden have been associated with 12-month 
nonadherence to AI therapy (Sedjo & Devine, 2011). In a qualitative analysis of the medication-
taking experiences for women with early-stage breast cancer who were midway through a five-
year course of anastrozole therapy (Wickersham, Happ, & Bender, under review; Wickersham, 
Happ, & Bender, 2011), most women (11/12) (91.7%) continued to take anastrozole due to a 
strong belief in its importance despite side effect severity.  
Adherence to oral hormonal therapy for women with breast cancer remains difficult. 
Patient-, illness-, and treatment-related factors have been associated with adherence to oral 
hormonal therapy with tamoxifen and AIs but with inconsistent findings, and menopausal status 
was not reported. Further exploration of pre-treatment predictors of nonadherence to oral 
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hormonal therapies, including women’s menopausal status (pre- or post-menopausal), may help 
identify women with early stage breast cancer who are at risk for nonadherence. Therefore, our 
aim was to explore pre-treatment patient-, illness-, and treatment-related predictors of short-term 
nonadherence to oral hormonal therapy for women with early stage breast cancer (Stage I, II, or 
IIIa) from the pre-treatment assessment (pre-hormonal therapy) to six months post-treatment. We 
hypothesized that (a) age and marital status are positively associated with nonadherence, and the 
number of years of education, employment status, and primary occupation are negatively 
associated with nonadherence. (b) Prior hormonal replacement therapy within the last three 
months, radiation therapy, and tumor type are negatively associated with nonadherence to 
hormonal therapy; women’s menopausal status (pre- or post-menopausal), stage of breast cancer 
and treatment with chemotherapy are positively associated with nonadherence to hormonal 
therapy. (c) Perceived severity of side effects of hormonal therapy, depressive symptoms, 
fatigue, and anxiety are negatively associated with nonadherence for women with early stage 
breast cancer. 
2.5.2.5 Methods  
This investigation was a secondary analysis of two longitudinal cohort studies: (a) The 
Anastrozole Use in Menopausal Women (AIM) Study, which examined the effect of anastrozole 
on cognitive function in women with early stage breast cancer and explores whether anastrozole 
adherence mediates cognitive function in this sample; and (b) Predictors of Adherence to 
Hormonal Therapy in Breast Cancer (The ONS Study), which examined the pattern of 
adherence, patient and illness/treatment predictors of adherence, and moderation effects between 
patient factors and illness/treatment factors to hormonal therapy in women with early stage 
breast cancer. The University of Pittsburgh Institutional Review Board approved both studies. 
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The ONS Study was guided by Christensen’s (2000) Interactionalist Framework for Adherence, 
which posits that the interaction of patient factors with illness/treatment factors provide the main 
influence over adherence in persons with chronic illness. 
Setting and Sample The present analysis was performed on one combined dataset from 
the baseline (pre-initiation of adjuvant endocrine therapy) assessments from both The AIM and 
ONS Studies. Both studies assessed adherence in the same manner and had similar inclusion 
criteria; therefore, the two samples were combined into one dataset. Both studies included 
women less than 75 years who were able to speak and read English and who had completed a 
minimum of eight years of education. Women were excluded for self-reported hospitalization for 
psychiatric illness within the last two years, prior diagnosis of neurologic illness, distant 
metastases including the central nervous system, and prior diagnosis of cancer. Because The 
AIM Study focused on women who were receiving therapy with anastrozole, only post-
menopausal women were included in the study; however, both pre- and post-menopausal women 
were enrolled into The ONS Study. Women who received oral hormonal therapy alone or in 
combination with chemotherapy were included in the present analysis.  
Variables and Measures Adherence to hormonal therapy was continuously assessed 
over the first six months of therapy with the Medication Even Monitoring System (MEMS) 
(AARDEX, Ltd.). The MEMS is a bottle cap fitted with a microprocessor that records the 
date/time the cap is removed from a standard medication vial. The MEMS cap records each 
medication-taking event, including patterns and timing of doses and allows for detection of 
missed and extra doses (Cramer, Scheyer, & Mattson, 1990). Nonadherence (dependent variable) 
was defined as the percentage of prescribed doses of hormonal therapy not taken during the first 
six months of therapy. For consistency with current literature concerning adherence for patients 
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with chronic illnesses, including patients with cancer, nonadherence was defined as < 80% 
(Osterberg & Blaschke, 2005). 
Patient-Related Variables Patient-related factors assessed included sociodemographic 
variables, hormone replacement therapy (HRT) use in the last three months, depressive 
symptoms, anxiety, and fatigue. Sociodemographic variables included women’s employment 
status, primary occupation, age, total number of years of education, HRT in the last three 
months, and marital status. Because the combined sample of women was 98.3% Caucasian, 
race/ethnicity was excluded as a predictor variable due its limited variability. Sociodemographic 
information was collected using the University of Pittsburgh, School of Nursing Center for 
Research in Chronic Disorders (CRCD) Sociodemographic Questionnaire. 
Women’s self-reported depressive symptoms were measured using the Beck Depression 
Inventory-II, a 21-item, self-report measure on which women rate depressive symptoms and 
attitudes on a four-point Likert scale (Beck, Steer, & Brown, 1996). The score is the sum of 
responses for items. The Cronbach’s alpha coefficient for 500 outpatients with mental disorders 
was .92 and for 120 college students was .93. The BDI-II correlates strongly with the major 
depression episode portion of the Structured Clinical Interview for DSM-IV Axis I Disorders 
(.83) (Sprinkle et al., 2002; Stukenberg, Dura, & Kielcolt-Glaser, 1990)  and the Revised 
Hamilton Rating Scale for Depression (.71) (Beck et al., 1996; Spreen & Straus, 1998).  
Anxiety was assessed with the Profile of Mood States (POMS) Tension-Anxiety 
subscale, a 9-item, self-report subscale in which women’s adjectives of heightened 
musculoskeletal tension (somatic and observable) are rated on a five-point Likert scale (McNair, 
Lorr, & Droppleman, 1992). The score is the sum of responses for items. Internal consistency 
was .92 and test-retest reliability was .70 in 1000 psychiatric outpatients (McNair et al., 1992). 
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The POMS is sensitive to changes in anxiety levels in patients with cancer (Cassileth et al., 
1992). Fatigue was measured using the POMS Fatigue-Inertia subscale, a seven-item, self-report 
subscale in which adjectives of weariness, inertia, and low energy levels are rated on a five-point 
Likert scale (Mason, Matsuyama, & Jue, 1995).  The score is the sum of responses for items. 
Illness- and Treatment-Related Variables Information concerning stage of breast 
cancer, tumor type, radiation therapy, and chemotherapy was abstracted from the patient medical 
record. Women’s menopausal status (pre- or post-menopausal) was determined using a 
combination of the women’s natural menopause status at entry into each study and the MEMS-
monitored medication. In the case where natural menopause status was missing, the MEMS-
monitored medication (anastrozole, letrozole, extramestane, multiple AIs, or tamoxifen) 
determined the participant’s menopausal status, since they are prescribed according to 
menopausal status.  
Side effects of hormonal therapy were assessed with the Breast Cancer Prevention Trial 
(BCPT) Symptom Checklist, a self report measure of the degree that women are bothered by 43 
treatment- and menopausal-related symptoms in the past four weeks (Ganz et al., 2000; Stanton, 
Bernaards, & Ganz, 2005). Women rate symptoms on a five-point Likert scale (0 = not at all to 4 
= extremely). Eight-factor (Stanton et al., 2005; Terhorst, Blair-Belansky, Moore, & Bender, 
2010) and seven-factor (Cella et al., 2007) structures have been reported for the BCPT. For 
consistency, the eight subscales used in The AIM Study were calculated in the present secondary 
analysis:  vasomotor symptoms, gastrointestinal (GI) symptoms, bladder control, cognitive 
symptoms, weight concerns, musculoskeletal pain, gynecological symptoms, and dyspareunia. 
Subscale scores are the average score for items in each subscale, and the total score is the 
average score across all items. Cronbach’s alphas for subscale scores range from .43 to .83 for 
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women with breast cancer receiving hormonal therapy. BCPT subscale scores are significantly 
related to scores on the SF-36 Physical Health and Mental Health subscales (p = .05 to .001) 
(Alfano et al., 2006; Terhorst et al., 2010). 
Statistical Analyses All statistical analyses were performed with IBM® PASW® Statistics 
v.19.0 (Armonk, NY). Descriptive statistics were performed to describe the data distributions 
and to characterize the study sample. The independent samples t-test (or Mann-Whitney U-test, 
if data were non-normal) and the Chi-square test of independence (or Fisher exact test, if cell 
sizes were sparse) were used to compare women in The AIM Study with women in The ONS 
Study at pre-treatment to investigate whether certain characteristics may be more associated with 
study membership. Data were screened for accuracy of input, univariate and multivariate 
outliers, missing data, multicollinearity and severe violations in the underlying assumptions for 
multiple linear regression. Linearity of continuous predictor variables was assessed by examining 
bivariate scatterplots. Participants with large amounts of missing data (e.g., entire BDI, POMS, 
or nonadherence values missing) were removed from the data set. For categorical predictors, 
sparsely populated categories were collapsed in a meaningful way to limit the sparseness of cells. 
Multiple linear regression analysis was used to examine patient-, illness-, and/or 
treatment-related factors that predict short-term nonadherence to oral hormonal therapy for 
women with early stage breast cancer from the pre-treatment assessment (pre-hormonal therapy) 
to six months post-treatment. Statistical analyses for evaluation of the candidate predictors were 
completed in two stages. The univariate associations between each candidate predictor variable 
and the outcome variable (six-month nonadherence) were assessed using a cut-off of p = .20. 
Those predictor variables meeting the criteria of p = .20 were retained for further consideration 
in the multivariate analysis using multiple linear regression. The second stage of analysis 
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employed multiple linear regression analyses using both stepwise and backward modeling 
algorithms to identify the predictors of six-month nonadherence. Candidate predictors were 
retained if they remained associated at p < .10 in the multiple linear regression analysis.  
Although the multicollinearity statistics were within acceptable limits for all variables, 
depressive symptoms, anxiety, and fatigue were highly correlated with each other. Thus, the 
potential for an interaction between depressive symptoms and anxiety were explored. An 
interaction variable was created using both the centered and un-centered values of depressive 
symptoms and anxiety. The interaction variable was then added to the baseline predictor model 
containing the main effects of predictors and assessed for the change in the model R2 and the 
statistical significance of the added interaction term. Minimal change in R2 was noted, and both 
were not statistically significant. When potential interaction variables were created for primary 
occupation, ductal carcinoma in situ (DCIS) tumor type, and weight concerns and tested in a 
similar fashion, no significant change to the stepwise model was noted; however, the backward 
elimination model demonstrated that primary occupation, weight concerns, and the interaction 
between primary occupation and DCIS tumor type were statistically significant. 
2.5.2.6 Results 
A summary of the descriptive statistics for both the combined sample and by study (AIM or 
ONS) is provided in Table 5.  
Table 5: Sociodemographic characteristics of the combined sample of women 
 AIM Study 
(n = 162) 
ONS Study 
(n = 36) 
Combined Sample 
(N = 198) 
Age (in years) 
     Mean (SD) 
 
60.6 (6.1) 
 
52.4 (9.5) 
 
59.1 (7.5) 
Education (in years)    
     Mean (SD) 15.1 (3.0) 14.8 (2.7) 15.0 (2.9) 
Marital status   
     n (%)    
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        Never married 
        Currently married 
        Widowed 
        Separated 
        Divorced 
18 (11.1) 
109 (67.3) 
13 (8.0) 
2 (1.2) 
20 (12.3) 
2 (5.6) 
27 (75.0) 
3 (8.3) 
0 (0) 
4 (11.1) 
20 (10.1) 
136 (68.7) 
16 (8.1) 
2 (1.0) 
24 (12.1) 
Ethnicity  
     n (%) 
        White 
        African American 
        Multi-racial 
        Latino 
 
159 (98.1) 
3 (1.9) 
0 (0) 
1 (0.6) 
 
35 (97.2) 
0 (0) 
1 (2.8) 
1 (2.8) 
 
 
194 (98.0) 
3 (1.5) 
1 (0.5) 
2 (1.0) 
Employed 
      n (%) 
        Yes 
        No 
 
 
111 (68.5) 
51 (31.5) 
 
 
27 (75.0) 
9 (25.0) 
 
 
138 (69.7) 
60 (30.3) 
Primary occupation 
     n (%) 
        Higher executive 
Medium-sized business, 
teacher, health care 
professional 
        Administrative 
        Clerical/sales 
        Skilled-manual 
        Non-skilled manual 
        Unskilled 
        Homemaker 
Disabled/student/ 
retired/no occupation 
 
2 (1.2) 
38 (23.5) 
 
 
19 (11.7) 
2 (19.8) 
3 (1.9) 
15 (9.3) 
2 (1.2) 
12 (7.4) 
39 (24.1) 
 
3 (8.3) 
7 (19.4) 
 
 
5 (13.9) 
8 (22.2) 
2 (5.6) 
2 (5.6) 
2 (5.6) 
0 (0) 
2 (5.6) 
 
5 (2.5) 
136 (68.7) 
 
 
24 (12.1) 
40 (20.2) 
3 (1.5) 
17 (8.6) 
4 (2.0) 
12 (6.1) 
41(20.7) 
Menopausal Status 
     n (%) 
        Pre-menopausal 
        Postmenopausal 
 
 
0 (0) 
162 (100) 
 
 
19 (52.8) 
17 (47.2) 
 
 
19 (9.6) 
179 (90.4) 
 HRT last 3 months   
     n (%) 
         Yes 
         No 
        N/A 
 
 
20 (12.3) 
65 (40.1) 
                      7 (19.4) 
 
 
3 (8.3) 
4 (11.1) 
29 (80.6) 
 
 
23 (11.6) 
69 (34.8) 
92 (46.5) 
MEMS-monitored medication    
     n (%) 
        Anastrozole 
        Letrozole 
        Examestane 
        Tamoxifen 
        Multiple AIs 
 
162 (100%) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
7 (19.4) 
7 (19.4) 
2 (5.6) 
19 (52.8) 
1 (2.8) 
 
169 (85.4) 
9 (3.5) 
2 (1.0) 
19 (9.6) 
1 (0.5) 
Radiation Therapy 
     n (%) 
        Radiation 
        Mammosite 
 
 
32 (19.8) 
12 (7.4) 
 
 
25 (69.4) 
0 (0) 
 
 
57 (28.8) 
12 (6.1) 
Chemotherapy 
     n (%) 
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        Yes 
        No 
25(15.4) 
39(24.1) 
12(33.3) 
21(58.3) 
37(18.7) 
60(30.3) 
Stage of Breast Cancer n (%) 
        LCIS 
        I 
        IIa 
        IIb 
        IIIa 
1 (0.6) 
119 (73.5) 
26 (16.0) 
9 (5.6) 
7 (4.3) 
0 (0) 
20 (55.6) 
9 (25.0) 
3 (8.3) 
4 (11.1) 
 
1 (0.5) 
139 (70.2) 
35 (17.7) 
12 (6.1) 
11 (5.6) 
Type of Tumor n (%) 
        DCIS 
        LCIS 
        Infiltrating ductal 
        Tubular 
        Mucinous 
        Infiltrating lobular 
        Combination 
 
71 (43.8) 
5 (3.1) 
142 (87.7) 
6 (3.7) 
2 (1.2) 
14 (8.6) 
1 (0.6) 
 
8 (22.2) 
2 (5.6) 
28 (77.8) 
0 (0) 
0 (0) 
6 (16.7) 
0 (0) 
 
79 (39.9) 
7 (3.5) 
170 (85.9) 
6 (3.0) 
2 (1.0) 
20 (10.1) 
1 (0.5) 
BDI Total Score  
     Mean (SD) 
 
5.83 (5.6) 
 
6.68 (6.0) 
 
5.97 (5.7) 
POMS Fatigue Total Score 
     Mean (SD) 
 
6.22 (6.1) 
 
5.66 (6.0) 
 
6.01 (6.1) 
POMS Anxiety Total Score 
     Mean (SD) 
 
6.79 (4.5) 
 
6.47 (5.0) 
 
6.73 (4.6) 
Note.  AI = Multiple aromatase inhibitors. DCIS = ductal carcinoma in situ. LCIS = lobular carcinoma in situ. 
POMS = Profiles of Mood State. BDI = Beck Depression Inventory-II. MEMS = Medication Event Monitoring 
System (AARDEX, Ltd.). 
*Women may have more than one type of breast cancer tumor type. Participants with DCIS also had another tumor 
to be eligible for the parent studies.
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Overall, the mean age of the women was 59.1 ± 7.54 years (range 39-75) and the mean 
number of years of education was 15.0 ± 2.91 (range 10-26). Overall, the mean nonadherence 
was 11.6 ± 23.3%. Women were similar between the studies in terms of self-reports of 
depressive symptoms, anxiety, fatigue, symptoms based on BCPT subscales, or adherence 
(transformed and untransformed). For The AIM Study, women were 13.2% nonadherent at six-
months post-treatment, and women in The ONS Study were 4.6% nonadherent. We found an 
expected significant difference in age at baseline between the two groups, t(196) = 6.497, p = 
.0001, given that only post-menopausal women participated in The AIM Study and were likely to 
be somewhat older than women in The ONS Study because the sample for that study was 
comprised of both pre- and post-menopausal women. As anticipated, the proportion of women 
being menopausal differed between the studies since only post-menopausal women participated 
in The AIM Study (Fisher’s exact test Χ2 =94.575, p = .0001). Also since no women in The ONS 
Study received mammosite therapy, the distribution of the type of radiation therapy received also 
differed between the studies (Χ2 =9.229, p = .026). No other differences between the two studies 
were observed. 
Candidate predictors identified through screening that were retained at p = .20 are listed 
in Table 6.  
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Table 6:  Stepwise and backward elimination models with candidate predictors 
Variable Description Sample Size (N) 
Univariate 
Analysis 
Multiple Linear Regression 
Analysis—Stepwise 
Multiple Linear Regression 
Analysis—Backward Elimination 
   p-value 
 
b SE p-value b SE p-value 
Age  Mean years 198 .266   
Education Mean years 198 .511   
Married/ 
Partnered 
Yes (0)/no (1) 198 .811   
Employed Yes (0)/no (1) 198 .074*   
Primary 
occupation  
1=high exec/medium 
manager 
0=admin/clerical 
2=semi-skilled/ 
non-skilled/ 
unskilled 
3=homemaker/ 
student/disabled /retired 
191 .014* .171 .017 .015** .171 .017 .015** 
Menopausal 
status 
Pre-/post-menopausal 
(0=post-, 1=pre-) 
198 .176*     
HRT in last 3 
months 
0=yes, 1=no 92 .505   
Stage of breast 
cancer 
0=I 
1=IIa, IIb, III 
198 .880   
Type of tumor 
DCIS   
Infiltrating 
ductal     
Infiltrating 
lobular 
 
Yes (0)/no (1) 
Yes (0)/no (1) 
 
Yes (0)/no (1) 
 
198 
198 
 
198 
 
.008* 
.270 
 
.088* 
 
.171 
 
.041 
 
.006** 
  
.191 
 
.041 
 
.004** 
 
Radiation 
therapy 
0=radiation  
1=mammosite  
 69   .250  
Chemotherapy 0=yes 
1=no 
97 .866   
Depression BDI sum 198 .139*   
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Note.  HRT = hormone replacement therapy; BCPT = Breast Cancer Prevention Trial Symptom Checklist; BDI = Beck Depression Inventory-II; POMS=Profile 
of Mood States; DCIS = ductal carcinoma in situ; b=unstandardized regression coefficient; SE=standard error of the unstandardized regression coefficient  
0 = reference group 
* = retained for multiple linear regression analysis p < .20 
** = retained for multiple linear regression analysis p < .10 
Stepwise:  R2 = .114 Adjusted R2 = .100  s = .27910 p <.0001 
Backwards Elimination: R2 = .123, Adjusted R2 = .109, s = .27765 p < .0001 
Anxiety POMs sum 198 .214*   
Fatigue POMs sum 198 .048*     
Vasomotor BCPT subscale 198 .759   
GI symptoms BCPT subscale 198 .025*       
Bladder 
control 
BCPT subscale 198 .212*   
Cognitive 
symptoms 
BCPT subscale 197 .199*     
Weight 
problems  
BCPT subscale 198 .001* .199 .038 .004** .199 .038 .004** 
Musculo-
skeletal pain 
BCPT subscale 198 .038*   
Gyne-cological BCPT subscale 198 .046*   
Dyspareunia BCPT subscale 198 .288   
BCPT Total 
Subscale Score 
 198 .004*   
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Candidate categorical predictors of nonadherence included employment status, primary 
occupation, DCIS tumor type, infiltrating lobular tumor type, and menopausal status. Depressive 
symptoms, anxiety, fatigue, GI symptoms, bladder control, cognitive symptoms, weight 
problems, gynecological symptoms, musculoskeletal pain, and total BCPT score were identified 
as continuous linear predictors of nonadherence. Using stepwise multiple linear regression 
analyses of these candidate predictor variables, primary occupation (p = .015), DCIS tumor type 
(p = .006) and weight concerns (p = .004) were identified as predictors of women’s 
nonadherence at six months post treatment (Table 6). Backward multiple linear regression 
analyses performed in the same manner identified the same three predictor variables (Table 6). 
The backward elimination model was selected as the final model. 
2.5.2.7 Discussion 
We examined potential patient-, illness-, and/or treatment-related factors and their relationship to 
short-term nonadherence to oral hormonal therapy for women with early stage breast cancer 
from the baseline assessment (pre-hormonal therapy) to six months post-treatment. We found 
that a backward elimination model best represented the data. Based on our findings, women with 
DCIS tumor type, whose primary occupation was clerical or administrative, or who had higher 
weight concern BCPT scores were associated with less adherence at six months post-treatment.  
Previous reports of predictors of nonadherence to hormonal therapy with tamoxifen or 
AIs have not addressed employment status or occupation. Our results suggest that women with 
more burdensome workloads may be more likely to be nonadherent; however, further 
exploration is needed. In our analysis, we collapsed seven categories of primary occupations into 
four (high executive/medium level manager; administrative/clerical; semi-skilled/non-
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skilled/unskilled; homemaker/student/ disabled/retired); it is possible that we lost information 
that may further explain our findings by using this technique.  
We found that weight concerns were associated with nonadherence six months post-
treatment, but no other symptoms were retained in either the stepwise or backwards-elimination 
models. Prior reports of the relationship between side effect severity and discontinuation of 
tamoxifen or AI therapy have been somewhat unclear. The types of weight concern side effects 
that women with breast cancer who are taking oral hormonal therapy have included 
attractiveness (Grunfeld et al., 2004), but this was not found to be a significant predictor of 
nonadherence. Other researchers have measured the severity of side effects (e.g., severe, 
moderate, mild, none) (Kahn et al., 2007) or the number of side effects (Lash et al., 2006), but 
we were unable to find specific reports regarding weight concerns and nonadherence for women 
with breast cancer taking oral hormonal therapy. Our findings are somewhat consistent with our 
qualitative analysis of medication-taking for women receiving anastrozole therapy (Wickersham, 
Happ, & Bender, 2011). In that study, women who were participants in The AIM Study provided 
rich description of their side effects of therapy, which included hot flashes, arthralgias, fatigue, 
sleep disturbances, and memory problems. Despite the severity of their symptoms, most (11 of 
12 participants, 91.67%) indicated that their side effects would not stop them from taking their 
anastrozole. The sentiments expressed by the women in that study (Wickersham et al., 2011) 
were consistent with the findings of the present study; however, only two of the women in the 
qualitative analysis (Wickersham et al., 2011) mentioned weight gain or weight loss in their 
descriptions of their medication-taking experiences with anastrozole. It is possible that women 
who had weight concerns had discontinued therapy with anastrozole before the interviews, or 
attributed weight concerns to another process, such as aging. 
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The interaction of DCIS tumor type and primary occupation is puzzling. Published 
reports examining similar interactions were not found. It is important to note that participants in 
both The AIM Study and The ONS Study with DCIS also had another tumor type to be eligible 
for the parent studies. While our findings suggest that women without DCIS tumor type and 
whose occupation was not administrative or clerical were more adherent at six-months post-
treatment, further discrimination of primary occupation and tumor type and their relationships to 
nonadherence is needed. 
The results of out study should be interpreted with several limitations in mind. The most 
important limitation is the cross-sectional nature of our analyses. While our findings have 
provided insight for future investigations of nonadherence and women with early stage breast 
cancer receiving hormonal therapy, no associations regarding causality can be made. All tumor 
types were examined as candidate predictors, but participants with DCIS also had another tumor 
type to be eligible for the parent studies. We chose a six-month summary statistic of 
nonadherence as the dependent variable, but we did not include examinations of dose intervals 
(the time between each dose of hormonal therapy), which may provide further information as to 
the patterns of the women’s adherence. Furthermore, several adherence rates were extremely low 
(e.g. 1.52%); they were verified to be correct, but the score may have reflected a testing of the 
MEMS cap or one use only. It is possible pill minders were used by the women but not reported, 
also potentially affecting our findings.  
The samples of women from The AIM and The ONS Studies examined in this analysis 
were uneven. While no unexpected differences between the two groups were noted at baseline, it 
is likely that the sample size of women selected from The ONS Study was too small to generate 
significant findings. We did not include lobular carcinoma in situ as a type of breast cancer in 
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our analyses because there was only one case in the combined sample; therefore, the results 
cannot be generalized to women with that type of breast cancer. Additionally, all women in our 
sample were white and well educated. Racial/ethnic disparities in treatment could have an effect 
on nonadherence and should be further investigated. 
Our findings suggest future directions of inquiry with regard to nonadherence for women 
with early stage breast cancer who receive therapy with oral hormonal agents.  First, we did not 
include type of surgery for breast cancer, social support, and beliefs about medicines in our 
analyses, all of which could provide additional insight for potential predictors of nonadherence. 
We used multiple linear regression analysis with a continuous nonadherence variable; other 
approaches could include logistic regression using 80% and/or 90% as cut-offs for adequate 
adherence. Future studies should also include exploration of employment and types of primary 
occupation and their relationship to nonadherence, as well as the effects of nonadherence on 
clinical outcomes and predictors of nonadherence for women with breast cancer taking oral 
chemotherapies or targeted therapies. Our study offers insight into potential predictors of 
nonadherence for women participating in one of two large cohort studies. The findings suggest 
additional examinations of nonadherence concerning work and symptom burden and their 
relationship to nonadherence are indicated. 
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3.0  RESEARCH DESIGN AND METHODS 
3.1 DESIGN 
We explored the process of medication-taking for adults with NSCLC receiving oral EGFR 
inhibitor therapy. We aimed to describe the process of medication-taking and identify factors 
influencing medication-taking of the prescribed regimen. The philosophical orientation that 
informed our methods and analysis was positivist grounded theory for the purpose of 
constructing, testing, and refining theory from data (Corbin & Strauss, 2008; Glaser & Strauss, 
1967). Medication-taking behaviors including factors or barriers influencing adherence to oral 
EGFR inhibitors in the target population were unknown; thus, a qualitative study to discern the 
perspectives of patients receiving these agents were needed to (a) organize the knowledge 
gained, (b) develop the appropriate theoretical basis to direct future investigations of medication-
taking of oral cancer therapies, and (c) eventually, once tested, guide clinical practice (Cobb & 
Hagemaster, 1987; Corbin & Strauss, 2008). Qualitative inquiry has provided essential and 
unique information regarding medication-taking behaviors and adherence in other patient 
samples (Erlen & Happ, 2006; Lehane et al., 2008; Lewis et al., 2006; Russell et al., 2003). 
Grounded theory study designs have been used in research seeking to develop a better 
understanding of similar phenomena, such as adherence of persons living with HIV/AIDS to 
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highly active antiretroviral therapy (HAART) (Gray, 2006), the work of adherence (McCoy, 
2009), and medication-taking behavior of older adult cardiac patients (Chen et al., 2007). 
3.2 SETTING 
Patients treated for NSCLC at the University of Pittsburgh Cancer Institute (UPCI) were the 
participants in this study. The UPCI is the only National Cancer Institute-designated 
Comprehensive Cancer Center in western Pennsylvania and includes over 40 locations in a 
radius of 200 miles around the greater Pittsburgh area. From 2008-2011, 3975 patients (1999 
male [50.3%], 1976 female [49.7%]) were diagnosed with NSCLC and underwent a first course 
of treatment at a UPMC Cancer Center. Of those patients, most were white (88.6%), aged 60 
years or older (79.5%), and diagnosed at stage III/IV (58.2%). Generally, most patients with 
advanced stage NSCLC who are treated at the UPCI receive therapy with an oral EGFR inhibitor 
at some point in their treatment trajectory. 
3.3 SAMPLE 
Based on the methodological literature and similar qualitative research reports, it was expected 
that 14-20 participants would be needed to achieve saturation and redundancy in the analysis and 
to fully address the research questions (Ledlie, 1999; Patton, 2002; Sandelowski, 1985). 
Theoretical saturation was achieved after 13 participants were enrolled. The University of 
Pittsburgh Institutional Review Board approved this study. Informed consent was obtained from 
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all participants prior to data collection. The sample included patients treated for NSCLC at two 
outpatient lung cancer clinics at a National Cancer Institute-designated cancer center. The 
primary investigator (PI; KW) was not part of the clinical care team and used clinic observations 
and chart reviews to screen eligible patients and to understand the participant’s treatment 
trajectory. Members of the clinical team comprised of an oncologist, a nurse practitioner or 
physician’s assistant, and a collaborative nurse identified potential participants and approached 
them to assess their interest in study participation. The PI met with interested patients in a private 
area (e.g., conference room, clinic exam room) or discussed by phone detailed information about 
the study’s requirements.  
3.3.1 Inclusion criteria 
Men and women over 18 years of age with NSCLC (any type/stage) receiving an oral EGFR 
inhibitor and able to speak, read, and understand the English language (since all interviews were 
conducted in English) were eligible to participate. Although patients with NSCLC are typically 
older than 65 years of age, patients 20 years of age and older with NSCLC have been treated at 
UPCI. Oral EGFR inhibitors are currently approved for 2nd and 3rd line treatment of advanced 
stage NSCLC adenocarcinomas and are recommended as 1st line treatment for patients with 
NSCLC and EGFR mutation. However, the disease type and stage of patients with NSCLC 
enrolled in clinical trials may vary; therefore, patients with any type and any stage of NSCLC 
receiving oral EGFR inhibitors were eligible for the study. Verification of NSCLC diagnosis was 
confirmed by the oncologist and identified using medical record review. 
  
 89  
3.3.2 Exclusion criteria 
Exclusion criteria included a primary cancer that had metastasized to the lung or a second 
primary cancer, current metastasis to the central nervous system, or evidence of cognitive 
impairment as assessed by the Mini-Mental Status Exam (MMSE) (Folstein, Folstein, & 
McHugh, 1975). Patients with treated brain metastases may still have had evidence of these on 
repeat imaging, although the brain metastases may be stable or have regressed, which is adequate 
response to treatment. The majority of patients with NSCLC are diagnosed over the age of 65 
and the central nervous system is a common site for metastases (NCCN, 2011). Because disease-
related oxygenation issues and age-related cognitive impairment may affect medication-taking 
behavior, participants were screened for cognitive impairment at baseline with the MMSE, an 
11-item screening test that includes an evaluation of higher level verbal and nonverbal 
functioning (Folstein et al., 1975). Age and level of education have been associated with 
cognitive function; therefore, eligibility was determined based on age and education scaled 
normative data when using the MMSE. Potential participants who scored are at or below the 
borderline range (1.4 standard deviations below the norm) were excluded (Folstein et al., 1975; 
Spreen & Strauss, 1998). 
3.3.3 Sampling procedure 
Participants were purposively selected for variation in gender, race/ethnicity, age and time in 
therapy (Sandelowski, Holditch-Davis, & Glenn Harris, 1989). Purposive sampling also included 
those who underwent reductions in dose of their EGFR inhibitor and those who discontinued 
therapy (e.g., due to disease progression), because dose reductions and therapy discontinuation 
  
 90  
are important variations (and perhaps consequences) of their medication-taking process. Four 
participants were well established in their therapy (e.g., taking for approximately 1 year) and 
nine were either in an early phase of treatment (e.g., first week to two months into treatment) or 
their medication-taking process changed during the course of the study (e.g., discontinued 
therapy due to disease progression). Research and clinical experiences show that EGFR 
inhibition-related rash commonly occurs during the first one to three weeks of treatment, 
although the time to rash appearance may be related to the agent and dose (Kris et al., 2003; 
Sipples, 2006). Additionally, EGFR-inhibition associated diarrhea is experienced by 
approximately 75% of patients taking erlotinib (Sipples, 2006). Therefore, participants at various 
points in their treatment trajectory were enrolled in the study to understand how targeted 
pathway-specific side effects may affect medication-taking. Theoretical sampling focused on age 
and type of health insurance coverage.  
3.3.4 Enrollment procedure 
After approval of the protocol by the UPCI Protocol Review Committee and the University of 
Pittsburgh Institutional Review Board (IRB), participants at a National Cancer Institute (NCI)-
designated cancer center were invited to enroll. Prior to the start of the study, the principal 
investigator (PI) met with the oncologists, the nurse practitioner, the physician’s assistant and the 
collaborative nurses at two lung cancer clinics at the cancer center to discuss the study, including 
eligibility criteria. Recruitment occurred in one of two ways: 
1. The oncologists, nurse practitioner, physician’s assistant, or collaborative nurses 
identified patients receiving therapy with oral EGFR inhibitors either through their daily 
practice or through review of a Health Insurance Portability and Accountability Act 
  
 91  
(HIPPA) compliant database. Once identified, the oncologist, the nurse practitioner or 
physician’s assistant, or the collaborative nurse approached patients to assess interest in 
study participation.  
2. IRB approved study advertisements were posted in the clinic waiting areas of UPCI 
(Appendix). The flyers directed interested potential participants to call the investigator 
for additional information concerning the study. 
3.3.5 Procedures for data collection 
After a member of the clinical team introduced the investigator to potential participants 
expressing an interest in learning more about the study, the PI either met with the patient in a 
private area (i.e., conference room, clinic exam room) or discussed by phone detailed 
information about the study’s purpose and requirements to determine the patient’s interest and/or 
responded to any questions participants may ask about the study. If willing to participate, 
patients were asked to sign an IRB-approved consent form that explained the study and its risks 
and benefits, and enrollment procedures commenced. Informed consent was obtained prior to the 
performance of any study procedures. Participants were informed that their desire to participate 
in the study would under no circumstances affect their care and treatment at the UPCI or UPMC 
Cancer Centers or their eligibility to participate in any other clinical trial. They were also 
informed that their data would be reported as a group. If the participant’s spouse or significant 
other wished to participate, the PI made it clear that the research concerned the participant’s 
responses and not the effect that their cancer may have had on loved ones or family members. If 
the participant or spouse/significant other insisted that the spouse/significant other be present for 
the interview, and the spouse/significant other’s volunteered information about the participant’s 
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medication-taking experiences, the information was viewed as a "data source" and not as a 
participant, and their information was retained in the interview transcript for analysis.  
Once participants were enrolled, data collection (Table 7) began in a private conference 
room at the UPCI or a private area in the participant’s home. If none of these locations were 
convenient for the participant, the interview was held at a location preferred by the participant 
that afforded privacy and convenience. 
Table 7: Summary of data collection procedures 
 Screening Baseline Initial 
Interview 
Follow-Up Interviews 
NSCLC diagnosis / 
Oral targeted therapy 
X  
(By health 
care 
provider.) 
X   
Informed Consent  X  
(Before any 
research 
procedures.) 
  
Mini Mental Status Exam 
(MMSE) 
 X   
Demographics  X   
Prior Chemotherapy / 
Radiation Therapy / Other 
treatment 
 
X   
Confirmation of Eligibility 
1. Confirmation of 
diagnosis/oral 
targeted therapy  
2. MMSE 
 
X   
Interviews   X X 
(For patients enrolled 
in an early phase of 
their treatment.) 
Note. NSCLC = non-small cell lung cancer. 
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3.3.5.1 Baseline procedures 
Sociodemographic information After informed consent, participant age, 
race/ethnicity, insurance coverage, religion, occupation, marital status, and level of education 
were recorded at the baseline visit using a sociodemographic case report form developed for this 
study (Appendix).   
Prior chemotherapy, radiation therapy, and/or other treatment for NSCLC Prior 
NSCLC treatment information including chemotherapy and radiation therapy (i.e. dose, timing) 
was extracted from the participant’s medical record and recorded on a case report form 
developed for this study (Appendix). In addition, the reason for discontinuation or dose reduction 
of oral targeted therapy was extracted from the medical records, where such changes are 
documented. EGFR mutation status was recorded; patients at the cancer center are told of their 
status, and are aware that as such they may respond better to their treatment. 
Assessing for cognitive impairment Participants were assessed for cognitive 
impairment through the use of the MMSE. Level of cognitive ability needed for any research 
study depends on the tasks required of the participant. "Most studies report that the MMSE is 
sensitive to the presence of dementia, particularly in those with moderate to severe forms of 
cognitive impairment. The test, however, is less than ideal when those with mild cognitive 
impairment are evaluated...” (Spreen & Strauss, 1998, p. 66). Participants in this study were 
required only to participate in interviews; mild forms of cognitive impairment should not 
preclude that participation. Because age and level of education are associated with cognitive 
function, eligibility was determined based on age and education scaled normative data. Potential 
participants whose scores were at or below the borderline range (1.4 standard deviations below 
the norm) were to be excluded.  
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Administration time for the MMSE is 5 minutes. Test-retest reliability of the MMSE, 24 
hours apart, is interpreted as r =. 88. Concurrent validity with the verbal intelligence quotient 
(IQ) of the Wechsler Audit Intelligence Scale in 137 psychiatric and healthy patients is 
interpreted as r = .77 (p < .0001) and with the performance IQ is r = .66 (p < .001) (Folstein et 
al., 1975). 
Confirmation of eligibility The oncologist verified the participant’s diagnosis of 
NSCLC. MMSE data were scored, interpreted, and reviewed with a faculty member with 
expertise in this area (Dr. C. Stilley, Neuropsychology Consultant). Once eligibility was 
confirmed, an interview was scheduled. 
3.4 INITIAL AND FOLLOW-UP INTERVIEWS 
Interviews were the primary data source for this study. We interviewed most participants (n = 
10) on multiple occasions over nine months to capture the medication-taking process in early, 
middle and later phases of medication use. In-depth semi-formal (n = 27) and brief (n = 5) 
interviews were conducted with 13 participants (1153 pages of data). Four participants were well 
established in their therapy (e.g., taking for approximately 1 year) and nine were either in an 
early phase of treatment (e.g., first week to two months into treatment) or their medication-taking 
process changed during the course of the study (e.g., discontinued therapy due to disease 
progression). The PI conducted digitally-recorded interviews ranging from 32 to 90 minutes 
from August 2011 to July 2012 either at the participant’s home or at a location convenient for the 
participant (e.g., private space at the cancer center, coffee shop) (Erlen & Happ, 2006; Lewis et 
al., 2006; Wickersham et al., 2011). The interview guide consisted of questions about oral EGFR 
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inhibitor medication-taking behaviors (Appendix). Brief telephone interviews were conducted 
for further validation or exploration of themes identified during data analyses. When a spouse or 
family support person was present during the interview (at patient’s request/agreement), their 
contributions were included in the transcript for analysis. The recorders failed for one interview, 
which was reconstructed immediately. Participants received $10 for each interview.   
Supplemental data sources included an erlotinib starter kit, journals/newsletters, 
prescription inserts, and personal documents (e.g., transcript of a speech) given to the PI by the 
participants or the clinical team. The ongoing analysis generated additional interview questions 
about treatment delays, usefulness of support groups for patients receiving oral EGFR inhibitors, 
prescription medication insurance coverage, and disclosure of lung cancer and/or EGFR inhibitor 
use to family or friends. 
3.4.1 Interview procedure 
An interview checklist was used to organize activities related to the interview (Appendix). Once 
an interview was scheduled, the participant study number and interview date were recorded on a 
tracking spreadsheet. One day before the interview, the PI called to confirm the interview and 
printed: two informed consent forms (one for signature to bring back and file and one for the 
participant), the interview guide and observational notes, and the participant payment form. At 
the time of the phone call, the PI confirmed the date, time, and convenience and privacy of the 
location with the participant. For the majority of the participants (12/13) the interview occurred 
on the same day the assessment procedures were completed for their convenience. On the day of 
the interview, the PI brought a digital tape recorder with a back-up recorder and batteries, 
directions to the interview location, informed consent forms, MMSE, sociodemographic case 
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report form, and participant stipend. After the informed consent process, MMSE administration, 
and confirmation of eligibility, the interview commenced Particular effort was made to place the 
subject at ease; a broad, grand tour question (Appendix) was used to gently open the 
conversation:  “Tell me what it is like for you to take that medication.” Questions about their 
medication-taking related to oral EGFR inhibitor use included how they took their EGFR 
inhibitor on a typical day and missing or skipping doses of their medication. Immediately after 
the interview, the PI checked the tape recorder to ensure the interview had been recorded, and to 
record impressions of the interview. Within 24 hours of the interview, the PI downloaded the 
interview, transferred it and the transcript template to the digital Dropbox, and entered the 
completion of interview onto the tracking sheet. The PI then emailed the transcriptionist to notify 
her that an audio-file was ready for transcription. 
3.5 DATA ANALYSES 
During analysis, emerging findings generated additions to the interview guide; new questions 
addressed delay in treatment, the usefulness of support groups for patients with lung cancer 
receiving oral targeted therapy, and disclosure of oral targeted therapy to family or friends. These 
concepts were explored in subsequent interviews with new participants, as well as with select 
participants who had already been interviewed. Analyses to characterize the study sample 
included descriptive statistics, including frequencies and percentages for categorical descriptors 
and means, medians, standard deviations and ranges for continuous-type patient descriptors for 
data concerning sociodemographic information and cognitive impairment screening, and median, 
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mode for categorical data including NSCLC diagnosis (type and stage), EGFR mutation status, 
and prior and current cancer therapy.  
Interviews were digitally recorded, with a back-up digital recorder and batteries 
available. To ensure the patient’s confidentiality, each participant was assigned a unique study 
identification number. To safeguard participant privacy, observational notes were kept in a 
locked drawer and will be kept for up to six years. A separate, encrypted document linking the 
study identification number to participant name was kept separately in a password-protected file. 
All electronic files were encrypted for participant protection. 
We reviewed each transcript while listening to the audio-recording for accuracy and to 
gain an overall impression of the participant’s focus. In a cyclical fashion, the transcribed data 
were examined line by line to label (open code) text that related to participants’ medication-
taking of oral EGFR inhibitor therapy. Similar codes were grouped into categories. We then 
examined the relationships between categories of codes (axial coding) among the participants. 
Selective coding was used to identify and systematically connect the core category with other 
categories (Corbin & Strauss, 2008). ATLAS.ti (6.2.27) (ATLAS.ti Scientific Software 
Development GmbH, Berlin, Germany) software was used for data management.  
Other analysis techniques included (Corbin & Strauss, 2008) questioning the data, 
thinking “outside of the box,” and developing provisional answers to become familiar with the 
data. Dimensional analysis was used to examine variations of a concept that give specificity and 
range to a concept (Schatzman, 1990). For example, the positive and negative experiences that 
patients encountered with their health care professionals were dimensionalized in tabular form. 
Additionally, dimensions and exemplars of prescription co-payment requirements (i.e., one co-
pay for each strength of erlotinib) and assistance programs utilized by the participants were also 
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examined in tabular form. We used matrix construction for comparison and pattern recognition 
(Miles & Huberman, 1994). Matrices were developed for side effect severity and for the 
comparison of the fifth and sixth participants, who were key informants but who had different 
health care professional experiences, issues with the cost of erlotinib, type of health care 
insurance, side effects and side effect severity, aging, and “death talk.” Three matrices were 
constructed for the purpose of comparing and contrasting all thirteen participants with the major 
themes we discerned from the data. Writing the story was especially important as more than one 
story was possible from the data. Case titles and story summaries were developed for each 
participant, as well as for the group to help identify the basic psychosocial process. Finally, the 
literature was used to make comparisons, stimulate analytic questions, confirm findings or show 
where our findings differ from the literature, or where the current literature only partially 
explains the medication-taking process for patients with NSCLC receiving therapy with oral 
EGFR inhibitors (Strauss & Corbin, 2008). 
Sampling, interviewing, and analysis continued until we reached informational 
redundancy (i.e., no new themes or patterns were recognized; n = 8); we then enrolled three 
participants for further sample diversity and to confirm existing findings. One woman was 
selected for type of health insurance carrier, because health insurance and cost of erlotinib were 
major concerns expressed by the participants. One man was selected for younger age. No new 
themes emerged; we achieved theoretical saturation after 13 participants were enrolled.  
3.5.1 Training 
The researcher completed initial ATLAS.ti training in July 2008. Qualitative interviewing skills 
and ATLAS.ti data management were reinforced through preliminary work with her NRSA Co-
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Sponsor (Dr. C. Bender) and Qualitative Methods Co-Investigator (Dr. M.B. Happ) (Preliminary 
Work) and independent studies (Advanced Qualitative Analysis) for implementation of research 
concepts and methods appropriate for the current study. A student worker transcribed interview 
data for the AIM nested companion study (Preliminary Work) and underwent transcription 
training at that time. The same person transcribed interview data for the current study. 
3.5.2 Trustworthiness 
To ensure rigor of this qualitative study, the following steps were implemented to assure the 
trustworthiness of the data, analysis, and research process. 
3.5.2.1  Credibility 
A faculty researcher (MBH) with experience in grounded theory audited all coding to ensure the 
credibility of the data analysis. Weekly analysis meetings were conducted with the faculty 
researcher and a qualitative work group to review and discuss data exemplars, coding, theoretical 
insights, and analytic decisions. Extensive member checking was conducted by use of several 
methods. Three key informants were selected to review and comment on the constructed theory 
to confirm or refine the interpretive analysis. The informants were well-educated and invested in 
the project; one asked to see her specific quotations that would be used in the final study 
summary. Thus, we provided a summary of the findings in lay language with quotations to the 
informants for their review. All three confirmed the conceptual model. We reviewed public 
websites (e.g., Cancer Grace and Inspire) demonstrated that patients with advanced stage 
NSCLC have similar concerns about treatment for lung cancer and management of side effects 
and provided external validation of the psychosocial process. We reviewed and coded a publicly 
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available interview transcript of a personal interest story. Findings were shared with the clinical 
team, who confirmed the difficulty that patients encounter in paying for erlotinib and with 
managing side effect severity. Findings were also shared with the infusion nursing staff of the 
second floor treatment center of the UPCI, who confirmed the study results. 
3.5.2.2  Confirmibility and dependability 
All interview data, field notes, and memos were documented to provide an audit trail. 
Methodological memos were used to document operational decisions, timing, or sequencing of 
data collection and participant selection (Corbin & Strauss, 2008). Theoretical memos were used 
to show the development of insights, dimensions of the process, and analytic decisions. All 
memos were recorded in Atlas.ti, dated, titled, and cross-referenced to provide a complete audit 
trail of the inductive logic of the PI and analytic team. 
3.6 PARTICIPANTS 
3.6.1 Research participant risk and protection 
Efforts were undertaken to minimize the risk to confidentiality of data and to anonymity of the 
participants. All participants were assigned a unique code number under which all data were 
stored. Security of the data was upheld through the use of password protection and restricted 
access to users. Consent forms and a list of the match between participant names and code 
numbers were retained in separate locked drawers of the PI’s desk, which is also in a locked 
room, providing further security. 
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This was a minimal risk study; however, during the interview process, participants could 
experience emotional distress or fatigue. 
3.6.1.1 Emotional distress 
Formal interview training was completed. During this training, the researcher had the 
opportunity to learn how best to assess for potential emotional distresses during the interview as 
this distress occurs on a continuum. Each participant was instructed that s/he could choose not to 
answer any question that caused uneasiness. Several participants became tearful during their 
interview; however, the researcher immediately addressed it and confirmed with the participant 
his/her willingness to continue. The plan established prior to the start of the study was as 
follows: should a participant express any emotional discomfort, the researcher would 
immediately address it. If not acute, such as a side effect not previously reported or discomfort 
felt as a result of the interview was brought to her attention the researcher would negotiate with 
the patient to report the problem him- or herself to the oncologist or primary care provider. The 
researcher would also offer to make this phone call, if needed. If the problem was acute, meaning 
the participant felt the need to stop the interview, the researcher would immediately offer to stop 
the interview and resume it at a later date. If participants became distressed while completing the 
interview and were in need of psychological counseling or psychiatric referral, appropriate 
referral information would be provided (Appendix). The informed consent form (Appendix) 
provided additional detail about the process for addressing emotional distress. 
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3.6.1.2 Fatigue 
To minimize fatigue, participants were offered breaks during the interview. Participants were 
instructed during the informed consent process that they could choose to discontinue the 
interview at any time for any reason, if needed. All potential discomforts and procedures to 
alleviate discomfort were discussed with the participants and were delineated clearly in the 
informed consent document. Participants did not directly benefit from participating in this study. 
However, they were helping to extend the knowledge of the process of medication-taking in 
patients with NSCLC taking oral targeted therapies, providing a basis for future work in 
developing an intervention to enhance medication-taking to be tested in future research.  
3.6.1.3 Risk of breach of confidentiality 
There was a possibility of the risk of breach of confidentiality of protected health information. 
The researcher took all necessary steps to ensure that this did not happen. All records related to 
the participant’s involvement in this research study were stored in a locked file cabinet. Their 
identity on these records were indicated by a case number rather than by their name, and the 
information linking these case numbers with their identity were kept separate from the research 
records.  They were informed that they would not be identified by name in any publication of the 
research results unless they signed a separate consent form giving their permission (release). 
Photographing objects related to the participant’s medication-taking process did not 
impose additional risks; the researcher ensured that there was nothing in the image of the object 
that would identify the participants, or that would identify the participants as a patient with non-
small cell lung cancer, or any cancer. The photographs of the objects taken during their 
interviews were for the purpose of recording and describing this project. These images may 
appear in academic publications, presentations given at academic conferences, or on the Internet.  
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These photographs may also appear in newspapers or newsletters. The participants were 
informed that they could participate in the research study, without being recorded, even if they 
did not sign this form. 
As the study was not a clinical trial, the PI was responsible for the ongoing evaluation of 
the progress of the study and was guided by the dissertation committee. Data safety and 
monitoring meetings were conducted on a bi-monthly basis to review study conduct, recruitment, 
accrual, confidentiality issues, and results and to make changes as needed.  
 
3.6.2 Participant characteristics 
This study enrolled both men and women with NSCLC. No participant was excluded based on 
race or ethnicity. In 2010, the composition of Allegheny county was 13.2% African American, 
1.6% Hispanic or Latino, and 2.8% Asian (US Census Bureau, 2012a). In 2010, the composition 
of the city of Pittsburgh was 26.1% African American, 2.3% Hispanic or Latino, and 4.4% Asian 
(US Census Bureau, 2012b). At the UPCI, from 2008-2011 patients with NSCLC were 
predominantly white (87.0%). These statistics differ from both those of the city of Pittsburgh and 
of patients with NSCLC nationally; the expectation was that at least 18% of the eligible sample 
for this study would be a minority, predominately black. In the participant sample, 15% of the 
participants were a minority. 
Although patients as young as 20 year of age with NSCLC have been treated at UPCI, no 
children were enrolled in this study. The study primarily focused on an older adult population, as 
this is the group that is most likely to be affected by NSCLC. In this participant sample, 
participants’ ages ranged from 52 to 83 years of age. 
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4.0  SUMMARY OF STUDY 
The purpose of this study was to explore the process of medication-taking for adult patients with 
NSCLC receiving oral EGFR inhibitor therapies. Specifically, we aimed to (a) describe the 
process of medication-taking, and (b) identify factors influencing medication-taking regarding 
their prescribed regimen. Three manuscripts were developed in support of this project. The first 
is an account of our preliminary work that was submitted to Nursing Research and Practice on 
June 11, 2012. The second is a report of a secondary analysis that examined pre-treatment 
patient-, illness-, and treatment-related predictors of adherence to oral hormonal therapy for 
women with early stage breast cancer. This report is in draft form and will be finalized after 
dissertation defense. It is formatted for Nursing Research. The third manuscript is a report of the 
main findings from the dissertation research, which has been formatted for submission to Social 
Science and Medicine.  
4.1 ISSUES 
Originally, enrollment was to occur through one of two ways:  by members of the clinical team 
and through the use of an IRB approved study advertisements. The advertisement was posted on 
the bulletin board of the UPCI 2nd floor treatment waiting area (Appendix); however, no 
participants were identified through this method. Initially, if needed, additional sites in the 
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UPMC Cancer Center system were to be added to improve enrollment. Ultimately, three 
additional oncologists and a second lung cancer clinic at the UPCI were added to improve 
recruitment; however, it was not necessary to add additional external sites. 
Although the PI was not part of the clinical team, she spent time in the lung cancer clinic 
as part of the BSN to PhD clinical exposure and training (oncology content) and to recruit 
participants directly from the clinic setting. The clinical training and observation did at times 
inform understanding and analysis. Memos were recorded in Atlas.ti about recruitment and chart 
review, which helped the PI understand the patients’ treatment trajectory and to identify patients.  
4.2 METHODS 
Following grounded theory methodology, emerging findings generated changes to the interview 
guide, including questions about delays in treatment, usefulness of support groups for patients 
with NSCLC receiving oral EGFR inhibitor therapy, and disclosure of lung cancer and/or oral 
EGFR inhibitor use to family or friends. These concepts were explored in subsequent interviews 
with new participants as well as with select participants who had already been interviewed.  
During the interviews, if the participant’s family support person wished to participate, the 
PI made it clear that the research concerned the participant’s responses and not the effect that 
their cancer may have had on loved ones or family members. If the participant or family support 
person insisted that he/she be present for the interview, and that person volunteered information 
about the participant’s medication-taking experiences, the information was viewed as a "data 
source" and not as a participant, and their information was retained in the interview transcript for 
analysis. Several of the participants wished to have their spouse or family support person present 
  
 106  
during the interview. Generally, these interviews went well, and in many cases, the support 
person provided key information concerning the participant’s medication-taking process. In one 
instance (third interview of 1003), the support person was unintentionally disruptive, requiring 
the PI to continuously refocus the interview to the participant. This single instance was 
documented in Atlas.ti. 
 During an analysis meeting in February 2012, the dissertation committee recognized that 
many participants mentioned artifacts that were important to them for their medication-taking 
process. Artifacts were defined as products that held meaning about the culture of the user 
(Tilley, 2000). For this study, artifacts related to medication-taking may have included a 
medication diary or notebook and storage containers. The dissertation committee agreed that 
photographs of these objects related to participant medication-taking were important in helping 
us to understand and to interpret the total process of how participants take their oral targeted 
therapy in the context of the participants’ culture (Tilley, 2000). Additionally, consistent with 
grounded theory methodology, analysis of these objects helped the researcher to determine the 
symbolic meaning of these objects for individual participants (Cutliffe, 2000). The choice of the 
object to photograph was co-constructed between the research participant and the PI. 
Participant’s personal objects were photographed, but not the participants themselves.  
 The original plan was for the PI to re-contact by phone participants who had already 
completed the interview procedures for their interest in allowing the study team to photograph 
their artifacts related to medication-taking. If interested, participants were to be re-consented 
with an informed consent addendum for their permission. Future participants were to be asked 
for their voluntary permission to photograph similar objects during the informed consent process. 
The use of artifacts was not approved by the IRB until enrollment was almost completed (April 
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2012). The PI approached one participant, who agreed, but the photograph of her pill container 
was not of adequate quality. Nonetheless, the PI did receive unsolicited artifacts (Tilley, 2000; 
Cutliffe, 2000) provided by the participants and the clinical team. These included an erlotinib 
starter kit that is distributed by the pharmaceutical company, several journals and newsletters 
related to cancer treatment, patient prescription inserts, and personal documents such as a speech 
prepared by one of the participants. The supplemental data were included with the analysis. 
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5.0  RESULTS—SURVIVING LUNG CANCER:  MEDICATION-TAKING AND 
ORAL TARGETED THERAPY 
5.1 COVER LETTER TO Social Science and Medicine 
September 25, 2012 
 
Ellen Annandale 
Department of Sociology  
University of Leicester  
University Road 
Leicester, LE1 7RH, UK 
 
Dear Dr. Annandale: 
 
We are submitting a manuscript entitled “Surviving lung cancer:  Medication-taking and oral 
targeted therapy” for review and possible publication in Social Science and Medicine.  The paper 
discusses the methods and findings for a qualitative study examining the medication-taking 
experiences for men and women with advanced stage non-small cell lung cancer receiving 
therapy with an oral epidermal growth factor receptor inhibitor.  This manuscript has been 
reviewed and approved by all authors.  The paper has not been submitted to any other journal; 
this work has not been published elsewhere. 
 
Thank you for your consideration.  If you need further information, please contact me by mail, 
telephone or e-mail at:  
 
Karen Wickersham, PhD, RN 
University of Pittsburgh 
School of Nursing 
415 Victoria Building 
Pittsburgh, PA 15261 
Telephone: 412-721-5899 
e-mail: kew44@pitt.edu 
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Sincerely, 
 
Karen E. Wickersham, PhD, RN 
Doctoral Candidate 
University of Pittsburgh 
School of Nursing 
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5.3 RESEARCH HIGHLIGHTS 
• Medication-taking with an epidermal growth factor receptor inhibitor was a vehicle for 
surviving lung cancer.  
• The participants framed Surviving Lung Cancer within the recognition of NSCLC as a 
life-limiting illness without cure. 
• Paying for treatment, cherishing family time, and living life to the fullest were key 
components of surviving lung cancer. 
• Access to affordable care and medication over time is crucial because insurance benefits 
can change or reach limits. 
• Support groups addressing concerns of survivorship are needed for persons with NSCLC 
and their caregivers.  
5.4 ABSTRACT 
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors increase survival and 
improve quality of life for patients with non-small cell lung cancer (NSCLC). Because oral 
EGFR inhibitors are a new therapy, the implications for medication-taking are unknown. We 
used grounded theory to explore the process of medication-taking for patients with NSCLC who 
were receiving therapy with oral EGFR inhibitors. We sought to describe the medication-taking 
process, and identify factors influencing medication-taking. We enrolled men and women from a 
National Cancer Institute-designated cancer center aged 18 years or older with NSCLC receiving 
oral EGFR inhibitors who were able to speak, read, and understand English. Exclusion criteria 
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included central nervous system metastases and evidence of cognitive impairment as assessed by 
the Mini-Mental Status Exam. Thirteen participants were purposively selected for variation in 
gender (5 men/8 women), race/ethnicity (2 non-whites), age (52-83 years), time in therapy (1 
week to 6 or more years), dose reductions (n = 5), and therapy discontinuation (n = 2). 
Theoretical sampling focused on age and health insurance carrier. Data were collected through 
32 semiformal and brief interviews concerning one’s medication-taking behaviors related to 
therapy with oral EGFR inhibitors. We employed constant comparative and dimensional 
analyses. The basic psychosocial process, Surviving Lung Cancer, which participants framed 
within the recognition of NSCLC as a life-limiting illness without cure, included a dynamic 
process of (a) Deciding to take targeted therapy with erlotinib, (b) Preparing for erlotinib, and 
(c) Treating lung cancer as a chronic condition. Participants described thresholds that may result 
in stopping erlotinib, including side effects and cost. Men described taking erlotinib therapy in 
partnership with their spouse; most women managed erlotinib alone. These findings may provide 
the theoretical basis for developing patient-centered interventions to address medication-taking. 
5.5 INTRODUCTION 
Lung cancer is the leading cause of cancer deaths in the US for both men and women, with 
approximately 160,340 deaths estimated for 2012 (Siegel et al., 2012). The 5-year relative 
survival rate for patients of all stages is 16% (Siegel et al., 2012). Traditionally, patients with 
non-small cell lung cancer (NSCLC) have been treated with surgery, radiation therapy, and/or 
intravenous chemotherapy. Recently, NSCLC treatment has shifted to the use of oral targeted 
therapies, such as tyrosine kinase inhibitors (Aisner, 2007). For patients with NSCLC, clinical 
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development of tyrosine kinase inhibitors has focused on the epidermal growth factor receptor 
(EGFR) with some agents already approved for clinical use. Erlotinib (Tarceva®, OSI 
Pharmaceuticals, Farmingdale, NY), an oral EGFR inhibitor, has been shown to increase 
survival, decrease symptoms, and improve physical functioning and quality of life for NSCLC 
patients (Bezjak et al., 2006). Furthermore, research has shown that patients with EGFR 
mutations, specifically deletions of exon 19 and exon 21, respond well to therapy with EGFR 
tyrosine kinase inhibitors (Miller et al., 2008; Sequist et al. 2008). As such, the National 
Comprehensive Cancer Network (2011) recommends treatment with erlotinib as first-line 
therapy for patients with NSCLC with an EGFR mutation. 
Oral EGFR inhibitors play a key role in the management of advanced stage NSCLC.  
Targeted therapy for NSCLC treatment is unique in its mechanism of action and side effect 
profile and is generally taken daily until disease progression (weeks to years), unlike oral 
chemotherapy (e.g., capecitabine) or hormonal therapy (e.g., anastrozole). Medication-taking 
requires activities such as identifying and counting pills, timing pill taking, and refilling 
medication prescriptions (Russell et al., 2003). Qualitative inquiry provides unique information 
about medication-taking behaviors and experiences of patients with chronic disorders (Chen et 
al., 2007; Erlen & Happ, 2006; McCoy, 2009; Russell et al., 2003). Most qualitative studies of 
medication-taking of patients with cancer, however, have focused on children or adolescents who 
have developmental issues such as egocentrism, concrete thinking, and parental involvement 
(Landier et al., 2011; Malbasa et al., 2007). The medication-taking process for individuals with 
NSCLC taking oral EGFR inhibitors has not been described and is crucial to providing 
comprehensive patient-centered care and developing and testing interventions tailored to the 
needs of individuals with NSCLC. 
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5.6 METHODS 
We explored the process of medication-taking for adults with NSCLC receiving oral EGFR 
inhibitor therapy. We aimed to describe the process of medication-taking and identify factors 
influencing medication-taking of the prescribed regimen. The philosophical orientation that 
informed our methods and analysis was positivist grounded theory for the purpose of 
constructing, testing, and refining theory from data (Corbin & Strauss, 2008; Glaser & Strauss, 
1967). 
5.6.1 Setting and Sample 
The University of Pittsburgh Institutional Review Board approved this study. Informed consent 
was obtained from all participants prior to data collection. The sample included patients treated 
for NSCLC at two outpatient lung cancer clinics at a National Cancer Institute-designated cancer 
center in the USA. The primary investigator (PI; KW) was not part of the clinical care team and 
used clinic observations and chart reviews to screen eligible patients and to understand the 
participant’s treatment trajectory. Members of the clinical team, an oncologist, a nurse 
practitioner, physician’s assistant, or a collaborative nurse, identified and approached potential 
participants to assess their interest in study participation. The PI met with interested patients in a 
private area at the recruitment sites or discussed the study by phone.  
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5.6.2 Participants 
Men and women over 18 years of age with NSCLC (any type/stage) receiving an oral EGFR 
inhibitor and able to speak, read, and understand English were eligible to participate. Exclusion 
criteria included a primary cancer that had metastasized to the lung or a second primary cancer, 
current metastasis to the central nervous system, or evidence of cognitive impairment as assessed 
by Mini-Mental Status Exam (MMSE) (Folstein et al., 1975) scores at or below the borderline 
range (1.4 standard deviations below the age and education scaled norm (Spreen & Strauss, 
1998).  
Participants were purposively selected for variation in gender, race/ethnicity, age, time in 
therapy, reductions in dose of their EGFR inhibitor, and discontinuation of therapy (Sandelowski 
et al., 1989). Theoretical sampling focused on age and type of health insurance coverage. Twenty 
patients were approached for their interest in the study; one was excluded for a second primary 
cancer and six did not enroll (e.g., unreturned calls, “too much going on,” disclosure concerns, 
declining performance status). The characteristics of the study participants were similar to those 
who did not enroll (data not reported). We achieved theoretical saturation after 13 participants 
were interviewed. The study sample (N = 13) consisted of five men (38.5%) and eight women 
(61.5%) ranging from 52 to 83 years of age (Table 8). 
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Table 8: Participant sociodemographic-, illness-, and treatment-related characteristics 
Characteristic Participants 
(N = 13) 
  
Age (in years)  
     Mean (range) 
 
70.5 (52 - 83) 
Years of education  
     Mean (range) 
 
14.6 (11 - 22) 
Marital status n (%) 
Married 
Never married 
Widowed 
 
9 (69.2) 
1 (7.7) 
3 (23.1) 
Ethnicity n (%) 
        White 
        African American 
        Asian 
 
11 (84.6) 
1 (7.7) 
1 (7.7) 
Gender n (%) 
 Male 
 Female 
 
5 (38.5) 
8 (61.5) 
Health care insurance coverage n (%) 
          Managed Medicare 
          Commercial Insurance 
          COBRA 
 
            8 (61.5) 
4 (30.8) 
1 (7.7) 
Stage at diagnosis n (%) 
          II/IIa 
          IIIb/IV 
 
2 (15.4) 
11 (84.6) 
Reductions in dose of EGFR inhibitor 
therapy 
5 (38.5) 
Discontinued therapy with EGFR 
inhibitor 
2 (15.4) 
Note:  COBRA = Consolidated Omnibus Budget Reconciliation Act health insurance; EGFR = epidermal growth 
factor receptor inhibitor. 
 
Most were retired (76.9%), white (84.6%), married (69.2%), had NSCLC 
adenocarcinoma (76.9%), and had managed Medicare health insurance (61.5%). Six (46.2%) had 
a documented mutation of the EGFR gene. Participants took erlotinib for 1 week to 6 or more 
years. Two participants took erlotinib as part of a clinical trial but received it through their health 
insurance. Three participants died during the study period. No participants were excluded due to 
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cognitive dysfunction. One woman declined further involvement after the first interview due to 
fatigue and “seeing too many doctors.” 
5.6.3 Interviews 
We interviewed most participants (n = 10) on multiple occasions over eleven months to capture 
the medication-taking process in early, middle and later phases of medication use. In-depth semi-
formal (n = 27) and brief (n = 5) interviews were conducted with 13 participants (1153 pages of 
data). Four participants were well established in their therapy (e.g., taking for approximately 1 
year) and nine were either in an early phase of treatment (e.g., first week to two months into 
treatment) or their medication-taking process changed during the course of the study (e.g., 
discontinued therapy due to disease progression). The PI conducted digitally-recorded interviews 
ranging from 32 to 90 minutes from August 2011 to July 2012 either at the participant’s home or 
at a location convenient for the participant that afforded privacy (Erlen & Happ, 2006; Lewis et 
al., 2006; Wickersham et al., 2011). The interview guide consisted of questions about oral EGFR 
inhibitor medication-taking behaviors (Table 9).  
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Table 9:  Sample interview guide 
Grand Tour Question Probes 
What is it like for you to take that medication? 
 
• Why/when/how did you start?  
• How does it make you feel?  
• What were you told? 
• How is it different from previous treatment? 
Tell me how you take erlotinib on a typical day. • What kind of strategies do you use to help 
you? 
• How do you decide when to take them? 
What do you find difficult? • What would be your “deal breaker”? 
Patients sometimes miss doses or find it difficult 
to take at the same time each day. How is that 
for you?  
• What happens when you miss a dose?  
• What happens when a dose is late? 
 
Some people don’t realize that they forget doses. 
Does that ever happen for you? 
• Were there unexpected, non-routine things? 
• What were you told to do if you missed a 
dose? 
Do you experience any side effects that interfere 
with taking your medicine?   
• How do you manage them? 
Who is helpful to you in taking erlotinib?  • In what ways does he/she help? 
• How have health care providers helped you? 
 
Brief telephone interviews were conducted for further validation or exploration of themes 
identified during data analyses. When a spouse or family support person was present during the 
interview (at patient’s request/agreement), their contributions were included in the transcript for 
analysis. The recorders failed for one interview, which was reconstructed immediately. 
Participants received $10 for each interview.   
Supplemental data sources included an erlotinib starter kit, journals/newsletters, 
prescription inserts, and personal documents (e.g., transcript of a speech) given to the PI by the 
participants or the clinical team. The ongoing analysis generated additional interview questions 
about treatment delays, usefulness of support groups for patients receiving oral EGFR inhibitors, 
prescription medication insurance coverage, and disclosure of lung cancer and/or EGFR inhibitor 
use to family or friends. 
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5.6.4 Data analysis 
We used descriptive statistics to characterize the sample. We reviewed each transcript while 
listening to the audio-recording for accuracy and to gain an overall impression of the 
participant’s focus. In a cyclical fashion, the transcribed data were examined line by line to label 
(open code) text that related to participants’ medication-taking of oral EGFR inhibitor therapy. 
Similar codes were grouped into categories. We then examined the relationships between 
categories of codes (axial coding) among the participants. Selective coding was used to identify 
and systematically connect the core category with other categories (Corbin & Strauss, 2008). 
ATLAS.ti (6.2.27) (ATLAS.ti Scientific Software Development GmbH, Berlin, Germany) 
software was used for data management. Other analytic techniques included questioning the data 
(Corbin & Strauss, 2008), dimensional analysis (Schatzman, 1990), matrix construction (Miles & 
Huberman, 1994), writing case titles and story summaries (Corbin & Strauss, 2008), and a 
literature review (Strauss & Corbin, 2008). 
Sampling, interviewing, and analysis continued until we reached informational 
redundancy (i.e., no new themes or patterns were recognized; n = 8); we then enrolled three 
participants for further sample diversity and to confirm existing findings. One woman was 
selected for type of health insurance carrier, because health insurance and cost of erlotinib were 
concerns frequently expressed by the participants. One man was selected for younger age.  
Rigor was maintained through vigilant documentation, member checking, dual coder 
review and discussion of all transcripts, and audit trails. Member checking was conducted by 
asking three key informants to review and comment on the constructed theory to confirm or 
refine the interpretive analysis. All three confirmed the substantive theory. In addition, publicly 
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available information (cancer support websites and personal interest stories) was reviewed and 
confirmed this process. 
5.7 RESULTS 
The basic psychosocial process constructed from the data is Surviving Lung Cancer framed 
within the context of the participants’ recognition of NSCLC as a life-limiting illness without 
cure (Figure 1).   
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Figure 1:  Surviving lung cancer:  Medication-taking and oral targeted therapy 
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Title:  basic psychosocial process 
Circles:  main themes 
 
Squares:  components of each theme (main tasks, process of each main theme) 
 
Older age and death as contextual factors:  occur along the continuum.   
 
Intervening factors:  occur usually at one point in time; for participants in this study, the intervening factors occurred during the treatment phase of 
the medication-taking process. 
 
Double arrow line:  represents that while these three phases overlap, they occur on a continuum. There is a beginning and an end to targeted 
therapy, but with multiple overlapping (or repeating steps) along the way.  
 
Single arrow lines:  represents the relationship between the contextual and intervening factors and the three phases. 
 
Dotted lines:  represent decision points in the process. 
 
Diamonds:  represent the decisions that were made by the participants 
 
Dimensions of the process (grey circles):  Constructs that crosscut each phase.  
 
HCP = health care professional (includes oncologists, thoracic surgeons, radiation oncologists, psychiatrist, radiation therapists, infusion nurses, 
nurses, collaborative nurses, nurse practitioner, physician’s assistant, clinical research coordinator, pharmacists, visiting nurse, or other health care 
providers that take part in the participant’s care) 
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Three dynamic phases comprise the process: (a) Deciding to take targeted therapy with 
erlotinib, (b) Preparing for erlotinib, and (c) Treating lung cancer as a chronic condition. Each 
phase includes components that participants addressed before proceeding to the next phase with 
forward and backward movement affected most often by the cost of erlotinib, disease 
progression, side effect severity, and/or anticipation of death. The patients’ survival is 
characterized by an ongoing struggle between their recognition of “what will be, will be” despite 
taking erlotinib every day and their continuing hope for survival. 
Nearly all participants (10/13) discussed taking erlotinib as a vehicle for hope of 
surviving their lung cancer, “If you care and you want to survive this cancer, then you do it.” 
Others referred to erlotinib as “the miracle drug” or a “magic pill” meaning that “it worked (took 
effect) right away.” Managing erlotinib therapy and contending with the hope of a miracle were 
issues participants faced “24/7.” They were surviving NSCLC for a period of time (weeks to 
years) and all that they managed in taking erlotinib centered on survival. The meaning of 
survival in the context of a chronic terminal illness differed among the participants (“Just a 
challenge to see how long I can live” “getting back into the mainstream”), but the process of 
surviving was similar for all. 
. . . If I stop the drug the tumors can grow back, so you either take it and deal with any 
side effects or little inconveniences like having to wear solar protective clothing . . . 
waiting the hour before you can eat . . . being faithful to taking the medicine, or you 
throw in the towel, give up and say, “What will be will be,” and I’m not going there . . . 
that’s not me. 
5.7.1 Deciding to take Erlotinib Therapy 
All participants described conditions central to a complicated decision-making process for 
choosing erlotinib therapy. Some took erlotinib on “doctor’s orders,” motivated by faith in their 
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oncologist, “I decided a long time ago to put my faith in Dr. (oncologist). And when he said, 
‘this is what I think you should do,’ that’s what I did.” Other participants initiated erlotinib 
therapy based on the combined advice of their clinical team, family, and/or friends. 
I don’t know if it’s blind faith…when I was first diagnosed, and you’re talking to various 
people about where to go, and everybody has some advice for you to go to Texas, go to 
Ohio . . .and I felt like [cancer treatment center] had a good reputation . . . I think it was 
a neurologist that I saw where this all started, and she recommended [surgeon] and 
[oncologist] because they had good reputations . . . plus we had a friend in Philadelphia 
that works for [pharmaceutical company], and she knows all the doctors there, and they 
knew [oncologist] and spoke highly of him. So it was all of these things kept leading back 
to [oncologist] . . . 
 
Unacceptable toxicities or failure of other therapies were also conditions for starting 
erlotinib therapy. For example, a woman took erlotinib after seven other therapies: 
I was able to tolerate it (chemotherapy) but . . . he (oncologist) said I can’t stay on it 
forever . . . he said to switch to the Tarceva® because I was starting to get numbness 
(from chemotherapy) . . . a little bit. The neuropathy in the hands and the feet-just a little 
bit but he said it’s irreversible if it gets too bad. 
 
Participants also took erlotinib because of an identified or presumed genetic mutation, 
framing this genetic compatibility as “what works best with my NSCLC.” Most were aware of 
their mutation status and some specifically sought erlotinib treatment. A participant’s daughter 
described:   
I had read a lot on there [a cancer website] about Tarceva® and the EGFR mutation . . . 
which is why we asked the doctor to test him for it because I tested positive for it-and I 
guess generally they won’t test somebody at his age group [80s] for it- but because there 
was a family history they tested. And he did test positive. 
 
A man who took erlotinib for over two years summarized the considerations in his treatment 
decision-making process as follows: 
I told my doctor . . . if he couldn’t improve on the first two experiences [chemotherapy], 
then I wanted to switch over to Tarceva®. And I came in with the knowledge about 
Tarceva-my cousin . . . had been on Tarceva® for three years. And the median longevity 
the doctor said was eleven months . . . so I was encouraged because its effectiveness kind 
of varied according to genotype . . . indeed I had a good match with the drug. 
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5.7.2 Preparing for Erlotinib 
Preparing to take erlotinib refers to undertaking steps toward obtaining and managing erlotinib, 
framed by the participants as “preliminary work.”  
It’s concerning . . . there’s so much preliminary that goes: first of all securing it . . . and 
then when you get it and read the directions, it’s, “keep it at certain temperature,” and, 
“wash your hands after taking the pill,” which I have never heard of before. So, just in, 
preparing and getting the pill . . . there is enough to let you know that this is something 
beyond an aspirin.  
 
This man’s description is evidence that the preparing phase serves to alert participants to 
the importance of erlotinib. Preparing for erlotinib included finding a specialty pharmacy, 
securing the medication through mail order, and deciphering the directions for taking erlotinib 
such as, “avoid grapefruit juice” or “I can’t sit in the sun.” Often, the directions for taking 
erlotinib were a hint for its potency:  
It’s an extremely powerful drug . . . of course when you get the drug, it tells you when you 
handle it, to wash your hands. That’s my first tip-off, “Hmm, ok, I should keep these in 
their own little bottle.” 
 
The participants obtained information about what erlotinib does, how to take it, and how 
to get it from brochures, books, and/or a starter kit. Some participants deliberately avoided 
searching the Internet for information because “sometimes, not knowing is better.” Others 
searched the Internet but were selective, “I go there (American Cancer Society) or I look in the 
information from (cancer center) … I just don’t get on and read . . . because I think there’s a lot 
of false information out there.” 
Paying for erlotinib was at the heart of the preparing phase. Nearly all participants 
referred to the high cost, “It’s expensive. I want them to know that.” Many felt the cost of 
erlotinib was prohibitive. A woman who stopped taking erlotinib due to expensive co-
payments affirmed:  
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Most patients figure it’s not worth it if you’re dying, you have cancer. Some would like to 
live but where’s the funds for you to survive? You can’t. They’ll break you, I tell you, this 
medication will break you . . . if you have to pay for it without insurance. It will break 
you in no time. In no time . . . Even if you pay with insurance, it’s (the cost) still high. 
 
Four participants received financial assistance either to pay for erlotinib or to defray the 
cost of prescription co-payments, but several struggled to obtain financial assistance and 
approval, “Well . . . the first time, the insurance kept denying it. And my son . . . works for 
Medicare . . . he’s the one that suggested, ‘Write a letter to the foundation’ . . . they can only say 
no.’” A daughter described her experience in obtaining funds for her father’s medication: 
They (health insurance company) decided they would cover 10% of it. Well 10% of $5000 
is [leaves] a lot of money every month [to pay] . . .  I talked with [foundation 
oncologist]…and he got me in touch with the [foundation]…once they got that paperwork 
and approved that yes, he did need the medication, and agreed that yes, he could take it 
first-line… literally within days they called, and said, “Ok, your dad’s been approved” . . 
.  “alright, what’s his co-pay?” “Zero.” And I was, “Are you kidding me?” 
 
Securing payment assistance approval for erlotinib resulted in a treatment delay (“So I 
got on the pill about 30 days later”), one that was not always apparent to the clinical team (“I 
don’t think that they [doctors] realize . . . he probably thought that I went to the pharmacy and 
got it”). Not meeting the assistance criteria and increasing drug prices added additional 
challenges for the participants. Furthermore, taking two strengths of erlotinib requires two co-
payments, adding an additional expense for a patient. In one case, the co-payment influenced the 
erlotinib dose that was acceptable to the patient, “ . . . You pay for 100 (mgs), and then 25 (mgs), 
there’re two prescriptions. There’s two co-payments there. So it costs a lot more. So if I go back 
to 150 (mg) then it’s just one co-payment.”   
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5.7.3 Treating Lung Cancer as a Chronic Condition 
The culmination of successfully navigating the deciding and preparing phases was advancement 
to treating lung cancer as “a chronic condition.” This phase represented the day-to-day 
challenges the patients experienced related to taking erlotinib and involved their recognition of 
the chronicity of therapy (“We need to see where this drug will take me and it’ll give me a break 
from [chemotherapy]. (The doctor’s) not guaranteeing that there’s going to be any, you know—
he’s just looking for maintenance.” “I don’t think that Tarceva will totally eradicate my lung 
cancer . . . but it’s . . . making things not grow”). Treating NSCLC as a chronic condition 
included one’s recognition of his/her ownership of the process of taking medication, “So I want 
to make sure that it’s effective by following . . . the directions and . . . if it says to take it the 
same time every day I want to be sure that I take it the same time every day.”  
The mechanics of taking erlotinib daily often included comparison to an over-the-counter 
medication, such as aspirin or iron tablets, “My iron tablet was worse, so I haven’t been taking 
those, but no, I haven’t really had too much of an adjustment.” All participants described 
routinization, the process by which taking erlotinib became a habitual or consistent practice, “It’s 
a matter of discipline.” Routinization was associated with timing erlotinib with an empty 
stomach (e.g., 2 hours before breakfast), a location (e.g., bedside table, dresser, living room 
table), time of day (e.g., AM or PM), and/or a storage strategy (e.g., pill minder or pill bottle). 
Routinization also involved the use of an alarm or other reminder (e.g., cats awaken a woman), 
visual aid (e.g., clear glass on a table filled with medication), or a physical or active cue (e.g., 
moving pill bottles from the front to the back of a table) to take erlotinib. 
Women who lived alone used a calendar or a steno pad to track their doses of erlotinib, 
while participants who lived with a spouse tended to rely on the storage strategy as a means of a 
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“checks and balances” system for remembering to take erlotinib. One woman admitted that she 
occasionally missed a dose (“I’m human, I miss some days”); however, most indicated that they 
never had difficulty remembering to take erlotinib because they associated it with a storage 
strategy and a location (“I know because it’s all in that jar, it’s all in that little glass that I put on 
the kitchen counter, so there’s no questioning later on”), time of day (“’Cause it is the first thing 
that I do in the morning”), or a proactive refilling strategy. Men often indicated that they never 
forgot to take erlotinib because their wives either prepared or gave it to them, so “there’s no 
question that the transaction takes place.”  
Participants recognized a need for “having help” in their daily survival. They 
described/found support from their family or friends, Internet blogs and chat rooms, and/or pets. 
Family/social support included both assistance with taking medication and active participation in 
special family connections, living the family moments, and being involved in the present. 
Enjoyment of family time served as further motivation for taking erlotinib daily (e.g., to see a 
grandson play baseball). The participant’s and his/her family’s prior experiences with cancer 
(e.g., spouse or parent who died from cancer) colored how they interacted with each other during 
their process of surviving lung cancer. These patients shared a perceived survival obligation to 
family members, friends, or prior research participants and to those who have died. 
. . . my brothers want me to survive this cancer, I guess maybe if I can survive this long, 
they want me to survive a little longer. . . and I shouldn’t let them down. 
 
The medication has unique side effects related to inhibition of the EGFR pathway. All 
participants experienced side effects and recognized this as a part of managing the disease. The 
most commonly reported side effects were rash, diarrhea, stomach cramping/gastrointestinal 
upset, nail issues (e.g., nail splitting), eye itching, long eyelashes (“it looked like spider legs, it 
was wild”), hair changes, nausea, and fatigue. Rash and diarrhea were referred to as “social 
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inhibitors”. The “social inhibitors” were especially bothersome and stigmatizing if one was 
working full-time: 
The biggest thing is you become . . . a little self-conscious because you know your face is 
all splotchy or red, and, although I’ve seen some of the pictures where it’s very severe-
thank God I haven’t gotten to that point, but you know, it’s a little bit of a pain . . . I don’t 
want people looking at me, so it’s almost like I cover it (rash) up because it’s just treat 
me like I’m the same old person and not “Hey, there’s a cancer guy.” 
 
Several participants (5/13) had reductions in their erlotinib dose due to side effect 
severity: 
I reached a point about 2 months into it where everything was changing…I said to 
my husband, “What’s on this sandwich?” . . . “It’s burning my mouth” . . . I 
noticed things burned when I ate, everything was hot to me, in my mouth, spicy 
hot . . . I went in, and I said, “I can’t take this drug, I can’t eat. Everything is hot 
to me in my mouth. And (oncologist) said, “no, no, no, no, no, you’re doing so 
good. We’ll lower the dose, we’ll put you on 100 mg dose.” I said, “OK, I’m 
willing.” 
 
Despite the severity of side effects, the participants expressed their commitment to taking 
erlotinib, “You know if it’s keeping me alive, I’ll accept it.” While some admitted to skipping a 
dose when they experienced a distressing side effect, others perceived the rash as a hallmark for 
the effectiveness of erlotinib, “ . . . I didn’t have the rash, but I’ve had a few pimples . . . and so I 
feel like because I have the side effects it must be working.” 
Surviving lung cancer included rigorous self-assessment, self-maintenance, and external 
assessments required of one with advanced cancer. All participants discussed the role of exercise 
(e.g., swimming, Jazzercise), nutrition, routine health screenings (e.g., mammograms), 
prevention of EGFR inhibition-related side effects (e.g., sun protective clothing, lotion without 
alcohol), and self-examination for new or worsening side effects as crucial activities for 
surviving lung cancer. Periodic reassessments of lung cancer could prompt an increase in the 
dose of erlotinib, no change in dose, or discontinuation of therapy. Participants discussed the 
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importance of “keeping busy” and “staying active” as a means of engaging the body and mind in 
their survival, particularly the older participants, “I’ve been really busy. I’m always busy. I like 
to be busy. I don’t want to sit around and—so.”  
If you have a lot of exercise, you don’t feel the effects of the drug so much. But if 
you don’t exercise, you feel it all the time. For some reason, you can’t take your 
mind off of it.  And I think it’s partly psychological . . . I don’t feel good, I pack 
my swim bag and I go out. If I don’t feel good at the swimming pool . . . I go out 
for a walk. You find something other than your own illness to look at . . . 
 
Paying for erlotinib was an ongoing struggle during the maintenance phase of the 
medication-taking process. Some became acutely aware of the cost associated with each pill, 
“Ok, I’m going to stick this in my mouth and this is $200, and I don’t want to waste it.” 
Difficulty with paying for erlotinib was particularly evident in the extreme case of a survivor 
who stopped taking erlotinib due to co-payments that had increased from $60 to $600 over a 6-
year period for a 90-day 100 mg prescription. Stopping erlotinib due to cost can be heartbreaking 
because the medication “gives you hope” and discontinuing it “takes that hope away.” 
After a woman mentioned the need for support groups for individuals who take erlotinib 
as a means for sharing experiences, we added a question about peer support groups to the 
interview guide. Subsequent participants concurred, “That’s the truth.  I agree. I wish I had had 
someone to talk to.”  
I definitely think it would have . . . no information has ever been given to us regarding 
small groups for lung cancer, lung cancer families, or Tarceva-taking patients. All of that 
would have been helpful. I don’t think there is a lot of that out there. 
 
Women who attended other types of support groups (e.g., American Cancer Society’s 
“Look Good, Feel Better” program), who had previous experiences with treatment with an 
intravenous EGFR inhibitor, or who began taking erlotinib immediately after approval (2004) by 
the Food and Drug Administration did not feel a lung cancer-specific support group would have 
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been helpful unless participants were grouped according to similar characteristics such as age, 
race/ethnicity, or time on therapy. 
5.7.4 Dimensions of the Process 
As analysis progressed it was evident that several dimensions of the survival process crosscut all 
phases, particularly advocacy and the related negotiation required for daily survival especially 
when weighing the benefits versus the risks of erlotinib therapy. Negotiating by the participant or 
by a family member or clinician on behalf of the participant was evident in every phase of the 
process. In particular, advocacy occurred on a continuum, ranging from a very active between a 
participant and a clinician to a more directive role, “You have to be very active in your own 
care.” 
I just asked him [oncologist] to lower it [dose of erlotinib]. I said I “don’t feel 
comfortable with it” so I just asked him to just lower it. It didn’t know what was 
bothering me, but something was bothering me. So I told him to lower it. 
 
Constant uncertainty related to the cause of side effects or of lung cancer, who to go to 
for information or treatment, or next steps in treatment (“where do we go from here?”) produced 
a longing for living life to the fullest because “you never know when your ship’s going down”. 
Participants discussed the wish for “quality of life, not quantity” or “feeling normal.” Family was 
central to living life to the fullest for these survivors who described prioritizing family time, 
planning exotic family vacations, and relishing “ordinary” events such as a grandchild’s baseball 
game. 
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5.7.5 Contextual Factors: Older Age and Death 
Older age provided context to surviving lung cancer. Participants recognized the vulnerability 
associated with being one who is aging with a terminal disease as both a barrier to and a reason 
for starting therapy and as a confounding factor in determining the causality of side effects or 
other symptoms. Age provided context to self-management of NSCLC for an older adult 
(especially a single older adult) on a fixed income who was facing challenges with diet, 
obtaining nutritious foods, meal preparation, exercise/activities, and payment for long-term 
medication. This was particularly significant when discussing the need for going to extremes to 
pay for erlotinib, “I wanted to exhaust all that (options) first and then use my retirement money.” 
“Death talk” was common in all interviews and provided additional context for 
participants’ view of survival.  Death talk referred to spoken or unspoken reference to 
anticipating death and was regularly intertwined with discussions about family and 
friends.  
[Spoken tearfully] When they (grandchildren) leave I come in the house and I cry 
because I just have so much fun with them. It’s not because I have cancer-it’s 
because I just have so much fun and that’s how I want them to remember me. 
 
Surviving to the fullest in the time the participants had remaining was key 
because “it could end in a year or two.” Death talk occurred in almost all interviews, but 
was more prominent in the final interview. Anticipation of death appeared in all points of 
the survival process, beginning with starting erlotinib therapy (“they told me it was 
eleven to twelve months median [survival]”) to treating lung cancer as a chronic 
condition:  
I’ve survived longer than they’ve thought, I guess. I remember the first year, I was 
diagnosed in the fall, the gardener puts in tulips, and I said to him, “I hope I see 
them in the spring.” You know, I did. And I’m very grateful. 
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5.7.6 Intervening Factors 
Factors occurring at one point in time during the surviving process, such as disease progression, 
anticipation of death, and real or hypothetical “thresholds” for reduction in dose, interruption, or 
discontinuation of erlotinib could derail taking erlotinib. Thresholds referred to reaching one’s 
limit; some participants had reached theirs at the time of their interview, while others knew what 
their limits would be but had not yet reached them. Actual thresholds included cost of erlotinib 
and side effect severity (e.g., rash, diarrhea, dehydration). Two participants stated that 
experiencing pain related to cancer would lead to stopping erlotinib. The potential for worse side 
effects with higher doses of erlotinib frequently brought feelings of dread: 
It’s a dread, I guess, it’s a dread of taking you know the 75 mg (from 50 mg) . . . 
I’ll just have to wait and see . . . because if the 75 makes me worse-or feel worse, 
I may just say “The hell with it.” 
5.8 DISCUSSION 
Our purpose was to develop a substantive theory that explained the process of medication-taking 
for individuals with NSCLC receiving oral EGFR inhibitor therapy. “Surviving lung cancer” was 
grounded in the data and fit the participants’ descriptions of their medication-taking process, 
which included deciding to take erlotinib, preparing to take an expensive and powerful daily oral 
medication for treatment of NSCLC, and treating lung cancer as a life-limiting chronic condition. 
Each distinct phase had crosscutting dimensions such as advocacy and uncertainty. Our findings 
illustrate the active participation and sacrifice that patients with NSCLC willingly endure in 
taking this class of medication. 
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We sought to understand how persons with NSCLC actually took erlotinib daily, rather 
than whether or not they took it as prescribed (McCoy, 2009). In their descriptions of surviving 
lung cancer, our participants voiced comparable aspects of medication-taking to those reported in 
grounded theory studies of older adults with heart disease (Chen et al., 2007) such as perceived 
effectiveness of medication (how well it works), developing partnerships with and trust in their 
health care team, and seeking and sharing information. Consistent with Gray’s (2006) study of 
persons living with human immunodeficiency virus, our participants realized the benefits of 
therapy and made a conscious decision to live through taking a ongoing therapy; however, 
published reports of grounded theory studies for persons with chronic conditions often use the 
terms “adherence” (following a regimen as prescribed) (Haynes et al., 2008) and “medication-
taking” (the work of adherence) (McCoy, 2009) synonymously. Unlike these reports, our 
findings describe not only the work required to take the medication, but also the processes and 
motivation required to survive a chronic terminal disease. The “adherence lens” excludes 
exploration of the meaning of the medication to participants and the larger social-psychological 
context within which medication-taking occurs. Our previous study of women with early stage 
breast cancer receiving therapy with an aromatase inhibitor, anastrozole, examined medication-
taking and discovered that value/importance of medication, side effect severity, and medication 
self-management were primary constructs in medication self-management in the early phase of 
breast cancer survivorship (Wickersham et al., 2011). These constructs are amplified in the case 
of persons with NSCLC for whom procuring erlotinib, sustaining erlotinib therapy, managing 
side effects, and spending time with family were key components to surviving lung cancer. 
Older age and anticipation of death provided context to the stories of the participants’ 
surviving process. Medication-taking processes included aspects of self-care for older adults with 
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a chronic life-limiting disease on fixed incomes who face challenges with meal preparation, diet, 
obtaining nutritious foods, exercise, activities, and payment for erlotinib. Anticipation of death 
was an undercurrent for all participants, but appeared more in the forefront when erlotinib was 
no longer effective in treating their lung cancer. 
The findings provide strong evidence for revisiting the definition of cancer survivorship, 
a term with inconsistent operational definitions (Khan et al., 2012). The National Coalition for 
Cancer Survivorship defines “cancer survivor” as one “from the moment of diagnosis and for the 
balance of life,” whereas the National Cancer Institute (2012) defines survivorship as focusing 
on the physical, psychosocial, and economic aspects of health and life post-treatment until end of 
life. Furthermore, the traditionally implemented five-year cut-off point does not apply for those 
with cancer who die within the first year of diagnosis (Kahn et al., 2012), such as patients with 
NSCLC (16% 5-year relative survival; Siegel et al., 2012).  
Regardless of the definition, “cancer survivor” usually infers one who is cancer free 
(Mullan, 1985). This was not true for our participants with advanced NSCLC. Our findings were 
similar to that of Kagan (1997) regarding older adults with cancer who were “integrating cancer 
into a life mostly lived” (p. 43). Our participants’ process concerned living with, managing, and 
integrating cancer into their daily lives (Kagan, 1997). The identification of thresholds for which 
older adults with NSCLC determine under what conditions one will or will not live with erlotinib 
therapy is also similar to Kagan’s (1997) findings. Our participants’ process adds to existing 
knowledge by including the economic realities of survivorship. Their narratives exemplified the 
tension between knowing the limits of treatment for a condition that is unlikely to be cured and 
their own limits with taking that treatment (e.g., cost, side effect severity). Family and social 
support went beyond medication assistance; rather, social support encompassed living in the 
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moment and cherishing family time. Family history influenced patients’ response to cancer and 
underscored the importance of surviving for as long as possible for friends or family members 
who did not or could not survive themselves.  
Our findings should be interpreted in light of several limitations to the study.  The sample 
was obtained from a single cancer center. Purposive sampling to maximize variation of 
participants was used to minimize this limitation. Our participants were similar in age and 
racial/ethnic make-up to the national NSCLC population (American Cancer Society, 2012); 
however, our sample included more women than men. Additionally, almost half of our 
participants had a documented EGFR mutation; the participants’ awareness of their mutation 
status may have led them to be more committed to treatment with erlotinib. To address these 
potential limitations, the developing theory was shared with key participants and clinicians at the 
cancer center to best understand comparability and transferability of the findings. 
Our findings provide the theoretical foundation for development of a tailored intervention 
for improving medication-taking.  The most striking implications of this study are in the areas of 
affordable care and prescribing practices. High costs of medication and prescription co-payments 
were thresholds for treatment discontinuation for some and a source of concern for all. Several 
participants, specifically older women who lived alone, charged the PI with addressing this issue. 
Plans for long-term survivorship for one with advanced NSCLC should include a plan for 
affordable care and access to medication over time because insurance benefits may change or 
reach limits. Current avenues for long-term access are unclear. Further study of cost and self-
advocacy as they relate to medication-taking, surviving NSCLC, and health policy is critical. 
Furthermore, we learned that patients manage two co-payments for two strengths of erlotinib 
(one co-pay for each strength). It is unclear whether this is due to usual practice or pharmacist 
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preference. Higher prescription co-payments have been associated with both nonpersistence and 
nonadherence to oral hormonal therapy for women over the age of 65 with early-stage breast 
cancer (Neugut et al., 2011). Assessment of access to medication is still needed for older men 
and women with advanced NSCLC on a fixed income. Moreover, clinicians must reassess the 
patient’s access to medication over time as insurance benefits may change or reach limits. 
We present the participants’ stories of surviving lung cancer, but the clinician perspective 
is an integral part of that story. Given the central role that clinicians play in assisting with 
procurement and maintenance of therapy and the suggestion from these data that clinicians may 
not be fully aware of cost and access to treatment problems, further studies of medication-taking 
that include the clinician perspective are needed.  
Generally, participants endorsed peer support groups for persons with NSCLC taking 
therapy with erlotinib. This suggests that support groups or group interventions based on select 
characteristics (e.g., gender, age, time in therapy) that address medication-taking and navigating 
concerns of survivorship are indicated for individuals with NSCLC. 
We sought to explore the process of medication-taking for persons with NSCLC 
receiving therapy with an oral EGFR inhibitor. We developed a substantive theory that explains 
the process of medication-taking as it relates to patient survival of NSCLC. Our results 
contribute to understanding how persons with NSCLC view themselves, the work they do to take 
an oral EGFR inhibitor, and their daily process of surviving lung cancer. 
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6.0  SUMMARY 
Our purpose was to describe the medication-taking process of and to identify factors influencing 
medication-taking for adult men and women with NSCLC who were receiving therapy with an 
oral EGFR inhibitor. Using grounded theory methodology and analyses (Strauss & Corbin, 2008; 
Glaser & Strauss, 1967) we developed a substantive theory for individuals receiving therapy with 
erlotinib that explained their process of medication-taking. Thirteen participants were 
purposively selected for variation in gender (5 men/8 women), race/ethnicity (2 non-whites), age 
(52-83 years), time in therapy (1 week to 6 or more years), dose reductions (n = 5), and therapy 
discontinuation (n = 2). Theoretical sampling focused on age and health insurance carrier. Data 
were collected through 32 semiformal and brief interviews concerning one’s medication-taking 
behaviors related to therapy with oral EGFR inhibitors from July 22, 2011 to August 6, 2012. 
We employed constant comparative and dimensional analyses. The basic psychosocial process, 
Surviving Lung Cancer, which participants framed within the recognition of NSCLC as a life-
limiting illness without cure, included a dynamic process of (a) Deciding to take targeted therapy 
with erlotinib, (b) Preparing for erlotinib, and (c) Treating lung cancer as a chronic condition. 
Older age and anticipation of death provided context to the stories of the participants’ surviving 
process. Participants identified real or potential thresholds that would determine the conditions 
under which one would or would not live with erlotinib, including cost of erlotinib, side effect 
severity, and pain related to cancer. Three key informants were selected to review and comment 
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on the constructed theory to confirm or refine the interpretive analysis, who confirmed the 
conceptual model. We reviewed public websites (e.g., Cancer Grace and Inspire), which 
demonstrated that patients with advanced stage NSCLC have similar concerns about treatment 
for lung cancer and management of side effects and provided external validation of the 
psychosocial process. Findings were shared with the clinical team, who confirmed the difficulty 
that patients encounter in paying for erlotinib and with managing side effect severity. Findings 
were also shared with the infusion nursing staff of the second floor treatment are of the cancer 
center, who confirmed the study results. 
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7.0  LIMITATIONS 
Our findings should be interpreted in light of several limitations to the study. First, the sample 
was obtained from a single cancer center. Purposive sampling to maximize variation of 
participants was used to minimize this limitation. However, it is possible that patients from more 
rural areas may have responded differently. Second, when compared to the national population 
of patients with NSCLC, our participants were similar in age and racial/ethnic make-up 
(American Cancer Society, 2012); however, our sample included more women than men. On 
reflection, it could be that women were more likely to share their stories than men. The findings 
of the study were shared with two women and one man to mitigate this potential limitation. All 
three participants confirmed the findings. Third, about 10% of patients with NSCLC have a 
mutation in the EGFR gene that is associated with better response to an oral EGFR inhibitor 
(Fukuoka et al., 2003; Kris et al., 2003). In our study, almost half of our participants had a 
documented EGFR mutation. Quite possibly the length of survival we saw in our patient sample 
was colored by the number of participants with the mutation. In addition, their awareness of their 
mutation status may have influenced their commitment to treatment with erlotinib. To address 
this potential limitation, the developing theory was shared with both key participants and 
clinicians at the cancer center to best understand comparability and transferability of the 
findings. 
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8.0  CONCLUSIONS 
We sought to explore the process of medication-taking for persons with NSCLC receiving 
therapy with an oral EGFR inhibitor. Using qualitative data obtained through 32 interviews with 
the 13 participants, we developed a substantive theory, Surviving Lung Cancer, that explains the 
process of medication-taking as it relates to the participants’ survival of NSCLC. Our results 
contribute to understanding how persons with NSCLC view themselves, the work they do to take 
an oral EGFR inhibitor, and their daily process of surviving lung cancer.  
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9.0  IMPLICATIONS 
Our results provide the theoretical foundation to guide future research concerning medication-
taking for individuals receiving therapy with an oral EGFR inhibitor with the goal of 
development of a tailored intervention for improving medication-taking. First, our results 
challenge the generally accepted definition of cancer survivor as one who has finished treatment 
for cancer. The paradigm shift to the use of more oral targeted therapies for persons with NSCLC 
also shifts the definition of cancer survivor from post-treatment to one who is integrating oral 
targeted therapy into daily life. Exploration of survivorship for persons with NSCLC is indicated, 
including comparisons to individuals with long-term conditions that have acute exacerbations 
(e.g., pulmonary fibrosis, acute respiratory distress syndrome) and to individuals with other types 
of cancer who are receiving oral targeted therapy (e.g., leukemia, breast cancer). 
Second, the most striking implications of this study are in the areas of affordable care and 
prescribing practices. High costs of medication and prescription co-payments were thresholds for 
treatment discontinuation for some and a source of concern for all. Several participants, 
specifically older women who lived alone, charged the PI with addressing this issue. Plans for 
long-term survivorship for one with advanced NSCLC should include strategies for affordable 
care and access to medication over time because insurance benefits may change or reach limits. 
Current avenues for long-term access are unclear. Further study of cost and self-advocacy as they 
relate to medication-taking, surviving NSCLC, and health policy is needed. Furthermore, we 
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learned that patients manage two co-payments for two strengths of erlotinib (one co-pay for each 
strength). It is uncertain whether this is due to usual practice or pharmacist preference. 
Assessment of access to medication is still needed for older men and women with advanced 
NSCLC on a fixed income. 
Third, all participants provided rich description concerning the side effects they 
experienced, side effect severity and management, and thresholds for discontinuing therapy with 
erlotinib. Five participants had reductions in their dose of erlotinib due to side effect severity, 
and at least one participant recognized skin toxicity as a proxy marker for clinical effectiveness 
of erlotinib. Such findings have been reported in the literature (Eames et al., 2010); however, an 
explanation for the relationship between the rash and response to EGFR inhibitor therapy is 
elusive (Amador et al., 2004). Genetic differences among individuals have been suggested as 
potential reason for this relationship (Amador et al., 2004). Given that persons with an EGFR 
mutation are more likely to respond to therapy (Miller et al., 2008; Sequist et al. 2008), 
exploration of the individual susceptibility to side effects for patients with cancer who are 
receiving an oral EGFR inhibitor may be indicated as a first step to further understanding who 
may be at risk for difficulty with taking their oral EGFR inhibitors. 
Age provided context to self-management of NSCLC for an older adult (especially a 
single older adult) on a fixed income who was facing challenges with diet, obtaining nutritious 
foods, meal preparation, exercise/activities, and payment for long-term medication. We also 
noted some gender differences in medication-taking of erlotinib; for example, men described 
taking erlotinib therapy in partnership with their spouse, but most women (5 were married) 
managed erlotinib alone. Future studies examining differences between older and younger 
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individuals as well as men and women are needed to further understand medication-taking with 
oral EGFR inhibitors. 
We present the participants’ stories of surviving lung cancer, but the clinician perspective 
is an integral part of that story. Given the central role that clinicians play in assisting with 
procurement and maintenance of therapy and the suggestion from these data that clinicians may 
not be fully aware of cost and access to treatment problems, further studies of medication-taking 
that include the clinician perspective are needed.  
Generally, participants endorsed peer support groups for persons with NSCLC taking 
therapy with erlotinib. This suggests that support groups or group interventions based on select 
characteristics (e.g., gender, age, length of time on therapy) that address medication-taking and 
navigating concerns of survivorship are indicated for individuals with NSCLC. 
Taken together, our findings provide direction for steps toward development of a tailored 
intervention for improving medication-taking for oral EGFR inhibitors for persons with NSCLC. 
These steps include the following possible studies: (a) a concept analysis of cancer survivorship 
for persons with NSCLC that includes comparisons to individuals with other long-term 
conditions with acute exacerbations (e.g., pulmonary fibrosis, acute respiratory distress 
syndrome) and to individuals with other types of cancer taking oral targeted therapies (e.g., 
breast cancer, leukemia, melanoma); (b) a qualitative descriptive study exploring clinicians’ 
perspectives of medication-taking, to be conducted at the same NCI-designated cancer center 
where our participants were recruited as well as at a second academic NCI-designated cancer 
center for comparison of findings; (c) a descriptive correlational study exploring individual 
susceptibility to side effects for patients with cancer who are receiving an oral EGFR inhibitor as 
a first step to further understanding who may be at risk for difficulty with taking their oral EGFR 
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inhibitor; (d) a descriptive cohort study, stratified by age and gender, examining potential 
patient- (e.g., age, gender, race/ethnicity, level of education, co-morbidities, concomitant 
medications, depressive symptoms, anxiety, fatigue), illness- (e.g., cancer type and subtype, 
stage, prior therapy for cancer), treatment- (e.g., side effects and side effect severity), and 
socially-related (e.g., advocacy, type of health insurance, prescription plan assistance, access to 
medication and health care) predictors of medication-taking with oral EGFR inhibitors; (e) 
development and pilot-testing of a theoretically-based tailored intervention that includes peer 
support or group interventions and the combined findings from the first four studies; and (f) a 
randomized controlled trial examining the effectiveness of the pilot-tested (adjusted as 
appropriate) theoretically-based tailored intervention for improving medication-taking with oral 
EGFR inhibitors. Findings from these studies may also lay the foundation for exploration of 
medication-taking for individuals with NSCLC receiving a different class of oral targeted 
therapy, such as crizotinib (Xalkori®, Pfizer, New York, NY) which targets EML4-ALK, and for 
individuals with other types of cancer who are receiving oral targeted therapies, such as persons 
with melanoma with a mutation of the BRAF gene who are taking vemurafenib (Zelburaf®, 
Genentech, San Francisco, CA). 
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SOURCE OF SUPPORT:   National Institute of Nursing Research 
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Why is this research being done? 
 
You are being asked to participate in a research study because we would like to explore the 
process of medication-taking for men and women who are or have received oral targeted therapy 
for treatment of their non-small cell lung cancer (a type of lung cancer).  Medication-taking can 
be described as a complicated set of activities concerning how you take your medicines.  Oral 
targeted therapies are medicines that act on, or “target”, certain sites on or in cancer cells to stop 
the growth of a tumor.  An example of oral targeted therapy is Tarceva® (erlotinib). 
 
The experiences of men and women about their oral targeted therapy, including adherence (the 
degree to which a person follows the instructions they are given for a prescribed treatment), are 
not well known.  Information learned from this study will add to our understanding about 
medication-taking related to oral targeted therapy. 
 
Who is being asked to take part in this research study? 
 
You are being invited to take part in this research study because you: 
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• Are a man or woman 18 years of age or older 
• Have been diagnosed with non-small cell lung cancer 
• Are or have received treatment with a type of oral targeted therapy, called an epidermal 
growth factor receptor inhibitor (EGFR inhibitor).    
• Are able to speak, read, and understand the English language. 
 
Approximately 14-20 men and women are being asked to take part in this study.  The research 
procedures below may take place at the Clinical Research Suites at the University of Pittsburgh, 
School of Nursing or at the University of Pittsburgh Cancer Institute at your convenience. If you 
choose, the procedures may also take place at your home, or at another location of your choosing 
that you consider private and is convenient for you. 
 
What procedures will be performed for research purposes? 
 
If you decide to take part in this research study, you will undergo the following procedures that 
are not part of your standard medical care: 
 
Screening Procedures: 
 
Procedures to determine if you are eligible to take part in a research study are called “screening 
procedures”.   For this research study, the screening procedures include: 
 
1. Cognitive Functioning Screening:  Because decreased cognitive functioning (the 
ability to maintain attention and remember things) can affect how you take your 
medications, we will need to assess for cognitive changes by asking you to complete a 
questionnaire. The questionnaire takes about 5 minutes to complete.   
 
2. Demographic Information: Information about yourself, such as your age, 
race/ethnicity, religion, occupation, marital status, insurance coverage, and level of 
education, will be recorded by asking you to complete a questionnaire. The questionnaire 
takes about 10 minutes to complete.  If you choose, we can help you complete this 
questionnaire by recording your answers to each of the questions. 
 
3. Lung Cancer Information:  Information about the type of lung cancer you have, prior 
treatment (such as chemotherapy or radiation), and current treatment of your cancer will 
be recorded on a questionnaire.  The researcher will obtain this information from your 
medical record. 
 
It is possible that as a result of these screening procedures, you may not be able to participate in 
this study.  If you are not eligible to participate in the study due to evidence of decreased 
cognitive functioning, we will refer you to your oncologist for further assessment and workup 
and your data will be destroyed. 
 
Interview Procedures: 
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If you qualify to take part in this research study, you will be asked to participate in an interview.  
The interview will take place at the Clinical Research Suites at the University of Pittsburgh, 
School of Nursing or at the University of Pittsburgh Cancer Institute at your convenience.  If you 
choose, the interview may also take place at your home, or at another location of your choosing 
that you consider private and is convenient for you.   
 
The interview will take about 45 minutes to complete. 
 
The interview will be conducted by a nurse researcher and will be digitally (audio) recorded so 
that there is an accurate record of what is discussed.  The tapes will only be reviewed by 
members of the research team, who will transcribe and analyze them.  All transcripts, field notes 
and digital recorders will be kept in a locked drawer for a period of at least 7 years.   
 
During the interview, you will be asked questions about your experiences taking oral targeted 
therapy; for example, you may be asked about why you began taking your therapy, how you take 
it on a typical day, what you find difficult or challenging about taking the therapy, etc. 
 
In addition, you will be asked for your permission for the researcher to photograph any objects or 
“artifacts” which are important to you in taking your oral targeted therapy.  Some examples of 
these objects may include a medication diary or notebook, storage containers, or other 
handcrafted objects.  Pictures of these objects are important in helping us understand the total 
process of medication-taking and how you take your oral targeted therapy.  The choice of the 
object to photograph will be decided between yourself and the researcher.  If you agree, the 
photograph will be taken during the interview.   
 
Follow-Up Interview Procedures: 
 
You may be asked to participate in another interview after you have finished at least 1-2 months 
of oral targeted therapy.  If you agree to another interview, the process will be the same as the 
one described above.  During the interview, you will be asked similar questions about your 
experiences taking oral targeted therapy. This interview will also take about 45 minutes to 
complete.  
 
What are the possible risks, side effects, and discomforts of this research study? 
 
Risks of Completion of the Questionnaires: 
 
It is possible that while you are completing of some of the screening questionnaires that you may 
become upset or fatigued.  To lessen any fatigue, which may occur, you will be offered breaks 
while you complete the questionnaires. 
 
Risks of Participating in the Interview: 
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It is possible that you may experience some fatigue or emotional discomfort as a result of the 
interview process. To lessen any fatigue, which may occur, you will be offered breaks during the 
interview.    
 
Should you tell the researcher that you are experiencing any emotional discomfort, the 
investigator will immediately address and will offer to make a phone call to your oncologist, if 
needed.  In addition, if you are in need of psychological counseling or psychiatric referral, we 
will provide you with referral information.  If at any time you feel the need to stop the interview, 
the researcher will stop the interview and offer to resume it at a later date. You may choose to 
stop the interview at any time for any reason, if needed.  
 
Risk of Breach of Confidentiality: 
 
There is a possibility of the risk of breach of confidentiality of protected health information.  The 
research staff will take all necessary steps to ensure that this does not happen, including but not 
limited to removing your identifying information from reports, keeping your records in a locked 
file room, and using passwords for computer files. 
 
Risk of Photographs 
 
Photographing objects related to your medication-taking process will not impose additional risks. 
The researcher will make sure that there is nothing in the image of the object that would identify 
you, or that would identify you as a patient with non-small cell lung cancer, or any cancer.  
 
We wish to use photographs of the objects taken during your interviews for the purpose of 
recording and describing this project.  These images may appear in academic publications, 
presentations given at academic conferences, or on the Internet.  These photographs may also 
appear in newspapers or newsletters. You will be asked to sign a separate consent form (release) 
giving your permission for publication of the photographs.  You may participate in the research 
study, without being recorded, even if you do not sign this form. 
 
 
What are possible benefits from taking part in this study? 
 
You will likely receive no direct benefit from taking part in this interview.  It is our hope that 
information from this research study may benefit patients with lung cancer or other types of 
cancer in the future. 
 
Will my insurance provider or I be charged for the costs of any procedures performed as 
part of this research study? 
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Neither you, nor your insurance provider, will be charged for the costs of any of the procedures 
performed for the purpose of this research study (i.e., the screening procedures, the interview, or 
follow-up interview described above). You will be charged, in the standard manner, for any 
procedures performed for your routine medical care. 
 
Will I be paid if I take part in this research study? 
 
You will be provided a stipend for participating in this research study.  You will receive $10 
after completion of each interview.   
 
Who will pay if I am injured as a result of taking part in this study?  
 
If you believe that the research procedures have resulted in an injury to you, immediately contact 
the Principal Investigator who is listed on the first page of this form. Emergency medical 
treatment for injuries solely and directly related to your participation in this research study will 
be provided to you by the hospitals of UPMC. Your insurance provider may be billed for the 
costs of this emergency treatment, but none of those costs will be charged directly to you. If your 
research-related injury requires medical care beyond this emergency treatment, you will be 
responsible for the costs of this follow-up care. At this time, there is no plan for any additional 
financial compensation. 
 
Who will know about my participation in this research study? 
 
Any information about you obtained from this research will be kept as confidential (private) as 
possible.  All records related to your involvement in this research study will be stored in a locked 
file cabinet.  Your identity on these records will be indicated by a case number rather than by 
your name, and the information linking these case numbers with your identity will be kept 
separate from the research records.  You will not be identified by name in any publication of the 
research results unless you sign a separate consent form giving your permission (release). 
 
Will this research study involve the use or disclosure of my identifiable medical 
information? 
 
This research study will involve the recording of current and/or future identifiable medical 
information from your hospital and/or other (e.g., physician office) records.  The information 
that will be recorded will be limited to your age, race, employment, number of years of education 
that you have completed and information about your lung cancer diagnosis and treatment. 
 
Who will have access to identifiable information related to my participation in this 
research study? 
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In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study:  
 
Authorized representatives of the University of Pittsburgh Research Conduct and Compliance 
Office may review your identifiable research information (which may include your identifiable 
medical information) for the purpose of monitoring the appropriate conduct of this research 
study.  
 
In unusual cases, the investigators may be required to release identifiable information (which 
may include your identifiable medical information) related to your participation in this research 
study in response to an order from a court of law.  If the investigators learn that you or someone 
with whom you are involved is in serious danger or potential harm, they will need to inform, as 
required by Pennsylvania law, the appropriate agencies. 
 
Authorized representatives of the UPMC hospitals or other affiliated health care providers may 
have access to identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for the purpose of (1) fulfilling 
orders, made by the investigators, for hospital and health care services (e.g., laboratory tests, 
diagnostic procedures) associated with research study participation; (2) addressing correct 
payment for tests and procedures ordered by the investigators; and/or (3) for internal hospital 
operations (i.e. quality assurance). 
 
For how long will the investigators be permitted to use and disclose identifiable 
information related to my participation in this research study? 
 
The investigators may continue to use and disclose, for the purposes described above, 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study for a minimum of six (6) years after final reporting or 
publication of a project.  
 
May I have access to my medical information that results from my participation in this 
research study? 
In accordance with the UPMC Notices of Privacy Practices document that you have been 
provided, you are permitted access to information (including information resulting from your 
participation in this research study) contained within your medical records filed with your health 
care provider. 
 
Is my participation in this research study voluntary? 
 
Your participation in this research study, to include the use and disclosure of your identifiable 
information for the purposes described above, is completely voluntary.  (Note, however, that if 
you do not provide your consent for the use and disclosure of your identifiable information for 
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the purposes described above, you will not be allowed to participate in the research study.)  
Whether or not you provide your consent for participation in this research study will have no 
effect on your current or future relationship with the University of Pittsburgh.  Whether or not 
you provide your consent for participation in this research study will have no effect on your 
current or future medical care at a UPMC hospital or affiliated health care provider or your 
current or future relationship with a health care insurance provider. 
 
Your doctor is involved as an investigator in this research study.  As both your doctor and a 
research investigator, s/he is interested both in your medical care and the conduct of this research 
study.  Before agreeing to participate in this research study, or at any time during your study 
participation, you may discuss your care with another doctor who is not associated with this 
research study.  You are not under any obligation to participate in any research study offered by 
your doctor. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
 
You may withdraw, at any time, your consent for participation in this research study, to include 
the use and disclosure of your identifiable information for the purposes described above.  (Note, 
however, that if you withdraw your consent for the use and disclosure of your identifiable 
medical record information for the purposes described above, you will also be withdrawn, in 
general, from further participation in this research study.)  Any identifiable research or medical 
information recorded for, or resulting from, your participation in this research study prior to the 
date that you formally withdrew your consent may continue to be used and disclosed by the 
investigators for the purposes described above.        
 
To formally withdraw your consent for participation in this research study you should provide a 
written and dated notice of this decision to the principal investigator of this research study at the 
address listed on the first page of this form.     
 
Your decision to withdraw your consent for participation in this research study will have no 
effect on your current or future relationship with the University of Pittsburgh.  Your decision to 
withdraw your consent for participation in this research study will have no effect on your current 
or future medical care at a UPMC hospital or affiliated health care provider or your current or 
future relationship with a health care insurance provider. 
 
If I agree to take part in this research study, can I be removed from the study without my 
consent? 
 
It is possible that you may be removed from the research study by the researchers if there is a 
change in your lung cancer treatment or as a result of the screening procedures.  If you are 
excluded from the study due to evidence of cognitive impairment, you will be referred to your 
oncologist for further assessment and workup. You may withdraw from the study at any time, if 
you wish. 
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Might I be contacted after I have completed my participation in this study? 
 
You may be contacted after you have completed this study if there is a need for more 
information from you for this study, or if the researchers have other studies in which you may be 
interested in participating. 
 
************************************************************************ 
VOLUNTARY CONSENT 
 
The above information has been explained to me and all of my current questions have been 
answered.  I understand that I am encouraged to ask questions about any aspect of this research 
study during the course of this study, and that such future questions will be answered by a 
qualified individual or by the investigator(s) listed on the first page of this consent document at 
the telephone number(s) given. I understand that I may always request that my questions, 
concerns or complaints be addressed by a listed investigator.   
 
I understand that I may contact the Human Subjects Protection Advocate of the IRB Office, 
University of Pittsburgh (1-866-212-2668) to discuss problems, concerns, and questions; obtain 
information; offer input; or discuss situations that have occurred during my participation.   
 
By signing this form, I agree to participate in this research study.  A copy of this consent form 
will be given to me. 
 
 
____________________________  ____________________________ ___________ 
Participant’s Signature    Printed Name of Participant  Date 
 
CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation.  
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise. I further certify that no research component of 
this protocol was begun until after this consent form was signed. 
 
___________________________________  ________________________ 
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Printed Name of Person Obtaining Consent  Role in Research Study 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent   Date 
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ADDENDUM 
 
CONSENT TO ACT AS A PARTICIPANT IN A RESEARCH STUDY 
 
TITLE:  A Study of Medication-Taking for NSCLC Patients Receiving Oral Targeted Therapy 
 
PRINCIPAL INVESTIGATOR:   Karen Wickersham, MSN, RN 
University of Pittsburgh 
School of Nursing 
440 Victoria Building 
3500 Victoria Street 
Pittsburgh, PA 15261 
Telephone: 412-721-5899 
 
CO-INVESTIGATORS: 
Judith A. Erlen, PhD, RN, FAAN 
Professor, PhD Coordinator, and Chair 
Department of Health and Community 
Systems 
University of Pittsburgh, School of Nursing 
415 Victoria Building   
Pittsburgh, PA 15261 
(412) 624-1905 
 
Catherine M. Bender, PhD, RN, FAAN  
Professor 
University of Pittsburgh, School of Nursing 
University of Pittsburgh Cancer Institute 
415 Victoria Building   
Pittsburgh, PA 15261 
(412) 624-3594 
Mary Beth Happ, PhD, RN, FAAN 
Professor and UPMC Health System Chair 
in Nursing Science 
Department of Acute and Tertiary Care 
UPMC  
University of Pittsburgh, School of Nursing 
336 Victoria Building 
Pittsburgh, PA 15261 
412-624-2070 
 
Lisa C. Villaruz, MD 
University of Pittsburgh Cancer Institute 
UPP10 Med Hematology-Oncology 
CNPAV 500 Pittsburgh 
Pittsburgh, PA 15232 
412-647-2811 
 
Sandra J. Engberg, PhD, RN, CRNP, FAAN 
Associate Dean and Associate Professor 
University of Pittsburgh, School of Nursing 
350 Victoria Building 
Ahmad Tarhini, MD, PhD, MSc 
University of Pittsburgh Cancer Institute 
HLMNC55 Pittsburgh 
Pittsburgh, PA 15232 
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Pittsburgh, PA 15261 
412-624-3835 
 
412-648-6507 
 
Carol S. Stilley, PhD, RN 
Associate Professor and Vice-Chair 
Dept of Health and Community Systems 
415 Victoria Building 
University of Pittsburgh, School of Nursing 
Pittsburgh, PA 15261 
412-383-7824 
Diane Gardner, CRNP II 
UPP10 Med Hematology-Oncology 
200 Meyran 
Pittsburgh, PA 15232 
412-23-5055 
 
 
Mark A. Socisnki, MD 
Hillman Cancer Center 
University of Pittsburgh Cancer Institute 
Pittsburgh, PA 15232 
412-647-2811 
David Friedland, MD 
Hillman Cancer Center 
OHA00-Hillman 
Pittsburgh, PA 15232 
412-235-1020 
 
Christopher Lindberg, PA II 
Hillman Cancer Center 
OHA00-Hillman 
Pittsburgh, PA 15232 
412-235-1020 
 
 
ADDITIONAL RESEARCH PROCEDURE: 
 
You are currently a participant in a research study that explores the process of medication-taking 
for men and women who are receiving or have received oral targeted therapy for treatment of 
their non-small cell lung cancer (a type of lung cancer).  Medication-taking can be described as a 
complicated set of activities concerning how individuals take their medicines. Oral targeted 
therapies are medicines that act on, or “target”, certain sites on or in cancer cells to stop the 
growth of a tumor.  An example of oral targeted therapy is Tarceva® (erlotinib). 
 
In addition to the interviews that you have or are completing, we would like to ask for your 
permission for the researcher to photograph any objects or “artifacts” which are important to you 
in taking your oral targeted therapy.  Some examples of these objects may include a medication 
diary or notebook, storage containers, or other handcrafted objects.  Pictures of these objects are 
important in helping us understand the total process of medication-taking and how you take your 
oral targeted therapy.  The choice of the object to photograph will be decided between yourself 
and the researcher.  If you agree, the photograph will be taken during the interview.   
 
Risk of Photographs 
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Photographing objects related to your medication-taking process will not impose additional risks. 
The researcher will make sure that there is nothing in the image of the object that would identify 
you, or that would identify you as a patient with non-small cell lung cancer, or any cancer. 
 
We wish to use photographs of the objects taken during your interviews for the purpose of 
recording and describing this project.  These images may appear in academic publications, 
presentations given at academic conferences, or on the Internet.  These photographs may also 
appear in newspapers or newsletters. You will be asked to sign a separate consent (release) form 
giving your permission for publication of the photographs.  You may participate in the research 
study, without being recorded, even if you do not sign this form. 
 
Might I be contacted after I have completed my participation in this study? 
 
You may be contacted after you have completed this study if there is a need for more 
information from you for this study, or if the researchers have other studies in which you may be 
interested in participating. 
 
Allowing us to photograph these objects is entirely voluntary.  Your refusal will not affect 
your participation in NSCLC and Medication-Taking Study.    
 
RIGHT TO WITHDRAW 
 
You understand that you can withdraw from this research study at any time. Your other care and 
benefits will be the same whether you participate in this research study or not. You also 
understand that you may be removed from this research study by the investigators in the event of 
a significant risk to your health. 
 
 
****************************************************************************** 
VOLUNTARY CONSENT 
 
The above information has been explained to me and all of my current questions have been 
answered.  I understand that I am encouraged to ask questions about any aspect of this research 
study during the course of this study, and that such future questions will be answered by a 
qualified individual or by the investigator(s) listed on the first page of this consent document at 
the telephone number(s) given. I understand that I may always request that my questions, 
concerns or complaints be addressed by a listed investigator.   
  
 171  
 
I understand that I may contact the Human Subjects Protection Advocate of the IRB Office, 
University of Pittsburgh (1-866-212-2668) to discuss problems, concerns, and questions; obtain 
information; offer input; or discuss situations that have occurred during my participation.   
 
 
__________________________         _____________________          ___________ 
Participant’s Signature         Printed Name of Participant  Date 
 
CERTIFICATION of INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation.  
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise. I further certify that no research component of 
this protocol was begun until after this consent form was signed. 
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent   Date 
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We are taping the conversation with your permission because I want to be sure not to miss or 
leave anything out that you are telling me. Is this ok? I may also take some notes as we go along. 
Introduction: I am interested in understanding/learning about your experience in taking the anti-
cancer medication (name of EGFR inhibitor [e.g. Tarceva®]) 
First, I would like you to tell me about your (name of medicine), 
(Probes)  Why and when did you start on the medication? 
How did you decide to start taking the medication? 
What is it like to be on that kind of treatment? 
How does the medication make you feel? 
How is this different from your previous treatment? 
What were you told about the medication? 
Tell me about how you take (name of medicine), during a typical day. 
(Probes)  What kind of strategies do you use to help you take them? 
   How do you decide when to take them? 
What do you find difficult or challenging (use their word) (barriers) about taking this 
medication? 
   What would be your “deal breaker”? 
Patients sometimes miss doses or find the medication difficult to take at the same time each day. 
How is that for you?  
(Probes)  Can you tell me more about that?  
   What happens when you miss a dose?  
   What happens when a dose is late? 
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Some people don’t realize that they forget doses.  Does that ever happen for you?  Tell me more. 
(Probes)  What was your reaction when you realized you forgot a dose? 
Were there unexpected, non-routine things? 
What were you told to do if you missed a dose? 
What would make it easier for you to take your medication at the same time each day? 
What would have to change to make taking your medication easier? 
Do you experience any side effects that interfere with taking your medicine?  If so, how do you 
manage them in terms of your medication (i.e. dose reductions?)? 
For those who had chemotherapy, how is the oral medication different from chemo/other 
treatments? 
What people in your life are helpful to you in taking the medication?  
(Probes)  Can you tell me more about that? In what ways does he/she help? 
How have health care providers helped you in taking the medication? 
 
Field Notes: 
Environment (lighting, noise, temperature): 
 
Positioning 
 
Body Language 
 
Appearance 
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Eye contact 
 
Tone 
 
Emotions 
 
Interruptions 
 
Impressions (Informative?  New issues raised?) 
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INTERVIEW CHECKLIST 
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____ Create participant folder on hard drive 
____ Enter interview information onto participant tracking spreadsheet 
Pre-Interview, 1 day before: 
____ Call to confirm interview 
____ 2 informed consent forms:   
• 1 for signature to bring back and file,  
• 1 for participant,  
• Participant to initial all pages. 
____ Print interview guide and field notes 
____ Print participant payment form 
____ Print WePay activation form 
____ $10 stipend (WePay Card) 
____ Set up transcript template 
Interview (Day of): 
____ Bring: 
• Digital tape recorder and bag with back-up recorder, batteries, USB. 
• Directions to location of interview (hard copy and GPS). 
• Cell phone 
• 2 informed consent forms 
• Participant payment form 
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• $10 stipend (WePay Card) 
• WePay Activation Form 
____ Informed consent process 
____ MMSE 
____ SDG Form 
____ Confirmation of eligibility 
Immediately Post-Interview: 
____ Check tape recorder 
____ Write impressions 
Post-Interview, within 24 hours: 
___ Load WePay card 
___ File: 
• Informed consent form 
• Participant payment form 
• Interview checklist 
• Interview guide with field notes 
____ Download interview 
____ Transfer interview and transcript template to Dropbox 
____ Enter completion of interview onto tracking sheet  
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PATIENT REFERRAL PAMPHLET 
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Crisis and Suicide 
Hotline 
412-820-HELP or 1-800-
SUICIDE 
24 hours day/7 days 
week 
 
The Crisis and Suicide 
Hotline offers immediate 
emotional support by 
telephone volunteers 
trained to help people of 
all ages who may be 
suicidal, in emotional 
distress or in need of 
reassurance.  Services 
are free, confidential, and 
anonymous. 
 
Reassurance for 
Seniors 
412-820-0100 
 
Reassurance for Seniors 
provides a free, friendly, 
daily (or weekly) call to 
senior adults, both for 
friendly conversation and 
for the primary purpose of 
confirming their health 
and safety.  A trained 
volunteer is assigned to a 
senior and makes the call 
at a mutually agreed upon 
time.  
   Information on Counseling 
and Referral Services 
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UPMC Cancer Centers 
Behavioral Medicine 
Services 
Phone: 412-623-5888 (for 
all locations) 
Magee-Women’s Hospital 
Hillman Cancer Center 
UPMC Passavant 
UPMC Cancer Centers 
Behavioral Medicine 
provides a range of 
supportive care and 
psychological services to 
patients and families. The 
diagnosis and treatment 
of cancer may be 
stressful and many 
experience distress and 
poorer quality of life than 
they had previously. 
Some want to take a 
more active role in 
prevention of recurrent or 
new cancers once 
treatments are 
completed. A number of 
patients and family 
members may experience 
transient depression, 
anxiety, or sleep loss and 
some experience 
persistent pain or fatigue. 
Behavioral Medicine has 
provided for cancer 
patients and their families 
with: 
Coping skills ●training 
relaxation ●training pain 
management ●stress 
management ●general 
psychological counseling 
and treatment support 
groups ●exercise 
programs ●behavioral 
treatments that decrease 
side-effects of treatments 
and improve quality of life 
UPMC Cancer Centers Social 
Work Services 
Magee Women’s Hospital:  
412-641-1178 
For other UPMC Cancer 
Centers, call your local center 
for referral. 
Social work services at UPMC 
Cancer Centers are provided by 
oncology social workers and 
include individual, family and 
group counseling, education, 
advocacy, discharge planning, 
case management and program 
development. These services 
are designed to maximize the 
patient's utilization of the health 
care system, foster coping and 
access community resources to 
support optimal functioning. 
The focus of care may relate to 
the following: 
Adjusting to the emotional 
impact of a cancer diagnosis ● 
realigning family roles ●coping 
with chronic illness ●stress 
management ●communicating 
with children about cancer 
●adjusting to changes in self-
image and sexuality ●learning to 
negotiate the complexities of the 
health care system ● managing 
financial and insurance 
concerns ●returning to the 
workplace ●planning for care 
after hospitalization ●coping with 
bereavement 
Oncology social workers also 
offer a number of 
support/educational groups to 
patients with cancer and their 
family members. 
Western Psychiatric 
Institute and Clinic 
3811 O'Hara Street 
Pittsburgh, PA 15213-2593 
 
Emergency and Crisis 
Intervention Services:  
412-624-2000 
The Diagnostic Evaluation 
Center (DEC) provides 24 
hour, seven day a week 
emergency and crisis 
intervention services, 
including psychiatric 
emergency evaluations, 
walk-in crisis therapy, 
referral to outpatient 
providers, and facilitation of 
inpatient admissions. The 
mission is to provide 
comprehensive mental 
health and substance abuse 
evaluations and referral to 
appropriate services for 
people of all ages, in various 
states of crisis. 
Consumers can access the 
DEC directly, or be referred 
by an outside source for 
evaluation of mental health 
or substance abuse 
problems. Consumers meet 
with a team that includes a 
nurse, clinician, and doctor, 
all specializing in the field of 
psychiatry. The team then 
works with the individual 
and family to determine the 
best options for treatment. 
Outpatient Services: 
412-624-1000 
Outpatient programs at 
Bellefield Towers treat a 
wide variety of conditions 
including depression, 
anxiety, compulsive 
disorders and phobias. 
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Note: To be abstracted from the medical chart or administered verbally (adapting 
language/clarifying where appropriate).  This information will be entered directly from this form 
into an SPSS database. 
 
Demographics 
Age in years: 
Gender: 
Occupation: 
Marital Status (married/single/divorced/widowed): 
Race (American Indian or Alaska Native; Asian; Black or African American; Native Hawaiian 
or Other Pacific Islander; White; Other): 
Ethnicity (Hispanic or Latino, Not Hispanic or Latino):  
Religion (self-identified): 
Level of education (in years): 
Insurance coverage: 
NSCLC History 
NSCLC type: 
Date diagnosed: 
Stage at diagnosis: 
EGFR mutation (yes/no): 
Radiation Therapy: 
Type of radiation (1): 
 Date began: 
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 Date ended: 
Type of radiation (2): 
 Date began: 
 Date ended: 
 
Chemotherapy: 
• Drug Name #1: 
  Number of cycles: 
  Dose/route 
• Drug Name #2: 
  Number of cycles: 
  Dose/route 
• Drug Name #3: 
  Number of cycles: 
  Dose/route 
• Drug Name #4: 
  Number of cycles: 
  Dose/route 
• Drug Name #5: 
  Number of cycles: 
  Dose/route 
Oral Targeted Therapy: 
Name: 
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Dose/Route/Frequency: 
Date started: 
Date stopped: 
Instructions given for taking medication: 
Discontinued? (yes/no)  
Reason discontinued and when? 
Dose reduced? 
Reason and when? 
Other therapy (e.g. bevacizumab): 
Name: 
 Dose/Route/Frequency:  
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Karen Wickersham, MSN, RN, University of Pittsburgh, School of Nursing is recruiting men 
and women with a diagnosis of non-small cell lung cancer to participate in a research study 
funded by the National Institute of Nursing Research and the American Cancer Society. 
The purpose of the study is to explore the process of medication-taking (how people take 
their medications) for men and women who are or have received oral targeted therapy for 
treatment of their non-small cell lung cancer.   
 
The study consists of 1 to 2 interviews at this site, or at a location that is convenient for 
you and gives you privacy (such as your home).  Each visit will take about 1 to 1 ½ hours. You 
will be paid for each interview. 
 
Study visits include: 
• Completing a questionnaire concerning cognitive function (the ability to maintain 
attention and remember things). 
• Answering questions about yourself such as your age and place of employment. 
 
To participate, you must: 
• Be 18 years of age or older (both men and women may participate). 
• Have been diagnosed with non-small cell lung cancer. 
• Are or have received treatment with a type of oral targeted therapy, called an epidermal 
growth factor receptor inhibitor (EGFR inhibitor) (e.g. Tarceva®).   
• Are able to speak, read, and understand the English language. 
 
Participation is voluntary and completely confidential. 
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ASK YOUR DOCTOR OR NURSE FOR MORE INFORMATION ABOUT THIS STUDY OR CALL:  412-721-5899 
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